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SUMMARY 
With a growing ageing population decline in physical function has become a major 
public health issue, as it is associated with disability in later life. Recent evidence 
suggests that blockade of the renin-angiotension-aldosterone system may have a role in 
improving physical function in older people.We hypothesised that inhibition of the 
renin-angiotensin-aldosterone system with spironolactone would improve physical 
function in older people without heart failure.  
 
In a double-blind, randomised controlled clinical trial 120 participants, aged >65 years 
with functional impairment were randomized to receive 25mg spironolactone or placebo 
for 20 weeks. The primary outcome was the change in six-minute walking distance over 
20 weeks. Secondary outcomes were change in Timed-Get-Up and Go test, Incremental 
Shuttle Walk Test, measures of health related quality of life (EuroQol health 
questionnaire and Functional Limitation Profile) and measures of psychological state 
(Hospital Anxiety and Depression Scale). Outcomes measures were repeated at 10 and 
20 weeks. 
 
Participant mean age was 75 years (SD 6), 65/120 (54%) were male. Only 8/120 
participants (6.6%) dropped out (5 from the placebo group, 3 from the spironolactone 
group). Of the 112 participants who completed the study 95% (106/112) remained on 
medication at 20 weeks. There was no significant change in six minute walking distance 
at 20 weeks with a -3.2 (95% CI -28.9, 22.5) metres difference between the 
spironolactone group related to the placebo group (p=0.81). There was however a 
significant improvement in quality of life at 20 weeks (a secondary outcome) with a rise 
in EuroQol EQ-5D score of 0.10 (95% CI 0.03, 0.18) in the spironolactone group 
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relative to the placebo group (p=<0.01). There were no significant changes between 
groups in the other secondary outcomes. This trial found that spironolactone was safe 
and well tolerated, but did not improve physical function in older people who did not 
have heart failure. Quality of life improved, but the biological plausibility and possible 
mechanisms for this require further study.   
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1. LITERATURE REVIEW 
1.1 Ageing population 
We live in an ageing society. The proportion of older people alive today is greater than 
any other time in history. The number of people aged over 65 years old is predicted to 
rise from 16% to 23% of the UK population over the next 30 years1. 
 
Reductions in fertility rates, accompanied by improvements in health care and living 
conditions, have contributed to this demographic redistribution and to a growing 
ageing population. Increases in the proportions of older people are being accompanied 
by a decline in the proportion of younger people under the age of 15 years old. By 
2050, the number of people over 60 years old is predicted to exceed the number of 
young people, worldwide. Data from the Department of Economic and Social Affairs 
for the United Nations shows that in 1950 the proportion of older people in the world 
was around 8%. This then rose to 10% in 2000. Estimations for 2050 are projected to 
reach 21 percent of the world’s population2. In Scotland, the number of people aged 65 
years or over is projected to increase from three quarters of a million in 2000 to 1.2 
million in 20313.  
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Age Structure 
The age structure of Scotland’s population has changed dramatically over the decades, 
as shown by the change in the population pyramids (Figure 1.1). Scotland appears to 
be in the advanced stages of demographic transition towards an ageing population. In 
addition to the natural phases of demographic transition, age structure has also been 
affected by unexpected events. National statistics produced by the General Register 
Office for Scotland in 2008 showed a trend in older women (over 75 years) 
outnumbering men of the same age4. This may correlate with the fact that women tend 
to live longer than men but it may also demonstrate the effects of higher male mortality 
rates during the Second World War.  
 
The changes in the population pyramids from 1951 to 2001 may be explained by a 
combination of a reduction in birth rates, increased life expectancy, overall improved 
health and living improvements along with the added effects of the ‘baby boomer’ 
period in the 1960s which has led to Scotland’s increasingly ageing population and 
current change in age structure. The latest population projections for Scotland have 
suggested that the total population of Scotland will reach a peak by 20315. Although it 
is speculated that the total population of Scotland will decline slightly in the future, we 
expect to see a reduction in the numbers of people in the younger age groups and a 
consequent rise in people in the older age groups. The ageing population changes 
within Scotland will broadly be in keeping with the rest of Europe, however the 
proportion of people age >65 years will rise faster in Scotland than the rest of the UK 
(Figure 1.2) 
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Figure 1.1 – Population pyramids 1951-2031 (Scottish Executive 2007)
5
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Figure 1.2 – The actual and projected changes in the proportion of the total older 
population, in Scotland other selected European countries. (Scottish Executive) 
5
 
 
 
 
EU-15 = 15 countries of the European Union established in January 1995.  
(Countries include: Belgium, Greece, Luxembourg, Denmark, Spain, Netherlands, 
Germany, France, Portugal, Ireland, Italy, United Kingdom, Austria, Finland and 
Sweden). 
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Changes in life expectancy 
Life expectancy of females in Scotland has risen from 78 years during 1997-1999 to 80 
years in 2006 with the gap between males and females narrowing3. Despite this 
improvement in life expectancy it was reported that Scotland’s overall life expectancy 
is poorer than the rest of Western Europe. 
 
The effect of social circumstances on older people has a huge impact on life 
expectancy as well as healthy life expectancy, defined as “the number of years a 
person can expect to live in good health” with the least well off and those living in 
areas of deprivation having poorer health and a shorter life expectancy. Healthy Life 
Expectancy was considerably lower in the most deprived areas of Scotland with a 
healthy life expectancy at birth of only 57.5 years and 61.9 years for males and females 
compared to 67.9 years and 69 years in males and females respectively for the rest of 
Scotland in 20096. 
 
This demonstrates the impact that socio-economic deprivation has on health status in 
older people. Living in areas of social deprivation can be detrimental to the lives of 
older people due to poor public transport and the poor quality of housing. In addition, 
high crime rates and social isolation, also impact on their health and wellbeing. 
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Morbidity and mortality 
Mortality rates rise with age. The causes of mortality also differ with age. 
Approximately 80% of deaths in people over 65 years old are attributed to 
cardiovascular disease, stroke and respiratory disease. Cardiovascular disease is by far 
the commonest cause of death in the young old (> 65 years old), whilst cancer 
accounts for relatively few deaths in the very old (>85 years old). (see Figure 1.3). 
Figure 1.3. – The relative contribution of specific causes of death to overall 
mortality; by age group in Scotland
7
. 
 
 
Chronic diseases are more common in older people and are associated with a higher 
use of primary and secondary care services7. The rates of chronic illnesses and 
disability increase dramatically with age especially in patients over 85 years. Around 
60% of people over 85 years report having longstanding limiting chronic illnesses and 
of these people, approximately 80% report having a disability8. Circulatory, respiratory 
and musculoskeletal disorders account for the largest proportion of illness and 
disability in older people in Scotland.  
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Implications of an ageing population on the health service 
Many researchers have predicted that an increased ageing population will have huge 
social, political as well as economic implications especially in the developed world, 
where an ageing population has been blamed for an increase in Health Care 
Expenditure (HCE)9. 
 
In Scotland £4.5 billion was spent on health and social care for people aged 65 years 
and older from 2006 to 2007. The majority of this was spent on hospitals and care 
homes with hospital emergency admissions costing £1.4 billion alone10. In the face of a 
rising older population, the total health and social care expenditure in Scotland would 
need to increase by 78% to £8 billion, if demand for services continues in this pattern. 
 
In contrast to other countries the rise in the number of older people has not meant a rise 
in healthcare expenditure. In a UK longitudinal study, NHS expenditure was shown to 
rise between 1985 and 1999. However, elderly patients had decreases in per capita 
costs compared to the middle age groups. Costs per capita for those individuals over 65 
years old in England and Wales showed a rise of only 8% compared to Japan, Canada 
and Australia where a larger increase per capita costs of 12%, 20% and 56% 
respectively has been recorded 11. However, it is important to note that this difference 
is more likely to account for different health care systems and the way in which 
funding is divided between the different health care sectors. In the United States 
Medicare Current Beneficiary Survey, information was gathered from over 12,500 
Medicare clients aged over 65 years. The survey showed despite their greater 
longevity, healthy older people had similar cumulative health care expenditures than 
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those in poorer health12. This suggests that efforts in health promotion and disease 
prevention may help people to live longer without increasing healthcare costs.  
 
Recent standards proposed by the National Service Framework for Older People in 
England have encouraged health promotion in older age. Studies have shown that 
identifying risk factors and implementing strategies to modify biological, social, 
psychological and environmental risk factors can reduce the onset of disability in later 
life13. This was demonstrated in a randomised controlled trial by Stuck et al, where 
functionally impaired older people had regular multidimensional geriatric assessments. 
The study showed that early intervention and risk stratification reduced disability, 
reduced nursing home admissions and also led to reductions in health care costs of 
$1403 per patient per year14. This demonstrates that developing interventions to reduce 
disability in later life may help reduce the health care costs for older people.  
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1.2 Decline in physical function in later life 
Background 
Impairment of functional status has frequently been associated with poorer health 
outcomes15. The Framingham Disability Study, one of the largest population studies to 
date, suggested a strong relationship between increasing physical disability and age, 
especially in people aged between 55 to 84 years old16.  
 
Within the Western World, approximately 13-14% of the total population suffer from a 
degree of disability which places a huge demand on rehabilitation services17. Disability 
among older people is not a new problem. Statistics from the Office of Population 
Censuses and Surveys (OPCS) estimated that there were approximately 4.3 million 
disabled people in the UK over 60 years of age, with functional impairment due to 
musculoskeletal disorders reported as a common cause of disability in the elderly 18. 
Unsurprisingly, the highest disability rates were in institutionalised people. Functional 
decline is a common yet serious problem in older people which can result in the loss of 
independence. More importantly, it can directly impact on quality of life19.  
 
Models of disability and functional impairment 
Models of illness are useful when conducting research, designing new interventions or 
aiding the allocation of resources. In 1980, a model of the disability process was 
published and the International Classification of Impairments, Disabilities and 
Handicaps (ICIDH) was subsequently developed by the World Health Organisation 
(WHO) (see Figure 1.4)20. The aim of the model was to allow an understanding of 
disability. It was thought that a universal classification system for disabilities would 
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lead to developments in public health and social policies. It also helped clarify 
definitions of functional impairment.  
 
Figure 1.4 – The Disablement Process (adapted from ICHDH, WHO 1980)
20
 
 
The model shows the pathway from pathology of a disease to disability. Both acute 
and chronic diseases can cause disability, however the onset of disability from chronic 
disease is more progressive. According to the model, an underlying disease or disorder 
can lead to dysfunctions or structural abnormalities of specific body systems i.e. 
musculoskeletal, cardiovascular or neurological system, resulting in ‘impairment’.  
This may lead to ‘functional limitation’, where an individual is restricted in performing 
basic physical or mental actions. Limitations in physical function can lead to 
difficulties performing basic activities of daily living (ADLs) such as personal 
hygiene, grooming, dressing, feeding, functional transfers, continence and ambulation 
or difficulties in household management, instrumemental activities of daily living 
(IADLs), such as shopping and cooking. ‘Disability’ occurs when an individual loses 
their ability to carry out daily tasks, preventing them from fulfilling their normal role20.  
History of disability can lead to a vicious cycle of further decline in functional state, 
flare-up or exacerbations of disease and the involvement of other body systems.  
 
 
 
 
Disease        #      Impairment #  Functional Limitation   #  Disabilty 
Or Disorder       (functional loss)     (activity limitation)       (social disadvantage) 
                            [organ level]          [personal level]               [social level] 
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Decline in physical function has been associated with higher rates of falls, loss of 
independence, institutionalisation and mortality21. Freedman et al showed how 
identifying and managing modifiable risk factors may alter the disablement process. 
Diseases such as musculosketal disorders or disabling strokes are strongly associated 
with functional impairment and physical disability. For example, in a patient who has 
suffered a recent fall resulting in an injury, introducing interventions such as a physical 
activity program may help promote muscle strength and balance and lead to a 
reduction in falls risk, therefore shortening the disability period, as shown in Figure 
1.522. Other useful interventions may include home modifications such as inserting 
hand railings and a shower seat may help the individual to regain their normal 
functioning and also prevent further functional decline and disability. As the majority 
of older people lie on or around the functional limitation threshold even a small change 
in their functional state can lead to increased disability and loss of independence. 
Therefore, identifying and managing risk factors to prevent decline in physical 
function at an early stage may help to delay the onset of disability and reduced 
morbidity and mortality in older people. 
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Figure 1.5 – Interventions which may alter disability trajectory. (taken from 
Freedman et al)
22
. 
 
 
 
Risk factors for decline in physical function 
Reduced lower extremity muscle mass 
Muscle strength is essential for overall physical performance, stamina and balance. 
Existing evidence has shown the importance of muscle weakness in predicting physical 
functional decline and future disability23.  Improving muscle strength through physical 
training can lead to improvements in physical function. More recently studies have 
also investigated the influence of muscle mass on physical function. In a study 
involving frail older community dwelling participants aged 65 years and above, the 
loss of total lean leg mass (TLM) was an independent predictor of functional 
impairment, after adjusting for underlying co-morbidities, body weight, body fat, 
physical activity and bone mineral density21. The study also showed that loss of TLM 
in older people was strongly associated with reduced muscle strength (p< 0.01, r= 
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0.78) as well as physical disability.  The study also showed that for every 1Kg increase 
in muscle mass there was a 53% reduction in functional limitation.  
 
There is growing evidence to suggest that other factors such as muscle composition 
including fat infiltration and type of muscle fibre could also influence muscle strength 
and functional performance24.  
 
Co-morbidities 
It has long been established that decline in functional status in older people has been 
linked to underlying diseases. This has been well represented in the WHO models for 
disability. It is thought that it is the loss of function at organ level due to an underlying 
disease process that contributes to loss of function. 
 
A number of studies have assessed the relationship between underlying disease and 
disability.  Several chronic diseases appear to feature more frequently in older people 
with disability than those without any disability. The Women’s Health and Aging 
Study screened over 3841 community dwelling female participants over 65 years. The 
study showed that women who were disabled reported more than a four-fold increase 
in the frequency of stroke, a three fold increase in heart disease and were twice as 
likely to suffer diabetes or arthritis compared to those who were classified as having no 
disease25. 
 
Several studies have tried to link certain chronic diseases which are most likely to 
cause disability. Patients with conditions such as osteoarthritis, stroke, heart disease 
and depression, report the highest levels of physical disability26. Despite the low 
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prevalence of stroke, it appears to have a large impact on functional limitations in a 
wide range of daily tasks.  
 
In reality, older people usually suffer from multiple co-morbidities. In fact, some 
cross-sectional studies have shown that the number of co-morbidities can be predictive 
of future disability. Patients with multiple chronic diseases are at increased risk of loss 
in mobility 27. This demonstrates the direct impact of co-morbid disease on functional 
state. This would suggest that providing early medical intervention in both single and 
multiple co-morbid diseases can minimize the degree of disability.  
 
Depression 
As well as affecting general well-being, depression is also thought to contribute to 
functional decline. A number of studies have observed an association between 
depression and disability in older people. In hospitalized patients with symptoms of 
depression, as measured by a Geriatric Depression Scale of >6, patients were more 
likely to be limited in at least one ADL on discharge and 90 days post discharge28.  
Even after adjusting for other confounding factors such as alcohol intake, cognitive 
function and chronic conditions, the presence of depression is still a significant 
predictor of functional decline29. This may lead to a spiraling effect as limitations in 
ADLs are themselves associated with a number of negative health outcomes such as 
hospitalization and mortality which in turn may cause further physical and 
psychological decline. The exact mechanism between depression and physical 
performance is still not clearly understood. It has been postulated that depression may 
be a pro-dromal syndrome for other medical conditions which precipitate functional 
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decline. A common feature of depression is apathy, which can lead to a lack of 
motivation required to maintain physical function.  
 
Slow gait speed 
Physical performance tests have been found to be valid predictors of morbidity and 
mortality as well as disability30. Of the available physical performance tests, gait speed 
has been one of the simplest yet effective tests to perform in a clinical setting. In a 
large prospective study, participants with a gait speed of less than 1 metre per second 
(m/s) had a two-fold increased risk of functional impairment of the lower limbs. The 
study also showed that a slower gait speed was associated with increased mortality 
(RR=1.64) and hospitalisations within 1 year (RR= 1.48)31. This demonstrates the use 
of gait speed as a valid predictor of functional impairment and mortality in older 
people32. 
 
Alcohol 
Lifestyle factors including alcohol consumption can influence physical function. La 
Croix et al showed that ‘heavy alcohol consumption’ in older people, regarded as >28g 
of alcohol per day, resulted in a 20% increased risk of a decline in mobility in men and 
a 40% risk of a decline in mobility in women33. It is possible that heavy alcohol 
consumers may be at risk of having falls and fractures as a result of their alcohol 
intake. Interestingly La Croix also showed that individuals with mild-to-moderate 
alcohol consumption were more likely to maintain their mobility than people who 
abstained from alcohol. This was supported by Guralnik et al, in a prospective study in 
older people, where people with moderate alcohol consumption were 2.4 times more 
likely to have a higher level of physical function compared to those who were 
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abstinent from alcohol34. These benefits may be explained by the fact that moderate 
alcohol consumption has shown to reduce the risk of cardiovascular heart disease and 
thus reducing related disability35.   
 
Obesity 
Obesity is growing in prevalence throughout the developed world and is associated 
with functional limitation and negative effects on quality of life. Increased body mass 
index (BMI) is closely associated with functional decline. Obesity, defined as a BMI > 
80th centile, was associated with a 20% reduction in mobility in men compared to a 
40% reduction in women33. A low BMI was not significantly associated with mobility 
decline in either sex. Studies have also shown that older people with a high percentage 
of body fat are also associated with functional decline and disability24. Possible 
mechanisms for the association between obesity and functional decline include its 
correlation with increased risk of cardiovascular disease events which independently 
leads to functional decline36. Obesity is also associated with decreased levels of 
physical activity which, in turn, can lead to de-conditioning and functional limitation. 
Obesity may lead to increased mechanical stress to joints and hence lead to possible 
debilitating bone disease such as osteoarthritis. Studies have demonstrated that 
inflammatory cytokines, including interleukin-6 and tumour necrosis are secreted by 
adipose tissue explants from obese individuals37. This has led to the hypothesis that 
obesity may represent a low-grade chronic inflammatory state. 
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Sensory impairment 
Many studies have suggested that self-reported poor vision is associated with increased 
risk of functional decline. There is evidence that patients with severe visual 
impairment, measured by visual acuity, had a three-fold greater risk of subsequent 
functional decline38. In comparison, the association between hearing loss and 
functional impairment is less significant, especially when data was controlled for age 
and other co-morbidities39. This may be due to the fact that in most studies hearing loss 
was self-reported. Visual impairment may lead to an increased risk as well as fear of 
falling which could influence functional impairment. 
 
Increased frequency in falls 
Unintentional injuries, as a result of falls, are still the fifth leading cause of death in 
older people in the US after cardiovascular disease, stroke, respiratory disorders and 
cancer40. It is thought that 12% of all falls will lead to serious injury, including 
fractures41.  In the UK, the incidence rate of falls in people >60 years old is 3.6/100 
persons per year, with mortality of people with recurrent falls twice that of people 
without falls42. Whilst a single fall is not significantly associated with an increased risk 
of future functional disability, recurrent falls are associated with an increase in 
functional disability and institutionalisation in older people43;44. People with recurrent 
falls have a four-fold increase in disability compared to those without falls45.Older 
people who fall are also more likely to experience a fear of falling, which may result in 
restriction of their ADLs46.  
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Cognitive impairment 
There is a strong association between progressive cognitive impairment and functional 
decline. A randomised controlled trial investigating the benefits of a home-based 
exercise training program in community dwelling frail older people, showed that 
subjects with poorer cognitive function Mini-Mental State Examination (MMSE) <24 
showed the least improvement physical function47. This maybe due to the fact that 
subjects with poorer cognitive function had more difficulties in following instructions 
and in retaining information and are therefore, less likely to benefit from physical 
interventions. 
 
Physical inactivity 
Physical activity is any bodily movement produced by skeletal muscles which require 
energy expenditure. It has been well proven that regular physical activity contributes to 
primary and secondary prevention of a number of chronic diseases as well as reducing 
overall mortality and premature death48;49;50.We know that increased physical activity 
reduces the risk of physical disability. People who engage in regular physical activity 
more than three times per week are less likely to have a decline in mobility than older 
people with sedentary lifestyles51.  The participation in regular physical activity can 
reduce mobility loss in healthy older people by up to 50% over several years52. 
 
However, there is controversy as to the type and level of activity required to achieve 
maximum reduction in the rate of decline in mobility and hence functional decline. A 
number of studies have shown that only vigorous or high intensity exercise regimens 
are beneficial in reducing functional decline53. However, more recently evidence has 
shown benefits in low intensity exercise such as walking, gardening and housekeeping, 
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on physical function, which is a more attractive goal especially in frail older people 
with multiple co-morbidities54. Although there is strong evidence to support physical 
activity reducing the risk of physical functional decline, most studies have only 
included people with preserved functional status at baseline.  This means that frailer 
older people have not been well represented. One large European observational study 
investigated the benefits of moderate physical activity in frail older people (‘frailty’ 
defined as problem in performing one or more ADL). It concluded that there was an 
almost two-fold increase in dying without disability among those who were physically 
active compared to those who led sedentary lifestyles55. This demonstrates the 
beneficial effects of physical activity in a large proportion of the older population but 
there is a need for further research into the influence of physical activity in 
functionally impaired older people. 
 
Functional decline is associated with a number of risk factors. Given our globally 
ageing population, there is pressing need to identify and evaluate interventions that 
have the potential to minimise functional impairment and delay the onset of disability 
in later life.  
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1.3 Ageing muscle and Sarcopenia 
Background 
Maintaining muscle function is vital to remain functionally independent. Muscle mass 
and force reach their peak between the fourth and sixth decades of life and thereafter 
show a steady decline with age56. With this progressive loss of skeletal muscle mass 
comes a reduction in mobility which, in turn, leads to increased frailty and disability.  
 
Epidemiology of sarcopenia 
‘Sarcopenia’ is a syndrome characterized by the progressive generalised loss of 
skeletal muscle mass, strength and quality which occurs with age. The word is derived 
from the Greek word ‘sarx’ meaning flesh and ‘penia’ meaning loss57. Sarcopenia is 
usually accompanied by physical inactivity, decreased mobility, slow gait and poor 
physical endurance which are common features in frailty syndrome58. Rockwood et al 
described the concept of frailty as “a multidimensional syndrome which involves loss 
of reserves of energy, physical activity, cognition and health, which give rise to 
increased vulnerability”59. The frailty process involves a cumulative decline in 
multiple physiological systems in particular there is a decline in the neuromuscular 
system that may be linked to the age-related development of sarcopenia. This loss of 
muscle mass has significant implications to a person’s functional status as it can cause 
a reduction in muscle strength and exercise capacity, which are required to perform 
ADLs. A reduction in muscle mass is also a strong predictor of mortality in later life60. 
As well as the huge burden of the clinical consequences of sarcopenia the economic 
impact on the health care system is substantial with annual costs attributable to 
sarcopenia estimated at $18billion in the United States61. With an estimated 15% of 
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people over 65 years old and 50% of people aged over 80 years62 developing 
sarcopenia, research into understanding the mechanisms behind this phenomenon and 
developing approaches to counter the effects of sarcopenia, should be a high priority.  
 
The overall prevalence of sarcopenia in our ageing population remains uncertain due to 
the lack of consensus on the definition and the variations in measuring age-related 
changes in skeletal muscle mass and strength. More recently, attempts have been made 
to refine the definition of sarcopenia. A joint effort was made between the European 
Society of Clinical Nutrition and Metabolism and the Special Interest Needs Group for 
geriatric nutrition on ‘Cachexia – anorexia and chronic wasting disease’63. They 
suggested that a diagnosis of sarcopenia could be made based on two of the following: 
i)  A low muscle mass, i.e. a percentage of muscle mass > 2 SD’s below the mean, 
measured in groups of young adults of the same sex, age and ethnic background. 
ii) Low gait speed, i.e. a walking speed of <0.8m/s in the 4-metre walk test. 
This definition included measures of physical performance while eliminating variance 
between ethnicity and sex. However, it failed to set age-specific populations. It has 
been suggested that a T-score system, similar to that used for diagnosing osteoporosis, 
could be useful to provide reference values for different populations. However, this too 
requires further refinement. 
 
The European Working Group on Sarcopenia in Older People (EWGSOP) (a steering 
group involving four European Scientific organizations of Geriatric Medicine and 
Clinical Nutrition) met in January 2009, to develop an operational definition and 
diagnostic criteria for sarcopenia for use in research studies and clinical practice64. 
This would help to identify the possible mechanisms of sarcopenia, thus enabling the 
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development of effective treatments to prevent the loss of independence and to limit 
disability in older people. With the knowledge that sarcopenia is a dynamic process, 
the EWGSOP recommended that sarcopenia should be diagnosed “in the presence of 
low muscle mass and low muscle function (strength or performance)”
64. Until recently, 
a major stumbling block for developing potential treatments for sarcopenia was the 
absence of standardized primary and secondary outcomes for clinical trials. However, 
the EWGSOP recommended primary outcome measures based on muscle mass, 
muscle strength and physical performance as shown in Figure 1.6. 
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Figure 1.6 Primary and secondary outcome domains for interventional trials in 
sarcopenia (adapted from the EWGSOP 2009
64
) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary outcome domains 
• Physical performance 
• Muscle strength 
• Muscle mass 
 
    Secondary outcome domains 
• Activities of daily living (ADL, basic, instrumental) 
• Quality of Life  
• Metabolic and biochemical markers 
• Falls 
• Admission to hospital or institutionalization 
• Social support 
• Mortality 
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Diagnosis of sarcopenia 
Until recently, the main difficulties in diagnosing sarcopenia was the lack of consensus 
in its definition in addition to difficulties in measuring changes in muscle mass and 
function over time in older people. Although sarcopenia is considered a dynamic 
process, incorporating both changes in muscle mass and function, many observational 
studies have concentrated on measuring muscle mass and in particular fat-free mass, 
but failed to measure this alongside physical function. 
 
Measuring techniques for sarcopenia. 
Muscle mass 
Previous cadaveric studies have shown that computerised tomography (CT) and 
magnetic resonance imaging (MRI) provide reliable measurements of skeletal mass. 
However, routine use of such technologies could lead to an escalation of cost as well 
as risks involves with exposure to radiation in CT scanning. More recently, Dual 
Energy X-ray absorptiometry (DXA) has become a possible alternative for skeletal 
muscle estimations as it measures both fat mass as well as bone mass and is accurate at 
measuring appendicular muscle mass.  DXA scanning correlates with measurements of 
skeletal mass achieved via MRI scanning65. However, the main limitation is the ability 
of the DXA scan to distinguish water retention and muscle fat infiltration. Studies have 
shown that muscle fat infiltration can over-estimate skeletal muscle mass by 1-8% and 
therefore may wrongly identify some individuals of the population as sarcopenic66. 
 
Other approaches of measuring body composition within the past twenty years include 
the use of bioelectrical impedance analysis (BIA). This method is a quick and non-
invasive approach for assessing body composition by measuring tissue conductivity 
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and is a relatively inexpensive alternative measuring technique for large population 
studies. Results from BIA have also shown to correlate with MRI measures of muscle 
mass67. Using BIA scanning, the New Mexico Elder Study calculated the skeletal mass 
by using an anthropometric equation for predicting appendicular skeletal muscle 
(ASM) as measured in all four limbs. In this study, sarcopenia was defined as 
ASM/height2 (Kg/m2) of less than two standard deviations below the mean of a young 
reference group. The prevalence of sarcopenia ranged from 13-24% in people aged 65-
70 years and the prevalence rose to 50 % in those aged over 80 years old. The study 
also showed that the prevalence was higher in men aged over 75 years (58%) 
compared to women in the same age category (45%). This was due to the fact that 
older men have a higher proportion of lean muscle mass than women68. It was later 
recognised that the results using the BIA method may be grossly overestimated and a 
subsequent study was done using DXA scanning. The results from the DXA scanning 
method showed a much lower prevalence with 16% of women and 29% of men over 
80 years being classified as sarcopenic69.  A cross-sectional survey in older community 
dwelling people in Minnesota defined sarcopenia using total rather than skeletal body 
muscle mass. The population prevalence was much lower with 6 to 15% of participants 
with sarcopenia70.  It is worth noting that using total body mass measurements may 
introduce errors as a result of a potential rise in water and fat content in ageing muscle. 
As the study involved a community based population, participants may have been 
slightly healthier with fewer underlying co-morbidities.  
 
Anthropometric measures, including mid-upper arm circumference (MUAC) and 
triceps skin fold (TSF) thickness, have been used to calculate muscle mass in many 
research studies. Rolland et al showed that calf circumference positively correlated 
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with muscle mass and that a calf-circumference of <31cms was associated with 
increased disability. However, the main disadvantage of using anthropometric 
measures is that they are subject to errors due a loss of skin elasticity in older people 
and in cases of  ‘sarcopenia obesity’, where there is a loss of lean muscle mass but an 
increase in muscle fat deposition71 . Therefore, anthropometric measures should not be 
used as a screening tool for sarcopenia.  
 
A summary of current measuring techniques used including their limitations is shown 
in Table 1.1.  
 
Table 1.1- Measuring techniques for sarcopenia (taken from Burton et al.) 
 
 
Muscle strength 
The main effect of loss of muscle mass is loss of strength. Low muscle mass is 
associated with increased mortality. Although complex measures of power and torque 
are available, one of the simplest measures of muscle strength is by using hand-held 
dynamometers that measure hand grip and quadriceps muscle strength. These have 
been used frequently in research. Hand grip strength is not only simple to use in a 
clinical setting but it has good reproducibility. Also, it also correlates to lower limb 
muscle strength72. A handgrip strength of <30Kg in men and <20Kg in women has 
 
 
 
46 
 
been associated with increased mobility limitation and disabilty73. One of the main 
disadvantages of using hand-held dynamometers is that patients with osteoarthritis and 
other co-morbidities may be limited in performing the technique due to pain. This may 
lead to under-estimation of muscle strength in some older people.  
 
Physical performance 
Physical performance measures can complement measures of muscle mass and 
strength in the diagnosis of sarcopenia. The Short Physical Performance Battery 
(SPPB) assesses muscle function and strength using measures which are relate to daily 
living activities. The assessment involves balance tests, a 4-metre walk test and a timed 
chair rise which gives an overall score and can be performed in a clinical setting. It can 
also predict future disability and therefore, may be useful at identifying people at the 
preclinical stage of sarcopenia, who may benefit from interventions74.  
 
Gait speed has shown to be an independent measure of physical performance and 
muscle strength and is a good predictor of disability32. Buchner et al showed that in 
frailer older adults there was a curvilinear relationship between walking speed and leg 
strength, showing that small changes in physiological capacity (muscle strength) may 
have substantial effects on physical performance (gait speed)75. 
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Aetiology of sarcopenia 
An understanding of the mechanism involved in the development of sarcopenia is 
essential in order to develop interventions. Research is still ongoing but, as yet, no 
primary cause has been identified in the development of sarcopenia. It appears that 
there are multiple risk factors and mechanisms which contribute to the development of 
sarcopenia as shown in Figure 1.7.  
 
Figure 1.7 – Mechanism of sarcopenia 
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Loss of neuro-muscular function  
Disturbances in neuro-muscular function increase with age. Ageing is associated with 
increasing muscle weakness and slowing of the muscle, resulting in a loss in power 
generating capacity. The combination of disturbed motor control and loss of muscle 
mass has a huge impact in physical functioning as well as quality of life in older 
people.  
 
In ageing muscle, loss of alpha motor neuron axons appears to be maintained until the 
sixth decade of life, after which there appears to be a rapid decline76.  Histological 
analysis, from muscle biopsy sampling, has given a great insight into age-related 
muscle atrophy. The loss of the alpha motor neurons appears to affect the longer axons 
in the lower extremities first before the upper limbs77.  
 
Muscle contraction is initiated and maintained by the successive recruitment of motor 
units. A motor unit encompasses an alpha motor unit and the muscle fibres which it 
innervates. One of the major contributing factors, to age-related loss of muscle force 
and power, is through motor unit re-modelling. During this process muscle fibres are 
progressively de-nervated and either irreversibly lost or re-innervated by the sprouting 
of the remaining motor neurons. 
 
Structural and functional changes occur with age in the skeletal muscle. The co-
expression of the two myosin heavy chain (MHC) isoforms determines the muscle 
fibre morphology. When MHC isoform 1 is predominant, it favours type I muscle 
fibres. Type I muscle fibres appear to be slow-twitch fibres which are fatigue resistant. 
They have a greater oxidative capacity and are associated with endurance. On the other 
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hand, when MHC isoform IIa and IIb are predominant, it favours type IIa and type IIb 
muscle fibres which, in contrast, are fast-twitch fibres that fatigue easily and have a 
high glycolytic capacity. Type II muscle fibres are associated with muscle power78.  
 
Both animal and human studies have shown a preferential loss of fast twitch type II 
muscle fibres with increasing age. The extent of muscle fibre loss between muscle 
fibre type in ageing muscle appears to vary between study, with some studies showing 
a decrease in type II fibres while others have found no difference in numbers between 
types79. Despite this, the evidence suggests that only 10-15% of motor neuron loss 
occurs with advancing age80. This demonstrates that muscle fibre loss alone is not 
sufficient to impact on functional loss in ageing skeletal muscle; rather it is the 
complex interaction between many factors including changes to neuromuscular 
transmission, muscle architecture, muscle fibre composition and muscle metabolism.  
 
Several studies have reported skeletal muscle de-nervation and re-innervation, motor 
unit remodelling or loss, both in humans and rodents. This remodelling leads to 
changes in the fibre type composition. During the ageing process, remodelling of the 
motor units appears to involve de-nervation of the fast muscle fibres with re-
innervation by axonal sprouting from the slow muscle fibres. This could be a major 
contributing factor for sarcopenia81. When the rate of de-nervation is higher than the 
rate of re-innervations, a proportion of the muscle fibres become atrophic leading to 
functional impairment with ageing. 
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Satellite cells 
The effect of ageing on human muscle fibres is unique. Satellite cells are key cells in 
the regeneration and growth of muscle fibres. They are effectively myogenic stem 
cells, located just outside the muscle fibre sarcolemma but beneath the basement 
lamina. They are quiescent cells that become activated by stimulation such as in 
muscle fibre injury. When injury occurs, they start replicating and are responsible for 
the repair of injured muscle fibres, differentiation of new muscle fibres and generation 
of new satellite cells.  
 
It is postulated that, during the ageing process, there is a reduction in the number of 
satellite cells and their capacity to differentiate muscle fibres may be altered as there is 
a greater reduction in type II rather than type I muscle fibres82. Despite the reduction in 
satellite cells, the remaining intact satellite cells must be sufficient to generate some 
muscle repair in ageing muscle83.  
 
Alterations in calcium homeostasis 
The ageing of skeletal muscle is also linked to age-related changes in calcium 
homeostasis. These alterations in calcium during ageing have shown to involve 
changes in the excitation-contraction coupling (EC) process, changes in transient 
Calcium (Ca2+) levels, alterations in the chloride and potassium channels as well as 
slowing down of contraction times. 
 
Skeletal muscle contraction is initiated from action potentials generated by the motor 
neuron and conducted via the axons, which causes the release of acetylcholine (Ach) at 
the motor end plate. Ach then binds to the nicotinic Ach receptors, which in turn 
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causes an increase in the conduction of sodium and potassium from the end plate 
membrane. End plate potentials at the muscle membrane lead to generation of action 
potentials and conduction to the sarcolemma T-tubules. This then leads to intracellular 
elevation in calcium concentration which precedes muscle contraction.  
 
In ageing, the muscle fibres exhibit a significant decrease in sarcoplasmic calcium 
concentrations as a result of a reduction in L-type Ca2+ channel charge movement. 
There also appears to be a decline in dihydropyridine receptors (DHPR).  DHPRs act 
as voltage gated sensors located in the sarcolemma T-tubules which when activated 
provoke Ca2+ release from the sarcoplasmic reticulum. This release of Ca2+ from the 
SR (sarcoplasmic reticulum) is also aided by the modulation of ryanodine-sensitive 
calcium channels and by sarcoplasmic reticulum protein calsequestrin. The ryanodine 
receptors act to release Ca2+ during the excitation and coupling process19. The 
consequence of a reduction in the number and function of these receptors and proteins 
causes a reduction in the intracellular Ca2+ movement and therefore a reduction in 
force which is common in ageing muscle.  
 
Reductions in peak intracellular Ca2+ levels appear to affect slow-twitch muscle fibres 
more than fast twitch muscle fibres in older rats, resulting in a prolonged time to peak 
force and a longer contraction duration84. The uncoupling of machinery for the 
excitation contraction process is a key factor in age dependent decline in the capacity 
of the muscle to generate force. In experimental rodent studies, de-nervation causes a 
decrease in expression of DHPR receptors and therefore may alter the excitation-
contraction coupling and muscle contraction. This demonstrates the importance of 
alterations in Ca2+ homeostasis on ageing skeletal muscle85.  
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Pro-inflammatory cytokines 
Along with a decrease in anabolic stimuli, ageing appears to produce increased 
catabolic stimuli. There is some evidence that ageing contributes to a rise in pro-
inflammatory cytokines.  
 
Cachexia of old age is thought to be “a cytokine-associated wasting of protein and 
energy stores due to an underlying disease process”86. It is thought to trigger an 
inflammatory response mediated through cellular injury or through activation of the 
immune system, which produces an acute inflammatory response. This process has 
shown to produce a sharp rise in inflammatory cytokines interleukin 1 (IL-1), 
interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-"). These cytokines have a 
direct negative effect on muscle mass and reduce lean muscle mass. High levels of 
cytokines are associated with cachexia which is a common occurrence in many chronic 
medical conditions affecting the elderly, such as heart failure, COPD and cancer. Pro-
inflammatory cytokines have also been found in otherwise healthy older people. 
Therefore, the ageing process itself has been associated with a mild inflammatory 
response and increased catabolic stimuli87.  
 
A number of studies have suggested a link between cytokine production, signalling and 
sarcopenia. Cytokines such as TNF-" and IL-6 appear to play an important role in age-
related inflammatory responses and may also play a role in the development of 
sarcopenia. Elevated levels of TNF-" in aged muscle are thought to stimulate muscle 
loss through the activation of apoptosis pathway and impair inflammatory response to 
injury 88. When IL-6 is expressed at low levels it appears to act as a muscle growth 
factor but, in contrast, when expressed at higher levels it appears to cause muscle 
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wasting 89.  In addition, higher levels of  IL-6 in community dwelling older people are 
associated with increased functional impairment and physical disability in old age90. 
Despite this, cytokine levels can often be inconsistent and therefore it still remains 
unclear as to whether the rise is solely due to the ageing process or whether there is 
indeed underlying disease. It is also worth noting that cytokines such as IL-6 can be 
stimulated by other factors such as smoking, obesity and stress and this should be 
taken in to consideration when interpreting the data 91.  
 
In experimental studies with rats, the administration of IL-6 or TNF-" increases 
skeletal muscle protein breakdown, decreases the rate of protein synthesis and caused 
muscle wasting92. In cross-sectional studies in humans, higher levels of IL-6 and TNF-
" have been associated with lower muscle mass and strength93. The Longitudinal 
Ageing Study of Amsterdam showed that high levels of IL-6 and CRP were associated 
with an increased loss in muscle strength94. In addition, the study demonstrated that the 
presence of high levels of anti-chymotrypsin (ACT), a serum protease inhibitor which 
regulates the activity of proteolytic enzymes during inflammation, which reduced the 
risk of muscle strength loss and therefore protected muscle tissue breakdown. 
However, in the presence of high levels of IL-6 and ACT there was increased muscle 
strength loss indicating that IL-6 inhibits the protective role of ACT. However, further 
research is required to support this suggestion.  
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Mitochondrial dysfunction  
There is increasing evidence now that muscle mitochondrial dysfunction occurs with 
age in both rats and humans. The changes which are thought to occur include: 1) a 
reduction in the copy numbers of mitochondrial DNA; 2) a reduction in the 
concentration of mRNA in genes encoding for muscle mitochondrial proteins; 3) a 
reduction in the rate of mitochondrial protein synthesis; 4) a reduction in muscle 
mitochondrial oxidative enzyme activities and 5) a reduction in ATP production95.  
 
At a cellular level mitochondria are the main producers of energy for skeletal muscles 
in the form of adenosine triphosphate (ATP) which is produced via the oxidative 
phosphorylation of adenosine diphosphate and is therefore crucial in the generation of 
muscle contraction. Mitochondria also act as a key regulator centre of programmed cell 
death (apoptosis). During ageing there is an acceleration in apoptosis of irreplaceable 
post-mitotic cells such as neurons, skeletal muscle fibres and cardiac myocytes which 
leads to loss of function. It is therefore postulated that increased apoptosis induced by 
age-related mitochondrial dysfunction plays an important role in sarcopenia.  
 
Apoptosis is essential for numerous biological processes including embryogenesis, 
tissue homeostasis and cell turnover. It is activated via specific cell signalling 
pathways which in turn causes the release of  ‘caspases’  leading to the ‘caspase 
cascade’ which acts as the executioner of enzymes in cell death96. Mitochondria induce 
apoptosis through a caspase-dependent or caspase-independent pathway. In the 
caspase-dependent pathway stimulation and activation of initiator caspases (caspases-
8, -9 and -12) leads to activation of effector caspases (caspases-3,-6,and -7) which 
cause cell degradation. Experimental studies analyzing the gastrocnemius muscle of 
 
 
 
55 
 
old rodents have shown a rise in capsase-3 levels which may indicate a possible link 
between stimulation of a caspase-dependent pathway in mitochondria and a rise 
apoptosis with age. Mitochondria may also induce apoptosis through a caspase 
independent pathway by the release of apoptosis inducing factor and endo-nuclease G 
which are responsible for DNA fragmentation97. It has also been reported that 
mitochondria interact with the endoplasmic reticulum (ER) and disrupt calcium 
metabolism and thereby disrupt E-C coupling.  
 
The mitochondrion is the main site for production of reactive oxygen species (ROS). 
Due to its proximity to the electron transport chain (ETC), mitochondrial DNA is 
therefore very susceptible to oxidative damage by free radicals98. Oxidative stress may 
be involved in ageing by enhancing mitochondrial DNA mutations and deletions. As a 
result there is a reduction in the process of oxidative phosphorylation and thus 
decreased mitochondrial ATP production.  
 
Experimental studies have shown that muscle biopsies of the vastis lateralis in a wide 
age range of healthy volunteers have an abundance of muscle mitochondrial protein 
and mDNA and mRNA. However, the muscle mitochondrial protein and mDNA and 
mRNA declined at a rate of 8% per decade. This is thought to occur as a consequence 
of an increase in oxidative damage with age99. This theory is supported by 
experimental studies conducted in rodents which showed higher mitochondrial DNA 
oxidation in older rats100. In particular, there was a 5% decline in citrate synthase 
which is a key oxidative enzyme required for ATP production as well as a decline in 
VO2. This supports the theory that age is associated with a reduction in muscle 
mitochondrial DNA and increased DNA oxidation which in turn reduces mitochondrial 
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gene transcription and proteins and reduced muscle ATP production. As a result these 
mitochondrial changes may collectively lead to lower physical function in older 
people. 
We know that physical inactivity contributes to sarcopenia101. More recently a link was 
found between mitochondrial function and physical activity. It appears that older 
adults may benefit from physical activity through exercise induced adaptation in the 
cellular antioxidant defence system. Aerobic exercise has been linked to increased 
ETC activity, mitochondrial biogenesis and reduced oxidative damage102. This 
demonstrates that mitochondrial dysfunction is involved in the ageing process and the 
potentially beneficial effects that physical activity may have in preventing sarcopenia. 
 
Hormonal changes 
Hormonal changes appear during the ageing process. Levels of growth hormone (GH), 
insulin-like growth factor (IGF-1) and androgens, which help regulate growth and 
development of skeletal muscle, appear to decrease with age.  
 
Growth hormone (GH) is required for maintenance of muscle and bone. GH exerts 
most of its anabolic actions through insulin-like growth factor 1 (IGF-1) which is 
synthesized in the liver for systemic release. IGF-1 helps improve muscle function by 
increasing production of muscle satellite cells as well as stimulating production of 
muscle contractile proteins103. Not only do GH and IGF-1 levels decline with age, the 
amplitude and frequency of pulsatile GH release is also significantly reduced104. 
The menopause is linked to reduced concentrations of circulating oestradiol in middle 
aged and older women. There appears to be impaired muscle performance during the 
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postmenopausal period when ovarian hormone production has decreased105. It seems 
obvious to hypothesize that oestrogen may play a role in sarcopenia in older women.  
Testosterone is secreted by the Leydig cells in men and ovarian thecal cells in 
women106. Testosterone appears to increase muscle mass and increase muscle protein 
synthesis107. It also increases the number of satellite cells in both animals and humans 
which are essential for muscle cell function108. 
 
A substantial number of older men are hypogonadal. Hypogonadism has been defined 
as a total testosterone concentration of <9.26nmol/l (2SD below the mean for healthy 
young men). As a result approximately 20% of men >60 years and 50% men > 80 
years are categorized as hypogonadal109.  Circulating testosterone is highly bound to 
sex hormone binding globulin (SHBG) and as SHBG increases with age the total 
amount of bioavailable testosterone decreases. This phenomenon has been termed the 
‘male menopause’ or ‘andropause’ in older men. Testosterone decreases gradually at a 
rate of 1-2% per year in males from the age of 30 years-old110. The overall reduction of 
testosterone is associated with loss of muscle strength, muscle mass, a reduction in 
bone mineral density and increased risk of fracture risk following falls111;112. 
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Potential interventions for sarcopenia 
Exercise and physical activity 
Physical activity refers to the body movement that is produced by skeletal muscle 
contractions and that increases energy expenditure113. Evidence has shown that older 
adults who are less physically active are more likely to have lower skeletal muscle 
mass and strength and are at increased risk of developing sarcopenia114.  
 
Exercise is a form of physical activity that is structured, repetitive and is performed 
mainly to achieve improvement in health or fitness. Although exercise is a form of 
physical activity not all physical activity is exercise. In aerobic exercise the larger 
muscles in the body move in a rhythmic manner for a prolonged period of time. 
Whereas resistance exercise (muscle-strengthening exercises) involves muscles 
working hard against an applied force or weight such as in weight-lifting. Both aerobic 
and resistance type exercise training have shown to improve the rate of decline in 
muscle mass and strength with age115. 
Aerobic activity (swimming, running and walking) has long been linked to 
improvements in cardiovascular fitness and endurance capacity. Although aerobic 
exercise is less likely to contribute to muscle hypertrophy, it can increase the cross-
sectional area of muscle fibres116. Mitochondrial volume and enzyme activity increase 
after aerobic exercise demonstrating that muscle protein synthesis and muscle quality 
improve irrespective of age117. Aerobic exercise can also reduce body fat including 
intramuscular fat which in turn improves the functional role of muscle relative to body 
weight118. In contrast to aerobic exercise training, resistance exercise training appears 
to have a larger effect on augmenting muscle mass and strength and attenuates the 
development of sarcopenia119;120. Improvements in muscle strength can be achieved 
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with as little as one resistance exercise training session per week121. Frontera et al 
demonstrated improvements in muscle cross-sectional area (CSA) by 11% as well as 
improvement in muscle strength (>100%) after a 12 week period of high intensity 
resistance exercise training in older men122. Similar improvements were seen in muscle 
strength even in the people >90 years with as little as 10-12 weeks of training123. 
Muscle hypertrophy occurs when muscle protein synthesis outweighs protein 
breakdown. Older people performing resistance exercise show a marked increase in 
skeletal muscle protein synthesis without an increase in whole body muscle 
breakdown. Resistance training in older people increases both mixed-muscle protein 
synthesis and specific MHC synthesis to the same levels as younger adults124.  
Evidence points to increases in size of both Type 1 and Type II muscle fibres which 
could explain the improvements in muscle strength and endurance124. More recently, it 
has been reported that when using moderate levels of resistance exercise training, 
improvements in muscle strength and size in healthy older people were comparable to 
muscle strength seen in younger individuals. Roth et al demonstrated that six months 
of whole body resistance training in older people (65-75 years) produced gains in 
muscle cross sectional area similar to those achieved in younger individuals aged 20-
30 years125. 
 
Progressive Resistance Training (PRT) is the most commonly used resistance therapy 
used in older people.  A Cochrane review of 121 randomized controlled trials  of PRT 
in older people  showed that doing PRT two to three times per week improved physical 
function, gait speed, timed get-up and go, climbing stairs and balance and more 
importantly had a significant effect on muscle strength especially in the high intensity 
training groups126. 
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The majority of studies have shown that resistance exercise training must be carried 
out at a high intensity in order to show substantial improvements in muscle 
strength122;125. In contrast, in a 26 week study in older healthy adults at both low and 
high intensity resistance exercise training programs found only a modest improvement 
in thigh muscle strength in the high intensity resistance exercise training group127. 
 
Resistance exercise training appears to be relatively safe to perform even in 
participants with multiple co-morbidities and can help in prevention of falls.128 It 
increases muscle cross-sectional muscle area as well as type II (fast twitch) muscle 
fibres, which leads to overall improvement in muscle power and the ability to improve 
physical functioning. As a result, this can lead to enhanced ability to perform ADLs, 
preventing functional decline and disability. Even in very old residents of nursing 
homes, resistance exercise training showed substantial improvements in muscle fibre 
cross-sectional area (3-9%), muscle strength (>100%) as well as improvements in 
physical performance such as gait speed and stair climbing129;126. However, 
participation in regular exercise training requires motivation by the individual which 
may be difficult for some older individuals. Therefore non-exercise interventions may 
offer a useful alternative.   
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Nutrition 
Many older adults do not consume sufficient amounts of dietary protein which leads to 
a reduction in lean body mass and increased functional impairment130. The current 
recommended dietary allowance (RDA) of protein is 0.8g per Kg per day, almost 40% 
of people >70 years, does not meet this131. A low protein diet below the RDA leads to 
a significant decline in muscle strength and muscle mass in older women132. However, 
even older people who take the recommended RDA for protein continue to have a 
negative nitrogen balance and may require a diet containing higher protein content 
than the RDA to maintain their skeletal muscle133. Protein and energy supplementation 
may increase muscle strength even in very old people in the short term but studies have 
found no definite functional benefit from nutritional supplementation134;135,136. 
Although older people who exercise have increased protein requirements, studies 
investigating whether nutritional supplementation in combination with resistance 
training can augment muscle strength gains in older people, have yielded inconsistent 
results. A randomized controlled trial in nursing home residents undergoing resistance 
training over 10 weeks, found that an additional 360 calorie supplement increased leg 
muscle strength129. The combination of protein supplementation with a 12 week 
resistance training program, increased muscle mass but not muscle strength137. Many 
of oral nutritional supplements used in clinical trials are milk based drinks. A 
randomised controlled trial involving nutritional supplementation in older people post 
hospital discharge, showed that 73% of eligible participants refused to enter the study 
as they disliked the milky consistency of the nutritional drinks135. This may lead to 
problems with adherence to nutritional supplementation.  
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Testosterone 
Evidence to support testosterone supplementation is variable. Gruenewald et al 
analyzed twenty-nine randomized controlled trials investigating the effects of 
testosterone replacement in older men. Some studies found an increase in lean body 
mass and hand grip strength but no effect on knee extension and flexion strength138. 
Other studies have shown up to 25% increase in leg strength in as little as 4 weeks of 
therapy139. Some studies have found no increase in muscle strength or function but an 
improvement in lean body mass140. Testosterone supplementation has been shown to 
increase the size of the prostate gland in men141. This could be detrimental to older 
men in whom the prevalence of early-stage prostate cancer is already high142. The 
Baltimore Longitudinal Study on Aging involving 781 men showed a positive 
correlation between prostate cancer and the blood concentration of free testosterone 
levels. The likelihood of acquiring a high risk prostate cancer in men >65 years 
doubled for every 0.1unit increase in free testosterone143. This along with other 
potential side effects of testosterone therapy like fluid retention, gynaecomastia, 
polycythaemia and sleep apnoea limit it’s potential use as an intervention for 
sarcopenia141. 
 
Oestrogens 
The effect of hormone replacement therapy (HRT) in women is controversial. HRT 
may attenuate the loss of muscle mass which occurs in the perimenopausal period144. 
Oestrogen replacement therapy has only modest benefits on muscle composition and 
this may not translate to improved physical functioning145. HRT combined with 
resistance training may have a role in improving lower extremity function. However 
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more evidence is needed146. HRT has been implicated as a risk factor for breast cancer 
and is therefore not recommended for sarcopenia147. 
 
Growth hormones 
Despite a number of studies which have assessed the administration of GH 
supplementation, there is still an ongoing debate as to the use of GH supplementation 
on muscle mass, strength and physical performance. The strongest evidence for the use 
of GH supplementation appears to be in states of reduced GH secretion. In younger 
GH deficient adults, GH supplementation for 3 years increased thigh muscle mass, 
strength and improved exercise capacity148. However, in healthy non-GH deficient 
older people results are more controversial.  Some studies have shown an increase in 
muscle mass but no improvement in muscle strength whereas others have shown an 
increase in both muscle mass and strength after administration of GH 
supplementation149-151. The failure of exogenous GH to mimic the pulsatile pattern of 
normal GH secretion has been blamed for the negative results.  Alternative potential 
hormonal interventions include the use of growth hormone releasing hormone (GHRH) 
which was found to have only a small improvement in muscle strength in older men152. 
 
Muscle strength increases as a result of resistance exercise training in older 
adults119;122. It was hypothesized that the combination of GH replacement and exercise 
training may have a synergistic effect on muscle function in older people. However, 
results proved disappointing and the addition of GH supplementation does not 
augment the improvements in skeletal muscle brought about by exercise alone153. Low 
GH levels alone may not be responsible for the levelling off of muscle strength seen in 
older exercising people and that other pathways may be involved. 
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As it currently stands, the evidence for the use of GH supplementation to counter the 
effects of sarcopenia in older people is weak. Moreover the majority of trials involving 
growth hormone replacement therapy in older people have reported a high incidence of 
side effects including: increased fluid retention, gynaecomastia, orthostatic 
hypotension and carpel tunnel syndrome154.  
 
Creatine 
Creatine plays an important role in protein metabolism and cellular metabolism. It has 
been hypothesized that creatine increases the expression of myogenic transcription 
factors such as myogenin which increases muscle mass and strength155. Creatine 
supplementation increases muscle phosphocreatine levels leading to a decrease in 
muscle relaxation time156. This may increase the ability to perform high-intensity 
exercise as well as enhance muscle protein synthesis, lean skeletal muscle mass and 
strength during periods of high intensity training. 
 
To date, several studies on creatine supplementation have shown increased muscle 
strength and power in both younger men and women but few studies have looked at the 
effect of creatine supplementation in older people. Some studies have reported no 
effect of creatine supplementation on muscle strength or function157. However, others 
have reported increments in muscle mass and increased muscle power without adverse 
effects158. There is controversy over whether creatine supplementation increases the 
benefits of resistance training alone in older people. Some studies have found no added 
benefit of creatine supplementation to resistance exercise training while other studies 
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have found a small increase in lean tissue mass with no residual benefit once training 
stopped159;160. 
 
Creatine is a natural ingredient of food and the main source is from meat products with 
an average daily intake of 1g per day. However, creatine supplementation may 
increase the risk of interstitial nephritis highlighting the need for particular caution 
about its use in older people161. Creatine is not currently recommended for sarcopenia. 
 
Myostatin 
Myostatin is a natural inhibitor of growth factor. It was initially discovered when 
mutations of the myostatin gene was found to correlate with exaggerated muscle 
hypertrophy162. The myostatin gene appears in skeletal muscle cells and functions as a 
negative regulator of muscle growth, antagonism of which increases satellite cell 
proliferation163. In animal models, it appears that over expression of myostatin induces 
extensive muscle loss164.  Polymorphisms of the myostatin gene in humans correlated 
with measure of muscle mass, strength and physical performance165. 
 
Agents that target the myostatin pathway may be useful in increasing muscle mass and 
therefore play a vital role in muscle wasting disorders as well as sarcopenia of old age. 
Phase II trials have been carried out in muscular dystrophy and initial results have 
shown that MYO-29 a recombinant antibody to myostatin, had good safety and 
tolerability profile166. Another potential therapeutic approach currently in development 
is a soluble activin type IIB receptor that binds to the myostatin therefore reducing its 
availability. Initial results in mice have shown an increase in muscle weight larger than 
those achieved with myostatin inhibitors167.  
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Inhibition of myostatin with follistatin (myostatin antagonist) may have potential 
therapeutic benefits in the treatment of sarcopenia. Although myostatin deficiency 
increased muscle mass in mice it impaired the structure and function of the muscle 
tendons thereby making the tendons smaller, stiffer and more brittle168. Older people 
who are already at increased risk of contraction induced injury may find it more 
difficult to sustain regular exercise. Further studies are required. 
 
Vitamin D  
Vitamin D levels decline with age and cutaneous vitamin D levels are up to four times 
lower in older compared to younger individuals169. It is known that vitamin D plays an 
important role in bone and muscle metabolism. Several mechanisms have been 
suggested for the role of vitamin D in muscle function. Vitamin D binding to the 
vitamin D receptor found in skeletal muscle promotes muscle protein synthesis and 
enhances calcium uptake across the cell membrane170. Low vitamin D levels result in 
atrophy predominantly of the type II (fast twitch) muscle fibres in common with 
sarcopenia171. In older people, low vitamin D levels may produce functional problems 
including proximal muscle weakness, difficultly rising from a chair, difficulties in 
ascending stairs and axial balance problems172.  
 
The evidence for a benefit in physical performance with supplementation of vitamin D 
is controversial. Some studies have shown an improvement in muscle strength with 
intermittent dosing and others have shown small gains in lower extremity strength and 
less body sway with daily dosing173. This improvement has been hypothesized as the 
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mechanism behind a fall reduction of 23%-53% in older nursing or residential home 
residents given vitamin D in addition to a reduction in fractures174;175. 
 
Conversely, other studies have found no benefits on physical function, falls risk or 
quality of life with vitamin D supplementation in vitamin D deficient people176-178. The 
difference in findings between studies may in part be attributed to differences in the 
dose of vitamin D used with better outcomes seen when higher doses are used.  It has 
also been suggested that there is a gender difference in outcomes with women standing 
to gain more from supplementation174. Variations between study populations may also 
affect outcomes with the biggest improvements in muscle function and physical 
performance seen in institutionalized older people. 
 
The prevalence of vitamin D insufficiency (25(OH)D levels <40nmol/L) in older 
people is high between 50- 75% especially in the northern latitudes and low levels 
have been found even in summer months179;180. A European epidemiological study 
showed the prevalence of vitamin D deficiency in older adults aged 71-76 years was 
36% in older men and 47% in older women181. It is recommended that 25(OH) D 
levels <40nmol/L requires supplementation and 25(OH) D levels of >75nmol/L is the 
level for optimum bone and muscle health182. The recommended daily intake of 
vitamin D is between 400IU-600IU per day which may be inadequate to raise serum 
vitamin D levels to a desirable level >70nmol/L183;184. Studies have shown that in order 
to achieve optimal levels of 75-100nmol/L of 25(OH) D doses of between 700-1000IU 
would be needed. In the US, fortification of food such as milk and orange juice is 
mandatory, whereas in the UK only margarine is fortified with vitamin D. The 
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question of whether it should be mandatory for UK food products to be fortified with 
vitamin D remains controversial. 
 
Although it is plausible to associate low levels of vitamin D with a reduction in muscle 
strength and physical function, the evidence for supplementation has been inconsistent. 
Safety issues surrounding vitamin D supplementation in older people include increased 
risk of nephrolithiasis and hypercalcaemia185. Further large randomized controlled 
trials are required with a longer follow up period in order to assess the safety profile of 
vitamin D supplementation in older people before it is recommended as a treatment for 
sarcopenia in clinical practice. 
 
ACE inhibitors 
ACE inhibitors have long been used as a treatment in primary and secondary 
prevention in cardiovascular disease as well as secondary stroke prevention. There is a 
growing body of evidence to suggest that ACE inhibitors may have a beneficial effect 
on skeletal muscle. ACE inhibitors may exert their beneficial effects on skeletal 
muscles through a number of different mechanisms (Figure 1.8). ACE inhibitors may 
improve muscle function through improvements in endothelial function, metabolic 
function, anti-inflammatory effects, and angiogenesis thereby improving skeletal 
muscle blood flow186;187. They can also increase mitochondrial numbers and IGF-I 
levels thereby helping to counter sarcopenia188.  People with the type II genotype of the 
ACE gene who have low serum ACE levels show an increased response to physical 
endurance189;190. Therefore, lowering serum ACE levels with ACE inhibitors may have 
a beneficial effect on physical function.  
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Figure 1.8 – Effects of ACE inhibitors on skeletal muscle 
 
 
 
Observational studies have shown that the long term use of ACE inhibitors was 
associated with a lower mean decline in muscle strength and walking speed in older 
hypertensive people191;192. Several studies have shown that ACE inhibitors improved 
exercise capacity in both younger and older people with chronic heart failure (CHF)193-
195. Although this could be largely attributed to improvements in cardiac function, 
skeletal muscle atrophy is also associated with CHF so the evidence in muscle gains 
should not be discounted. 
 
Few interventional studies using ACE inhibitors for physical function have been 
undertaken. One study, looking at functionally impaired older people without heart 
failure, has shown that ACE inhibitors increase six minute walking distance to a 
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degree comparable to that achieved after 6 months of exercise training196. Another 
found that ACE inhibitors increased exercise time in older hypertensive men197. 
However, a study comparing the effects of nifedipine with ACE inhibitors in older 
people found no difference between treatments in muscle strength, walking distance or 
functional performance198. It is possible that frailer subjects with slower walking 
speeds, who have a tendency to more cardiovascular problems, benefit more. This is 
reflected in the fact that adults with severe peripheral vascular disease significantly 
increase their walking time following treatment with ACE inhibitors199. This again 
highlights the significance of ACE inhibition on physical performance albeit in variety 
of patient groups. However, further trials are needed with longer follow up periods, to 
establish whether ACE inhibitors can improve physical function with chronic ACE 
inhibitor use. 
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Summary 
Sarcopenia is a global health concern. It is usually accompanied by physical inactivity, 
decreased mobility, slow gait speed and poor physical endurance. With a growing 
older population there is now great interest in developing approaches to counteract the 
effects of sarcopenia and thereby reducing disability and dependency.  A summary of 
the potential treatment options for sarcopenia is shown in Table 1.2. 
 
The evidence suggests that regular physical activity can prevent physical functional 
decline in old age. In particular, aerobic or resistance exercise training has shown to 
improve muscle strength with as little as one exercise training session per week. 
Resistent exercise training has shown to increase muscle CSA as well as increasing the 
number of type II (fast twitch) muscle fibres, which leads to overall improvement in 
muscle power and physical functioning. However, participation in regular exercise 
requires motivation by the individual which may be difficult in some older sedentary 
people. Therefore, non-exercise interventions may offer a useful alternative which I 
will explore in this thesis.  
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Table 1.2 Summary of treatment options for sarcopenia. 
Intervention Effect Comments 
Exercise 
- Aerobic exercise 
 
- Resistance exercise 
 
 
$ cardiovascular fitness,$ endurance 
$ mitochondrial volume and activity 
 
$ muscle mass and strength 
$ muscle protein synthesis,  
$ muscle fibre size 
$ physical performance 
 
 
 
Pros: overall beneficial 
effects on physical  
 
Cons: motivation to exercise 
remains low 
Nutritional supplementation  
Varying evidence for $ muscle mass 
and $ muscle strength 
Pros: ensures good protein 
intake 
 
Cons: problems with 
adherence 
Hormone Therapy 
- Testosterone 
 
 
- Oestrogen 
 
- Growth Hormone 
 
 
Varying evidence for $ muscle mass 
and $ muscle strength 
 
 
 
 
Poor evidence for $ muscle mass but 
not function 
 
 
Some evidence for $ muscle mass 
Varying evidence for $ muscle 
strength 
 
 
Cons: masculinisation of 
females, $ risk of prostatic 
cancer 
 
 
 
Cons: $ risk of breast cancer 
 
 
 
Cons: adverse effects; fluid 
retention, orthostatic 
hypotension 
Vitamin D Variable evidence for $ muscle 
strength 
 
% falls in nursing home residents 
Pros: % fracture risk 
 
Pros: possible cardiovascular 
benefits 
ACE inhibitors Some evidence for $ exercise capacity Pros: other cardiovascular 
benefits  
 
Cons: renal function needs 
monitoring 
Creatine Variable evidence for $ muscle 
strength and endurance when 
combined with exercise 
 
Cons: reports of nephritis 
Myostatin antagonists No trials in older people  
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1.4 Renin-Angiotensin-Aldosterone System 
Background 
The renin-angiotensin-aldosterone system (RAAS) plays an integral role in the 
homeostatic control of arterial blood pressure, tissue perfusion and extracellular 
volume. In 1898 a substance synthesised in the renal cortex of a rabbit was discovered 
to result in a sustained increase in arterial blood pressure. The substance was thought 
to be a hormone secreted by the kidney and was later known as ‘renin’200. This finding 
was reinforced when it was found that hypertension could be prompted by renin 
release due to renal ischaemia induced by clamping the renal artery. It was later shown 
that ‘renin’ caused the proteolytic cleavage of a precursor initially named 
‘angiotensinogen’ which in turn, produces angiotensin I (Ang I) and angiotensin II 
(Ang II). Ang  I is cleaved by a co-existing enzyme angiotensin-converting enzyme 
(ACE) which is required to generate the active peptide Ang II201. It was later 
discovered that Ang II stimulates the release of the hormone aldosterone from the 
adrenal cortex which is required for the regulation of sodium and potassium balance.  
 
The classical RAAS pathway 
The renin-angiotensin-aldosterone system (RAAS) is depicted in Figure 1.9. Evidence 
has shown that a reduction in circulating blood volume results in a reduction in renal 
perfusion pressure. Subsequently, this triggers the release of renin from the 
juxtaglomerular (JG) cells lining the afferent arterioles in the renal glomerulus. Renin 
is an aspartyl protease synthesised from the pre-hormone pro-renin.  Renin is then 
stored in the granules of the JG cells, it is then stimulated by an exocytic process and 
released into the systemic circulation. Renin regulates the initial rate-limiting step of 
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the RAAS pathway by cleaving the N-terminal amino acids of circulating alpha 2 
globulin angiotensinogen, to form the decapeptide Ang I. This in turn, is converted to 
the active octapeptide Ang II by removal of the C-peptide through the action of ACE. 
ACE is a membrane bound exopeptidase produced in the lung and vascular endothelial 
cell luminal membrane and locally in the glomerulus.  
 
Ang II is one of the most important biological components of the RAAS and has a key 
role in maintaining circulatory homeostasis. Ang II primarily stimulates the release of 
aldosterone from the zona glomerulas in the adrenal cortex but it is also a potent 
vasoconstrictor. Ang II promotes vasoconstriction of the renal and systemic arterioles. 
ACE also helps regulate vasoactivity by inactivating bradykinin, a potent vasodilator. 
The potent actions of Ang II occur as a result of its binding to specific receptors (AT-1 
and AT-2). Both act as G-protein coupled cell surface receptors but they differ in their 
effects. AT-1 receptors (divided into subtypes alpha and beta) are present in the cells 
of the target organs of Ang II and mediate most of the biological effects of Ang II 
including the secretion of aldosterone.  Studies have shown the majority of the 
physiological actions of angiotensin II are mediated by AT-1 receptor. Two subtypes 
of AT-1 receptor have been identified AT-1 alpha (AT-1a) and AT-1 beta (AT-1b) 
receptors. The two receptors are thought to signal in a similar manner but are derived 
from two different genes and are expressed differently202. It appears that AT-1a 
receptor is found in most organs whereas AT-1b is more prominent in the adrenal and 
pituitary glands. In contrast AT-2 receptors appear to be present during fetal life in the 
brain, kidney and adrenal sites and levels appear to decrease in the postnatal period203.  
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Figure 1.9 – The Renin-Angiotensin-Aldosterone System 
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Tissue RAAS pathway 
There is now evidence to suggest that Ang II and aldosterone are synthesised in a 
variety of tissues in addition to the kidneys including the brain, heart, adipose tissue 
and blood vessels202.  
 
Much of local Ang II is synthesised when angiotensinogen penetrates from the plasma 
into the tissue. Angiotensinogen is enzymatically cleaved by renin which is either free 
or bound to the cell membrane. Alternatively, it has been postulated that other 
pathways for the synthesis of Ang II from angiotensinogen are present independent of 
renin. Studies have suggested that non-ACE pathways may be responsible for up to 
40% of local Ang II204. Unfortunately, most of the evidence for the presence of 
alternative Ang II synthesis pathways derives from in vitro or indirect observational 
studies205;206. The presence of the alternative pathways in humans remains uncertain. 
 
Aldosterone 
There is now increasing data to support suggestions that the adverse effects of Ang II 
are mediated through aldosterone. It is known that aldosterone is synthesised in the 
mitochondria of the zona glomerulosa cells of the adrenal gland. Cholesterol is 
converted to pregnenolone by a series of enzymes to progesterone, 
deoxycorticosteroid, corticosterone and lastly to aldosterone (Figure 1.10)207. Two 
forms of the P-450 cytochrome enzymes catalyse the final step in the synthetic 
pathway. These enzymes are encoded by two genes CYP11B1 and CYP11B2 which, 
although closely related, appear to differ in their activation and tissue distribution208. 
11-beta-hydroxysteroid dehydrogenase (11!-HSD) catalyses 11-deoxycorticosterone 
(DOC) to corticosterone in the zona fasiculata and reticularis, under the regulation of 
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ACTH. Aldosterone synthase catalyses DOC to aldosterone in the zona 
glomerulosa209. Aldosterone synthesis is stimulated by Ang II, potassium and to a 
smaller extent adrenocorticotrophic hormone (ACTH). Aldosterone release is inhibited 
by somatostatin, atrial natriuretic factor and dopamine. 
 
Classically, aldosterone binds to the mineralocorticoid receptor (MR) in the renal 
epithelial cells and stimulates the expression of genes encoding for aldosterone 
induced proteins. These proteins subsequently stimulate activation of sodium and 
potassium channels, mitochondrial adenosine triphosphate (ATP) and sodium-
potassium ATP synthase (ATPase) (Na+/K+/ATPase). This leads to sodium retention 
potassium excretion and thus increases systolic blood pressure. 
 
Aldosterone is an important regulator of blood pressure, with up to 15% of unselected 
patients with hypertension noted to have a high aldosterone/renin ratio210. It has been 
well known that a sustained increase in systolic blood pressure can cause numerous 
deleterious effects including tissue damage to the brain, kidneys and myocardium. 
Increasing levels of aldosterone and Ang II can also produce tissue damage directly by 
increasing blood pressure.  
 
 
 
 
 
   
7
8
 
 
F
ig
u
re
 1
.1
0
. 
A
ld
o
st
er
o
n
e 
sy
n
th
es
is
 p
a
th
w
a
y
 (
A
d
a
p
te
d
 f
ro
m
 W
h
it
e 
e
t 
a
l2
0
7
) 
 
  
 P
re
g
n
e
n
o
lo
n
e
 
  
  
P
ro
g
e
s
te
ro
n
e
 
  
 C
h
o
le
s
te
ro
l 
  
D
e
o
x
y
c
o
rt
ic
o
s
te
ro
n
e
 
C
o
rt
ic
o
s
te
ro
n
e
 
 1
8
-0
H
-c
o
rt
ic
o
s
te
ro
n
e
 
 
  
  
A
ld
o
s
te
r
o
n
e
 
1
7
-O
H
 P
re
g
n
e
n
o
lo
n
e
 
D
e
h
y
d
ro
e
p
ia
n
d
ro
s
te
ro
n
e
 
1
7
-O
H
 P
ro
g
e
s
te
ro
n
e
 
1
1
-D
e
o
x
y
c
o
rt
is
o
l 
C
o
rt
is
o
l 
T
e
s
to
s
te
ro
n
e
 
A
n
d
ro
s
te
n
e
d
io
n
e
 
D
ih
y
d
ro
te
s
to
s
te
ro
n
e
 
C
h
o
le
s
te
ro
ld
e
s
m
o
la
s
e
 
(C
Y
P
1
1
A
1
) 
3
!
-H
y
d
ro
x
y
s
te
ro
id
 
d
e
h
y
d
ro
g
e
n
a
s
e
 
2
1
-H
y
d
ro
x
y
la
s
e
 
(C
Y
P
2
1
A
2
) 
1
1
!
-H
y
d
ro
x
y
la
s
e
 
(C
Y
P
1
1
B
2
) 
  
1
8
-H
y
d
ro
x
y
la
s
e
 
(C
Y
P
1
1
B
2
) 
   
1
8
-O
x
id
a
s
e
 
(C
Y
P
1
1
B
2
) 
1
7
-"
 H
y
d
ro
x
y
la
s
e
 
(C
Y
P
1
7
A
1
) 
1
1
!
-H
y
d
ro
x
y
la
s
e
 
(C
Y
P
1
1
B
1
) 
1
7
-!
 H
y
d
ro
x
y
s
te
ro
id
 
d
e
o
x
y
g
e
n
a
s
e
 
5
-"
 R
e
d
u
c
ta
s
e
 
 
78 
  
 
  
 
79 
 
More recently studies have suggested that factors in early life can determine the 
control of aldosterone secretion. A cross-sectional study of 311 older men and women 
of 67-78 years of age, showed that patients with a low birth weight and high blood 
pressure had increased aldosterone levels, with patients with the highest aldosterone 
levels showing a 10mmHg difference in systolic blood pressure compared to those 
with the lower aldosterone levels
211
.  
 
There is growing evidence to suggest that aldosterone may be involved at extrarenal 
sites. Animal and human studies have identified the presence of the CYP11B2 gene 
which codes for aldosterone synthase enzyme, responsible for last step in aldosterone 
biosynthesis and 11!-HSD enzyme, involved in regulating the binding of aldosterone 
to the MR, at various sites including the brain, heart and vascular tissue
212-214
. 
Therefore, it is believed that aldosterone has paracrine actions. We know that high 
levels of aldosterone have deleterious effects on the cardiovascular system and other 
systems (Figure 1.11). In heart failure, high levels of aldosterone are closely associated 
with increased mortality
215
. Therefore, reducing aldosterone levels at a tissue level may 
have other beneficial effects. 
 
Aldosterone induces myocardial fibrosis 
Aldosterone promotes myocardial fibrosis and remodelling which are characteristic of 
left ventricular hypertrophy (LVH) and heart failure. Brilla et al showed that 
aldosterone induced myocardial fibrosis in the hypertrophied left ventricle and non-
hypertrophied right ventricle in rat models, which was prevented by spironolactone 
without significant changes to blood pressure
216
. In human studies, patients with 
chronic heart failure (CHF) and hypertension, showed increased expression of 
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aldosterone synthase which was associated with an increase in myocardial fibrosis and 
LVH
217
. This suggests a role of locally produced aldosterone in the development of 
myocardial fibrosis. Plasma levels of procollagen type III amino peptide (PIIINP) are a 
useful marker of collagen turnover in the myocardium and hence a useful marker for 
myocardial fibrosis. The aldosterone antagonist, spironolactone has shown to reduce 
PIIINP levels in patients with CHF, suggesting that aldosterone promotes myocardial 
collagen formation
218
.  
 
Aldosterone induces vasculopathy 
Aldosterone also promotes vascular fibrosis and induces tissues damage. In rabbit 
models of vascular damage, aldosterone administration enhanced neointimal 
thickening in the iliac artery and aorta. Spironolactone significantly inhibited the 
neointimal thickening, suggesting a role for aldosterone in neointimal proliferation
219
.  
 
It has been shown that aldosterone and Ang II produced tissue damage independently 
of their effects on blood pressure. Rocha et al suggested that aldosterone blockade by 
selective aldosterone blockers or adrenalectomy, significantly reduced the 
development of stroke and development of renal microvascular lesion, in salt-drinking, 
spontaneously hypertensive rats
220
. Importantly, these effects of aldosterone blockers 
occurred without changes in blood pressure. This suggests that aldosterone may play a 
role in vascular lesion development in the brain and kidneys and that theses effects are 
independent to its effects on blood pressure. 
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Aldosterone promotes autonomic imbalance 
Autonomic balance involves the balance between the sympathetic and parasympathetic 
nervous system. Autonomic balance can be measured through baroreflex testing and 
heart rate variability. In a study in patients with CHF, the presence of autonomic 
dysfunction as measured by reduced heart rate variability was associated with 
increased mortality
221
. Aldosterone has shown to increase sympathetic activity and 
reduce parapsympathetic activity. In animal studies, Wang et al showed that 
aldosterone reduced parasympathetic activity by reducing the baroreceptor discharge 
from the carotid sinus and reduced heart rate response
222
. In patients with CHF, 
spironolactone reduced early morning heart rate and improved heart rate variability, 
suggesting spironolactone improves parasympathetic effects
218
. 
 
Aldosterone blockade 
With growing evidence of wider extrarenal effects of aldosterone, finding methods to 
counter these patho-physiological effects has become clinically important. As 
aldosterone is a terminal hormone of the RAAS it would be feasible to suggest that 
pharmacological agents which interrupt this system proximally via ACE inhibitors or 
AT-1 receptor blockers would block aldosterone synthesis. However, recent in-vivo 
studies have shown this not to be the case. In a randomized evaluation of strategies for 
left ventricular dysfunction (RESOLVD) pilot study, patients with congestive heart 
failure were given both an ACE inhibitor and AT-1 receptor blocker
223
. Aldosterone 
levels fell within the first 17 weeks. However, the mean aldosterone levels 
subsequently returned to baseline by 43 weeks. We know that ACE inhibitors block 
the formation of Ang II by inhibiting the conversion of Ang I to Ang II. However, 
despite blocking Ang II, aldosterone levels can still rise in a phenomenon known as 
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‘aldosterone escape’. Therefore, it may be impossible to completely block aldosterone 
inhibiting Ang II through ACE inhibition. This may be because ACE inhibitors 
eventually increase serum potassium levels and potassium is a powerful secretagogue 
for aldosterone release. Aldosterone is stimulated by both Ang II and potassium. 
However, ACE inhibitors only reduce Ang II levels and in fact increase potassium 
levels. The question now is whether another therapy directed at RAAS overactivity, in 
particular aldosterone receptor blockers, can have a greater effect at countering other 
extrarenal effects such as tissue damage. 
 
 
Figure 1.11 – The deleterious effects of aldosterone 
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1.5 Evidence suggesting a role for aldosterone 
blockade in muscle function 
It is possible that aldosterone blockade with spironolactone may well deliver benefits 
in conditions other than heart failure. In particular, aldosterone blockade with 
spironolactone may play a key role at maintaining muscle function and preventing 
physical decline in later life, which is the central focus of this thesis. 
 
Aldosterone blockade reduces myocyte apoptosis 
We know that prolonged activation of the renin-angiotensin-aldosterone system is the 
hallmark for many cardiovascular diseases including hypertension and heart failure, 
where it is believed that cell death may contribute to ventricular damage. 
Catecholamines, Ang II and aldosterone are all capable of causing cardiomyocyte 
death. The loss of cardiomyocytes leads to loss in cardiac structure and function 
resulting in a reduction cardiac reserve capacity
224
.  
 
Experimental studies in Wistar rats have shown that infusion with aldosterone 
increased the risk of both cardiac myocyte apoptosis as well as skeletal myocyte 
apoptosis. In the study, spironolactone was shown to reduce cardiac myocyte apoptosis 
by 90% and reduce skeletal myocyte death of soleus muscle in normotensive rats by 
79%
225
.  
 
The mechanism by which aldosterone induces apoptosis is not yet fully understood. 
However, it has been suggested that the apoptotic effect of Ang II may be due to 
increased production of aldosterone which can up regulate AT-1 receptor 
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expression
226
. As skeletal muscle myocytes are known to express AT-1 receptors, it 
could be speculated that over-activation of the RAAS may contribute to myopathy. 
This demonstrates the potential role of spironolactone in reducing myocyte apoptosis.  
 
We know that myocyte apoptosis occurs in the skeletal muscles of patients with 
chronic heart failure in a phenomenon known as ‘cardiac cachexia’. This in turn can 
lead to muscle wasting, weakness and reduced exercise tolerance in a process similar 
to sarcopenia
227;228
.  The plasma concentration of aldosterone in CHF patients with 
cachexia is three fold greater compared to age-matched non-cachectic patients without 
heart failure
229
. It may be postulated that the aldosterone receptor antagonist 
spironolactone may prevent the adverse effects of aldosterone on skeletal muscle, 
which includes, myocyte apoptosis, muscle wasting, muscle weakness impaired 
exercise tolerance, which are hallmark features in the process of sarcopenia.  
 
Aldosterone blockade effects muscle metabolism 
Aldosterone increases the re-absorption of sodium and chloride from the renal tubules. 
It also increases the excretion of potassium and independently causes loss of 
magnesium from the body by increasing urinary magnesium output. Aldosterone 
receptor blockade with spironolactone may improve muscle contractility by increasing 
skeletal muscle magnesium. It has been well documented that patients on long-term 
diuretic therapy have substantial losses of urinary potassium and magnesium
230
. 
Patients with CHF and arterial hypertension often have electrolyte disturbances. The 
addition of conventional diuretics, including loop and thiazide diuretics can further add 
to these electrolyte disturbances and possibly lead to serious adverse effects including 
cardiac arrhythmias.  
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Magnesium plays an important role at a cellular level and is used in many metabolic 
processes requiring the hydrolysis of phosphate groups. The energy required to 
activate the Na
+
/K
+
 pump on the cell membrane is provided by the hydrolysis of ATP, 
which requires magnesium to act as a co-factor. This process is essential for muscle 
contractile performance. Dyckner et al demonstrated that aldosterone blockade with 
spironolactone, increased both skeletal muscle magnesium and potassium levels, in 
CHF patients already on long-term potassium and magnesium wasting diuretics
230
.  
 
Patients with alcoholic liver cirrhosis have impaired functional capacity as a result in 
loss in muscle strength. This may occur due to a reduction in muscle magnesium and 
muscle potassium which deteriorates with increasing severity of liver disease. Alcohol 
ingestion appears to double renal excretion of magnesium along with secondary 
aldosteronism and poor nutritional intake can lead to further magnesium depletion.  
 
A study by Aagaard and colleagues demonstrated that patients with alcoholic liver 
cirrhosis showed deterioration in muscle strength with a reduction of up to 41% in 
comparison to the control group
231
. The study also showed that there was a significant 
reduction in muscle magnesium and to a lesser extent muscle potassium levels. The 
addition of spironolactone treatment over a two week period increased muscle 
strength, muscle magnesium and contents of Na
+
-K
+
 pumps. Muscle potassium levels 
were not significantly different. This would indicate that improvements in muscle 
strength by spironolactone may be accounted for by its action on increasing muscle 
magnesium. The importance of muscle magnesium on muscle strength was also 
supported in an earlier study by Gullestad and colleagues who demonstrated that the 
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addition of oral magnesium supplementation to the diet of chronic alcoholics 
significantly increased hand grip strength
232
. 
 
It is possible that spironolactone could improve muscle strength and muscle 
contractility by increasing skeletal magnesium levels. It is this rise in magnesium 
levels which is thought to facilitate ATP production in skeletal muscle and thus 
increase contractility in skeletal muscle. Spironolactone may also aid muscle 
contractility by increasing levels of muscle Na
+
-K
+
 pumps.  
 
Aldosterone blockade reduces oxidative stress and improves 
endothelial function 
Nitric oxide (NO) is a free radical synthesised by NO synthetase. Nitric oxide (NO) is 
a multi-functional molecule synthesised from L-arginine by a family of enzymes called 
nitric oxide synthases (NOS) which are found in skeletal muscles but also in the brain 
and vascular endothelium. Recent studies have shown that skeletal muscle is the main 
source of NO
233
. Endogenous NO released from the skeletal muscle modulates skeletal 
muscle function including; regulation of muscle metabolism, muscle contractility and 
regulation of skeletal muscle blood flow
234
. NO is produced at high concentration 
during increased activity to prevent muscle fatigue, however persistent high levels of 
NO may lead to oxidative stress and tissue damage
235
. NO inhibits muscle contractility 
and reduces isometric force, mediated through cyclic guanosine monophosphate 
(cGMP) and targets regulatory proteins. It also inhibits mitochondrial respiration and 
glycolysis, thereby promoting glucose uptake
233
.  
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There are three different isoforms of NOS. Endothelial cell NOS (eNOS), neuronal 
NOS (nNOS) which are present in skeletal muscle and inducible NOS (iNOS) which is 
normally expressed at low levels in skeletal muscle and increased during 
inflammation
236
. The eNOS and nNOS isoforms are involved in regulating skeletal 
muscle contraction, glucose uptake and metablolism
237
. The nNOS isoform is located 
in the sarcolemma of muscle fibres and is expressed at higher levels in fast-twitch 
muscle fibres when compared to slow-twitch muscle fibres. The eNOS is associated 
with mitochondria in mammalian muscle and is found in the endothelium of large 
blood vessels.  
 
There is growing evidence that ageing alters the expression of NOS isoform profile 
with ageing increasing the iNOS/nNOS ratio shifting the function from contractile to 
inflammatory
238
. Studies have shown that an overproduction of NO and iNOS may be 
involved in muscle wasting, inflammatory myopathies and cachexia
239;240
. The 
mechanism is still poorly understood. It has also been suggested that nNOS expression 
in skeletal muscle is reduced during extreme disuse which might suggest that a similar 
process may occur in sedentary or physically disabled older people. Chronic inhibition 
of NOS can result in a 40% reduction in muscle CSA, a 30% loss of muscle mass as 
well as a reduction in walking speed
241
.  
 
The endothelium is responsible for maintaining a balance between vasoconstriction 
and vasodilatation of blood vessels including blood supply to skeletal muscles. If this 
balance is upset endothelial dysfunction occurs, causing damage to the arterial wall. 
Endothelial dysfunction occurs where there is a reduction in NO bioactivity and an 
increase in free radical production. Endothelial function declines with age, due to 
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blunting of vasodilator responses in vessels. Ageing has been associated with a 
reduction in expression of eNOS proteins in feed arteries of the soleus muscle in rats, 
thus reducing endothelial dependent vasodilatation
242
. 
 
Aldosterone may enhance vascular endothelial dysfunction by reducing nitric oxide 
bioactivity. This was demonstrated when healthy human volunteers were infused with 
aldosterone which did not alter blood pressure but did cause endothelial dysfunction. 
This phenomenon was called ‘aldosterone induced vasculopathy’
243
. A similar effect 
might be seen in ageing, hypertension and atherosclerosis where there is inadequate 
NO bioavailability
244
.  
 
Aldosterone may reduce NO bioactivity by increasing nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase, inducing free radical production which 
leads to the degradation of NO. NADPH oxidase is a major determinant of vascular 
tissue redox state which, in turn, is influenced by neuro-hormones such as angiotensin 
II, aldosterone and catecholamines
245
. NADPH oxidase catalyses the reduction of 
oxygen to superoxide anion which, reacts with NO to form reactive NO (peroxynitrite) 
resulting in oxidative stress.  
 
The importance of aldosterone blockade on oxidative stress was demonstrated in a 
rabbit model of dietary hyperlipidaemia which is associated with high levels of 
circulating aldosterone levels. The model showed a significant reduction of NADPH 
oxidase dependent free radical production in the vascular wall as well as improved 
endothelial dependent vasodilatation, when given the selective mineralocorticoid 
antagonist, eplenerone over six weeks
246
. A subsequent experimental study in a rat 
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model of heart failure showed that the addition of spironolactone and ACE inhibition 
reduced NADPH oxidase subunit p22phox levels and improved endothelial function 
more than ACE inhibitors alone
247
. This suggests a potential role of the RAAS in the 
development of structural and functional vascular changes, aldosterone antagonists 
may therefore enhance endothelial function and increase skeletal muscle blood flow 
required during periods of increased physical activity.  
 
In a double-blind placebo-controlled trial, Farqhuarson and Struthers demonstrated that 
aldosterone blockade with spironolactone, improved forearm blood flow by improving 
endothelial function and vascular NO bioactivity, in 10 patients with CHF
248
.  The 
study also showed that spironolactone reduced Ang I but not Ang II mediated 
vasoconstriction despite chronic ACE inhibition. It was suggested that spironolactone 
reduced the vascular response to exogenous Ang I but not Ang II by reducing vascular 
ACE activity, raising the possibility that aldosterone may exert a positive feedback 
effect on vascular ACE. Therefore, aldosterone antagonism may exert extra ACE 
inhibition over and above standard ACE inhibitor therapy.  Both blood pressure and 
degree of heart failure, as measured by the New York Heart Association (NYHA) 
functional class, remained unchanged during the study.  This suggests that the effects 
of spironolactone on endothelial function were not related to its systemic effects. A 
similar improvement in the calf blood flow was also seen in hypertensive patients 
without heart failure who were treated with spironolactone
249
.   
Although some studies have shown partial improvement in endothelial function in 
patients with heart failure, it appears that aldosterone blockade has less of a benefit on 
endothelial function in patients with angina or diabetes mellitus. We know that 
spironolactone is effective in blood pressure control in poorly controlled hypertensive 
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type II diabetic patients. However, it doesn’t appear to improve endothelial function in 
this group of patients
250
. It is speculated that the beneficial effects of blood pressure 
lowering by spironolactone is offset by its tendency to worsen glycaemic control, 
increase Ang II and cortisol levels. 
 
It has been suggested that the age-related decline in endothelial function, associated 
with a decline in vasodilator response, could contribute to impaired muscle blood flow 
and reduced oxygen delivery during exercise. Aldosterone blockade, with 
spironolactone, improves NO bioavailability and endothelial function in patients with 
heart failure. As endothelial dysfunction is common in older people it could be 
speculated that spironolactone may have similar beneficial effects in improving 
endothelial function, skeletal muscle blood flow and thus reduce physical impairment 
in older people.  
 
Aldosterone blockade reduces proinflammatory cytokines 
Inflammation may interfere with endothelial function through the action of 
proinflammatory cytokines by stimulating the release of nitric oxide and endothelium 
derived hyperpolarizing factor.  
 
Tumour necrosis factor alpha (TNF-") plays a key role in the initiation and 
amplification of the inflammatory cascade in many pathological processes including 
muscle decline with old age
251
. TNF-" is produced by the macrophages and T-
lymphocytes and activates other inflammatory cells through the production of 
chemokines, the induction of adhesion molecules in endothelial cells and lymphocytes. 
It also induces the production of other cytokines involved in the inflammation process 
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including interleukins (IL)-", IL-1!, IL-6 and granulocyte-macrophage colony 
stimulating factor (GM-CSF). It has been suggested that TNF-" blocks the activation 
of eNOS by interfering with the phosphorylation and directly degrading eNOS 
messenger RNA (mRNA), thus inhibiting NO release which is essential for 
vasodilatation of blood vessels. TNF-" also stimulates muscle apoptosis and is 
associated with lower muscle mass and strength which accompanies sarcopenia. High 
levels of TNF-" are also associated with impaired exercise tolerance in CHF patients
252
 
 
Studies in normal rats have shown that the addition of 11-deoxycortisone, an 
aldosterone precursor, stimulated central mineralocorticoid receptors and subsequently 
caused a rise in plasma and tissue TNF-"
253
. Blocking the mineralocorticoid receptors 
with spironolactone reduced the release of TNF- ". This may suggest that 
spironolactone may have anti-inflammatory potential which may be beneficial in 
pathological processes including muscle decline in old age. 
 
In a study involving ex-vivo activated human blood leucocytes from patients with 
chronic arthritic diseases using gene expression analyses, the transcription of several 
pro-inflammatory cytokines including TNF- ", interferon-#, GM-CSF and interleukin-
6 were suppressed with spironolactone
254
. Spironolactone also reduced in-vitro 
cytokine production by human peripheral blood mononuclear cells in patients with 
congestive heart failure
255
. These studies have shown an anti-inflammatory effect of 
spironolactone at a transcriptional level. Although both animal and transcriptional 
studies have shown that aldosterone blockade have anti-inflammatory effects there is a 
lack of evidence that this occurs in man.  
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The levels of inflammatory cytokines including TNF-" rise with age and are associated 
with low muscle mass, low muscle strength and reduced exercise tolerance which are 
common features of sarcopenia. Therefore it is possible that aldosterone blockade may 
inhibit these effects.  
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1.6 Evidence suggesting aldosterone blockade 
improves exercise capacity 
Maximal oxygen consumption during peak exercise (VO2) is an objective way of 
measuring exercise tolerance and is an important component of physical function. Peak 
VO2 declines with age
256
. As a result older people function close to their maximal 
effort when carrying out sub-maximal tasks. A reduction in exercise tolerance is 
associated with increased mortality, morbidity and increased future disability
256
. 
 
Modulation of the RAAS can improve exercise tolerance in patients with CHF. Studies 
have shown that ACE inhibitors, when used alone or in combination with Ang II 
receptor blockers, can improve exercise capacity in patients with heart failure
194;228
 and 
also in patients without heart failure
196
. However it is possible that inhibiting other 
neurohormones in the RAAS, such as aldosterone, may have similar effects.  
 
Elevated levels of aldosterone are associated with impaired exercise tolerance in 
patients with CHF
257
. Cicoira and colleagues showed that aldosterone blockade with 
spironolactone, improved left ventricular function in CHF patients already on standard 
heart failure therapy and improved exercise capacity by increasing peak VO2 levels
258
. 
Cicoira also highlighted that improvements in exercise capacity were seen with 
spironolactone over and above the use of ACE inhibitors at baseline. 
 
The syndrome of clinical heart failure, in the absence of left ventricular systolic 
dysfunction and in the absence of cardiac valvular lesions, is known sometimes as 
diastolic heart failure (DHF). DHF commonly occurs in older people with a prevalence 
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of around 5.5% in older people aged 70 years or above in a community dwelling 
population
259
. Previous studies have shown that older patients with diastolic heat 
failure have a reduced exercise tolerance
260
. There is some evidence to suggest that 
patients with DHF have significant activation of the RAAS and that aldosterone may 
play a key role in this pathophysiological process by promoting collagen deposition 
and promote myocardial fibrosis.  In a prospective trial involving 11 women aged 60 
years and above with diastolic heart failure, there was an improvement in exercise 
capacity with a 8.3% increase in peak VO2, improved after taking 25mg of 
spironolactone for 4 months. The study also showed improvements in quality of life 
and diastolic filling paralleled with a reduction in myocardial fibrosis
261
. The study 
showed no change in six-minute walk distance. However, the study sample size was 
small and lacked a control group. 
 
The mechanism underlying these effects of aldosterone blockade on exercise capacity 
is still unclear. It is possible that the effects of spironolactone on exercise capacity may 
be attributable to improved cardiac function, by a reduction in collagen deposition at 
the myocardium, thereby altering left ventricular remodelling and improving left 
ventricular systolic function and cardiac output. However, an effect at a peripheral 
level cannot be ruled out. An earlier study by Cicoira, showed that elevated levels of 
aldosterone were associated with impaired exercise capacity without any changes to 
resting haemodynamics or muscle mass
257
. Spironolactone has been shown to improve 
vascular endothelial function
248
. It may be speculated that improvements in vascular 
endothelial function with spironolactone may promote vasodilatation and muscle blood 
flow during periods of exercise, and possibly improve exercise tolerance, thus 
preventing decline in physical function with age.  
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1.7 Safety profile of spironolactone 
Spironolactone is a mineralocorticoid receptor antagonist which was initially 
developed over 30 years ago. Although its plasma half life is relatively short (1.6 
hours), after oral administration spironolactone is converted in the liver to its active 
metabolites canrenone and canrenoate which have half-lives of between 17-22 hours. 
Spironolactone lacks first pass metabolism and appears to have good oral 
bioavailability of around 90%. When it was initially developed, spironolactone was 
classified as a potassium-sparing diuretic due to its effects on epithelial ion 
transportation. However, spironolactone also has other biological effects. 
 
Spironolactone is efficacious in the treatment of patients with heart failure. It is also 
used to treat resistant hypertension, primary hyperaldosteronism and cirrhosis with 
secondary aldosteronism. Prescription rates for spironolactone have risen in recent 
years following results from the RALES study, which showed the benefits of 
spironolactone on mortality rates in patients with congestive cardiac failure
262
. More 
recently guidelines from the British Hypertension Society, recommended 
spironolactone as a fourth line treatment for hypertension
263
.  
 
Side effects exist with spironolactone use. The pro-gestational and anti-androgen 
effects include gynaecomastia, breast pain, abnormal menstrual cycles and impotence. 
In the RALES study, the incidence of gynaecomastia or breast pain in men was greater 
in those receiving spironolactone compared to those on placebo (10% spironolactone 
versus 1% in placebo group; p<0.01)
262
. Other adverse effects include gastritis or 
gastrointestinal disorders which occurred in up to 2% of patients on spironolactone
264
.  
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One of the most important side effects of spironolactone is an increase in serum 
potassium concentrations. In the RALES study severe hyperkalaemia, defined as 
serum potassium concentration >5.5mmol/L, increased with increasing doses of 
spironolactone from 5% in patients receiving 12.5mg/day to 20% in patients receiving 
50mg of spironolactone per day
262
. In patients with reduced glomerular filtration rates, 
worsening heart failure or dehydration the risk of serious hyperkalaemia whilst taking 
spironolactone is greater. One study showed that more than 25% of patients were 
found to have serious hyperkalaemia (serum potassium >5.2mmol/L). Another study 
found that over 10% of patients treated with a combination of an ACE inhibitor and 
spironolactone were found to have serious hyperkalaemia. Patients who are more 
susceptible to hyperkalaemia appear to be older with a poorer baseline renal function. 
Therefore, long-term monitoring of serum potassium and renal function is required.  
 
Following the outcome of the RALES study, there was an increased use throughout the 
developed world of spironolactone in heart failure patients concurrently treated with 
ACE inhibitors. In a Canadian observational study, the increased use of spironolactone 
in these patients was paralleled with an increase in hospital admissions and subsequent 
deaths from serious hyperkalaemia
265
.  
 
Following this a similar observational study was conducted in the Tayside area. The 
study evaluated prescription rates for spironolactone, rates of hyperkalaemia and renal 
impairment associated with spironolactone. Despite an increase in the prescription of 
spironolactone there was no increase in hyperkalaemia or renal toxicity. In contrast to 
the Canadian study hospital admissions for hyperkalaemia and outpatient 
hyperkalaemia actually fell (9.9 per 100 patients in 1999 to 2.9 per 100 patients in 
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2007) (Figure 1.12)
266
. This shows that spironolactone can be a relatively safe drug if 
patients’ electrolytes and renal function are carefully monitored. Spironolactone is also 
well tolerated in a variety of patients including older people for which this thesis 
focuses on.  
 
Figure 1.12 - Rates of spironolactone prescriptions and associated  
hyperkalaemia (Taken from Wei et al
266
) 
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1.8 Summary 
With a growing ageing population decline in physical function has become a major 
public health issue, as it is associated with disability in later life. Although regular 
exercise has been shown to increase muscle strength and slow functional decline, the 
majority of the older population are either unable or unwilling to contemplate adequate 
exercise participation. Alternative interventions are needed to improve physical 
function in later life. 
 
There is now growing evidence to suggest that blocking the RAAS may help improve 
physical function in frail elderly people
196
. Previous randomised controlled trials have 
shown an improvement in physical function with ACE inhibitors in older people with 
and without heart failure
194;196
. Initially the adverse effects were initially thought to be 
mediated through activation of Ang II. However, it is now speculated that the effects 
of Ang II are mediated downstream via aldosterone.  
 
Recent evidence suggests a possible role for the aldosterone receptor blocker, 
spironolactone, in improving physical function in older people. Firstly spironolactone 
may improve muscle function by: reducing skeletal myocyte loss
225
 and improving 
skeletal muscle contractility
231
. Secondly spironolactone may improve vascular 
endothelial function, enhance skeletal muscle blood flow and inhibit pro-inflammatory 
cytokine production
255
. Finally in a randomised controlled trial, the use of 
spironolactone resulted in improved exercise capacity over and above that achieved 
with standard ACE inhibitor therapy in patients with heart failure due to LV systolic 
impairment
258
. Although this improvement may have occurred due to improved cardiac 
function, it is possible that spironolactone, an inexpensive, widely used medication, 
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may also have direct effects on skeletal muscle. A study was therefore designed to 
evaluate the effect of spironolactone on physical function in functionally impaired 
older people without heart failure.  
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2. METHODS 
2.1 Study Design 
This study was a randomised, double blind parallel group placebo controlled trial. The 
study was approved by Tayside Committee on Medical Research Ethics (reference 
number 08/S1402/34) and was funded by the Chief Scientist Office (CBZ/4/635) as 
shown in Appendix A. This study conformed to the Declaration of Helsinki. The aim of 
the study was to examine whether inhibition of the renin-angiotensin- aldosterone 
system (RAAS) with spironolactone would improve physical function in older people 
without heart failure. 
 
Figure 2.1 shows the inclusion and exclusion criteria used in the study. Participants 
aged 65 years and above were eligible if they had self-reported problems of activities of 
daily living. Self-reported functional dependence was assessed by asking participants 
questions using the Barthel Index which was documented on a screening proforma (see 
Appendix A). The Barthel Index consists of 10 items describing activities of daily living 
and mobility. The 10-items include the need of assistance in each of the following tasks; 
dressing, grooming, feeding, transferring from chair to bed, bathing, walking, toileting, 
climbing stairs as well as the presence or absence of faecal or urinary incontinence. 
Participants were eligible if they were dependent in one or more of the 10 items of the 
Barthel Index. The Barthel Index was initially introduced by Mahoney and Barthel in 
1965 and is now a widely used measure to assess functional status in rehabilitation
267
. It 
was initially developed for the assessment of patients with neuromuscular and 
musculoskeletal disorders. It has subsequently been used to measure functional change 
in rehabilitation of patients who have had a stroke. Now it is widely used for assessing 
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functional status in older people. It has good intrarater reliability (0.95) and good test-
retest reliability (0.89) and has been used to assess treatment outcomes in numerous 
studies
268
.  
Participants with cognitive impairment (MMSE<20/30) were excluded as they are less 
likely to give informed consent. Participants were also excluded if there were 
wheelchair bound or requiring assistance to mobilise, as outcome measures such as six 
minute walk test are designed for ambulant people.  
 
Figure 2.1 – Recruitment criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 Recruitment  
Recruitment criteria 
 
Inclusion criteria 
 
• Aged >65 years old 
 
• Self reported problems with activities of daily living 
 
Exclusion criteria 
 
• A clinical diagnosis of symptomatic heart failure (according to European 
Society of  Cardiology guidelines) 
• Asymptomatic LV systolic or diastolic dysfunction  
• Already taking spironolactone, ACE inhibitors or Angiotensin II receptor 
blockers 
• Previous reported intolerance to spironolactone 
• Hypotension (systolic blood pressure <100mmHg) 
• Cognitive impairment precluding informed consent (MMSE<20/30) 
• Serum creatinine >200umol/L (eGFR<30ml) 
• Serum sodium <130mmol/L 
• Seru  potassium >5.0mmol/L 
• Symptomatic orthostatic hypotension 
• Wheelchair bound 
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2.2 Recruitment 
Participants were recruited through two different methods: 
 
The Scottish Primary Care Research Network (SPCRN) 
Participants were recruited using the East of Scotland node of the Scottish Primary Care 
Research Network (SPCRN) formerly known as Scottish Practices and Professionals 
Involved in Research (SPPIR). The network was established in 2002 to help co-ordinate 
national research activity in primary care. It is funded by the Chief Scientists Office, 
centrally managed by the Scottish School of Primary Care (SSPC) and operationally 
managed at a regional level in Scotland.  It provides an essential link between 
researchers and primary care.  
 
The East of Scotland node of SPCRN comprises of 30 GP practices who are interested 
in being involved in research, across Tayside and Fife across 8 LHCC areas. The co-
ordinator from the East node of SPCRN contacted GP practices within the network by 
post to invite them to be involved in the study. Practices willing to be involved in the 
research project were visited by a SPCRN research officer. Using study eligibility 
criteria and the patient computer data base system within the practice, the research 
officer generated a list of potentially eligible participants. The list was then scrutinized 
by the practice GP to exclude patients who had suffered from a recent illness, recent 
hospitalisation or if they had died shortly after the patient list had been generated. 
 
A letter of invitation along with a Patient Information Leaflet (PIL) (Appendices B and 
C), reply slip and a stamped addressed envelope were sent from the GP to patients who 
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were considered potentially eligible to participate in the study. Only those individuals 
who were interested to know more about the study were asked to reply. Individuals who 
replied were contacted by telephone by LB.  
 
During the telephone screening, a brief but clear outline was given of the purpose of the 
study and details of participant’s involvement within the study. Eligibility was also 
checked by asking individuals date of birth and asking whether they had problems with 
activities of daily living (ADLs). Individuals were encouraged to ask questions at any 
point during the screening.  
 
Medicine for the Elderly services 
Participants were also recruited from the Medicine for the Elderly outpatient services in 
Tayside. The medical records of patients attending the Medicine for the Elderly 
services, located at the Royal Victoria Hospital Dundee or Perth Royal Infirmary, were 
screened for potential eligibility to the study. Patients were either approached at the Day 
Hospital at either the Royal Victoria Hospital or Perth Royal Infirmary in person by LB 
or were posted a study information pack containing a letter of invitation to take part in 
the study, a PIL, reply slip along with a stamped addressed envelope.  
 
All potential participants approached at the Day Hospital were given adequate time to 
study the PIL. Potential participants were contacted by telephone by LB within 7 
working days to determine whether they were willing to participate in the study. 
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Patients attending the Day Hospital for physical rehabilitation were not approached until 
at least 4 weeks had elapsed after they had been discharged from the Day Hospital to 
avoid the risk of physical co-intervention which may introduce confounding variables. 
 
Informed consent 
Verbal consent 
All potential participants gave verbal consent for LB to review their hospital medical 
records to further scrutinize eligibility for the study prior to arranging an appointment 
for baseline screening visit. 
 
Written consent 
All potential participants were given the opportunity to ask questions. All participants 
gave written informed consent at baseline screening visit. (See Appendix D for patient 
consent form).   
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2.3 Clinical assessments  
Clinical assessment was performed at the point of baseline screening for eligibility to 
the study. The assessment comprised of: 
- Past medical history 
- Concomitant medication 
- Use of walking aids (none, 1 or 2 sticks, zimmer frame or triwheel walker) 
- Height (cms) 
- Weight (Kgs) 
- Physical examination 
- Lying / standing blood pressure (mmHg)  
- Echocardiograph 
 
Lying and standing blood pressure  
Blood pressure was measured using a standard automatic sphygmomanometer (A&D 
UA-779), which has been validated according to protocol of the European Society of 
Hypertension on the measurement of ambulatory blood pressure
269
. Participants rested 
in a supine position for 5 minutes before blood pressure was recorded. Measurements 
were recorded in the supine position and then standing after 30 seconds, 2 minutes and 3 
minutes to measure for orthostatic hypotension
270
. Symptoms of dizziness and light 
headedness were noted. 
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Echocardiography 
Echocardiography was performed by LB using the SonoSite® TITAN™ ultrasound 
system at baseline and 20 weeks in order to assess left ventricular (LV) systolic function 
at baseline and whether the participant had developed left ventricular dysfunction 
during the course of the study.  
 
Participants were asked to position themselves in the left lateral position and the couch 
was tilted so that the participant was lying at 30
0
. Images were viewed in the parasternal 
long axis, short axis, 4-chamber and 2-chamber view. A subjective assessment was 
made of left ventricular function to rule out LV systolic dysfunction. If LV systolic 
impairment was detected it was recorded as ‘mild’, ‘moderate’ or severe’ impairment. 
Doppler studies were also used to estimate the pressure gradient across the aortic and 
mitral valves. 
Subjective visual assessment of LV function has good reproducibility compared to other 
methods of echocardiography such as contrast ventriculography
271
. Visual estimation of 
LV systolic ejection fraction has correlated closely and reliably to more formal and time 
consuming methods such as Simpson’s rule and wall motion score index
272
. The 
accuracy of subjective assessment of LV function has also been demonstrated using a 
hand held device in a busy outpatient clinic and was comparable to the accuracy of 
echocardiography using Simpson’s bi-plane method, in patients with at least moderate, 
left ventricular dysfunction
273
. Visual assessment of LV systolic function has also been 
used in frail older patients with multiple co-morbidities
196;274
. 
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2.4 Study visits 
Baseline assessments 
Baseline screening visits were carried out at either the Royal Victoria Day Hospital 
Dundee or Perth Royal Infirmary, depending on where the participants lived. After 
screening for eligibility and clinical assessments, baseline measures were taken for the 
primary outcome, the six minute walk test (6MWT) and secondary outcomes were 
change in; Timed-Get-Up and Go test (TGUG), Incremental Shuttle Walk test (ISWT), 
EuroQuol and Visual Analogue Scale questionnaire (EQ-5D and EQ-VAS), Hospital 
Anxiety and Depression Scale (HADS) and Functional Limitation Profile (FLP). Blood 
tests were also taken to measure serum urea and electrolytes (U+E’s), magnesium, B-
type natriuretic peptide (BNP), aldosterone and random cortisol.  
 
Follow up assessments 
Follow up assessments during the study are shown in Figure 2.2. 
 
Home visits (weeks 2 & 5) 
A follow up clinical assessment was carried out at the participant’s home at 2 and 5 
weeks after randomisation. During these visits safety bloods tests were taken for serum 
urea and electrolytes and serum magnesium to monitor for changes in renal function. 
Sitting blood pressure was also recorded to rule out hypotension. If the 12.5mg 
spironolactone or matching placebo dose was tolerated and renal function remained 
stable after 2 weeks, the dose was up-titrated to 25mg of spironolactone or placebo.  
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Participants with a rise in creatinine >20% of baseline values or serum potassium 
>5.2mmol, remained on the starting dose (spironolactone 12.5mg or placebo). 
Participants had their study medication withdrawn if serology showed a rise in 
creatinine >25% from baseline, serum potassium >5.5mmol, creatinine above 
200µmol/L or their systolic blood pressure <100mmHg. However, participants 
remained in the study and underwent their remaining follow-up visits in order to 
preserve intention-to-treat analysis.  
 
Return visits to Day Hospital (weeks 10 & 20) 
Participants returned to Day Hospital at weeks 10 and 20 for assessment of outcomes 
(6MWT, TGUG, ISWT, EQ-5D and EQ-VAS, FLP, HADS). Blood samples were also 
taken for BNP, aldosterone, cortisol, urea & electrolytes and serum magnesium. All 
assessments were done without reference to baseline values. At 20 weeks 
echocardiography was repeated.  
 
Adverse events 
All adverse events were reported in accordance with the Medicines for Human Use 
(Clinical Trials) Regulations 2004. At each study visit (baseline, 2 weeks, 5 weeks, 10 
weeks and 20 weeks), patients were asked about any adverse events since their last 
study visit, including any hospitalisation, unscheduled GP visits or new disabilities. The 
sponsor was notified if there was a serious adverse event (SAE) or serious adverse 
reaction (SAR) except, if it was a known adverse drug reaction that was set out in the 
Summary of Product Characteristics of spironolactone. 
 
A record was also kept of any changes to a participant’s medication during the study.  
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Figure 2.2 – Flow diagram of study assessments 
 
(U+E = Urea and electrolytes, Mg
2+
 = serum Magnesium) 
 
Screening visit (0 week) 
Clinical examination, echocardiography, consent 
Baseline outcomes measured: 6MWT, TGUG, ISWT, FLP,  
EQ-5D, EQ-VAS, HADS 
Blood samples (U+E, Mg
2+
, BNP, aldosterone & cortisol) 
 
Randomised to 
Spironolactone  
Randomised to 
 Placebo  
Day 1 – given either spironolactone 
12.5 mg or placebo 
Week 2 – Home visit; blood pressure and blood 
samples (serum U+E & Mg
2+
) 
Dose up-titrated to 25 mg Spironolactone or placebo 
Week 5 – Home visit; blood pressure and blood tested 
(serum U+E & Mg
2+
) 
Week 10 – Visit to Day Hospital; blood pressure and 
blood samples (serum U+E and Mg
2+
) outcomes 
measured 
Week 20 – Visit to Day Hospital; blood pressure and 
blood samples (serum U+E, Mg
2+
, BNP, aldosterone 
& cortisol) outcomes measured 
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2.5 Randomisation & medication dosage 
Randomisation 
Participants were given a sequential randomisation number on entry to the study and 
were given the medication with the corresponding randomisation number. 
 
Randomisation of medicine was performed by Tayside Pharmaceuticals, Ninewells 
Hospital, who over-encapsulated the spironolactone and placebo in order to give them 
an identical appearance. The medication bottles were labelled with sequential patient 
numbers. Tayside Pharmaceuticals used a computer generated randomisation number 
table for randomisation. Block randomisation was done in batches of 20 in order to 
ensure equal group numbers between spironolactone and placebo. As randomisation 
was carried out by staff at Tayside Pharmaceuticals ‘allocation concealment’ was 
ensured. 
 
Medication dosage 
Participants were randomised to receive either spironolactone or placebo for the 20 
weeks. The starting dose for medication was 12.5mg of spironolactone or placebo which 
was given on day 1 after screening. If tolerated this dose was then increased after two 
weeks to 25mg of spironolactone or placebo.  
 
The medication was delivered to the participant at home by LB along with instructions 
on how the medication was to be taken. A contact telephone number was given to the 
participant and was also printed on a label on the medication bottle. The participant was 
advised to contact LB or their own General Practitioner if there were any adverse 
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effects. A letter was also sent to the participants GP informing them that the participant 
had commenced the study. A copy of the letter was also filed in the participants’ 
medical records.  
 
Medication adherence 
Participants’ ability to open childproof tops was assessed. Any participant who had 
difficulty in opening a child proof top was given a standard non-childproof bottle top. 
 
Medication compliance was assessed by tablet counting at weeks 2, 10 and 20. The 
number of tablets returned was then documented in the participant’s case report form 
(CRF) and in a drug accountability log, held by the Clinical Trials Pharmacist at 
Ninewells Hospital, Dundee.  
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2.6 Outcome measures 
Primary outcome measure – Six Minute Walk Test 
The primary outcome was the change in the distance walked in the six minute walk test 
(6MWT) from baseline over the twenty week period.  
 
The 6MWT was conducted in a quiet enclosed corridor. The 25 metre course was 
marked at one metre intervals and chairs were placed at each end of the course. The 
participants were instructed to walk from one end of the course to the other for six 
minutes using their usual walking aid if needed. The participants were encouraged to 
exercise to the point of maximum ability but also were advised to rest if necessary.  
Participants only terminated the walk prior to 6 minutes if they experienced severe 
shortness of breath, dizziness, angina, or muscular pain. Standardized encouragement 
was given to every participant every 30 seconds. At the end of the six minutes the 
participants were asked to stop. The total 6MWT distance was recorded to the nearest 
metre. The 6MWT was performed at baseline and then repeated at weeks 10 and 20.  
 
Functional walk tests are exercise tests that measure physical performance or exercise 
capacity as well as measuring the ability to undertake physically demanding activities of 
daily living
275
. They are considered to be an objective way to measure response to 
treatment and are reproducible in an older population compared to treadmill testing and 
cycle ergometry. 
 
In 1968 a 12 minute run test was carried out in 115 healthy male US Air force Officers. 
The test correlated closely with maximal oxygen consumption (VO2) and was therefore 
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a useful measure for physical fitness
276
. This was then modified to a 12 minute indoor 
walk test to disability in patients with chronic bronchitis
277
.  Later the concept of a 
shorter 6MWT was developed in a similar population. It was found that decreasing the 
time to 6 minutes did not significantly reduce the reproducibility of the test. The 6MWT 
was also found to be better tolerated and less exhausting in patients with moderate 
respiratory disease than the 12 minute walk test
278
. 
 
The 6MWT has been widely used in a number of studies to measure functional status in 
patients with COPD, heart failure
279
, peripheral vascular disease
280
, fibromyalgia
281
 and 
in older patients
282
. It has also been used for measuring response to medical 
interventions as well as a predictor for morbidity
283
 and mortality
284
.  
 
The 6MWT has shown to be a validated measure of functional status in older people. 
Compared to other functional walk tests i.e. the self-paced walk test or the shuttle walk 
test, it appears to be better tolerated and more reflective of activities of daily living
285
. 
In frail older patients with heart failure a strong correlation was found between the 
distance walked in 6MWT and quality of life assessment as measured by the Chronic 
Heart Failure Questionnaire (CHQ). The study showed the 6MWT had good test-retest 
reliability with a high intra-class correlation (ICC) of 0.91
286
.  
 
The 6MWT has also shown to be a useful integrated measure of physical activity in a 
community dwelling older population, with a significantly greater increase in distance 
walked for physically active older adults compared to those who are less active 
(p<0.001). It has moderate correlation to other measures of physical function such as 
chair stands (r=0.67) and gait speed (r=0.73)
287
. Recent studies have shown the 6MWT 
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to be a useful measure of frailty in older adults with heart failure, frailer patients with 
lower endurance walked a shorter 6MWT distance. The study not only highlighted the 
use of the 6MWT in identifying frailer patients but it also showed the 6MWT to be a 
useful measure at identifying individuals with intermediate frailty who maybe in 
transition to becoming frail
288
. This demonstrates the utility of the test in predicting 
disability and, more importantly, at identifying patient’s risk of future frailty who may 
benefit from interventions aimed to prevent decline to frailty.  
 
Although the 6MWT has been widely used to measure physical performance in older 
people few studies have established the ‘normal ranges’ for 6MWT distance in normal 
healthy elders. In one study 700 metres was suggested to be a ‘normal’ 6MWT distance 
in healthy adults but did not specify whether this was applicable for all ages
289
. A 
subsequent study in healthy older subjects showed that adults aged 50-85 years had a 
mean 6MWT distance of 631+93 metres. However, the study showed considerable 
variability in the 6MWT distance ranging from 383-820 metres
290
. Multiple regression 
analysis showed that age, height, sex and weight were independent contributors of the 
6MWT distance and gave 66% of the variability. Therefore, it is difficult to fix the 
normal range of the 6MWT in older adults without taking these factors into 
consideration. In 2002 the American Thoracic Society published guidelines for the 
6MWT and stated that the distance covered in the 6MWT was influenced by a number 
of factors (Figure 2.3)
291
.  
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Figure 2.3 - Factors reducing the 6MWT distance (taken from 2002 ATS 
guidelines
291
) 
 
 
 
 
 
 
 
 
Factors reducing the 6MWT distance  
 
Short stature 
Older age 
Increased body weight 
Female sex 
Cognitive impairment 
A shorter corridor (more turns) 
Chronic diseases –   pulmonary disease (COPD, asthma, cystic fibrosis) 
- cardiovascular disease (angina, MI, CHF, PVD) 
- musculoskeletal disorders (arthritis, muscle wasting) 
 
Factors increasing 6MWT distance 
Taller height  
Male sex 
High motivation 
Medication for disabling disease taken immediately prior to test 
Oxygen supplementation for exercise induced hypoxaemia 
Patients who previously performed the test 
. 
 
 
 
  
 
116 
 
In a large prospective Cardiovascular Health Study healthy older adults aged >68 years 
were asked to perform the 6MWT along with other performance based measurements 
(gait speed, chair stands and grip strength). The study showed a shorter 6MWT distance 
corresponded to older age, higher weight, larger waist circumference and weaker hand 
grip strength
282
. Factors of psychological health such as depression were also found to 
correlate to 6MWT distance
292
. 
 
A negative correlation was also found between 6MWT distance and age (r=-0.42) with 
subjects aged >75 years covering a shorter distance than those <65 years (p<0.05) 
regardless of their health status
293
. Other studies have shown that in healthy older people 
there was a moderate degree of negative correlation between a cognitive function and 
6MWT distance. Encouragement can also influence the 6MWT distance. Guyatt et al 
showed that standardised encouragement at regular intervals compared to no 
encouragement produced a change in 6MWT distance of 20 metres which was 
statistically significant
294
. The layout of the test also plays an important role in the 
6MWT distance. Individuals who performed the test in a considerably shorter corridor 
had a much lower mean 6MWT distance
295
. This is probably due to the fact that 
participants lost additional time on turning more frequently on a shorter course. This 
demonstrates the need for the same protocol on repeated assessments. 
 
As well as being a useful measure of function and predicting disability the 6MWT has 
also shown to provide valuable information regarding prognosis. Studies involving 
patients with left ventricular dysfunction have shown that individuals who walked <300 
metres in the 6MWT had a 3.7-fold increased risk of dying than those who walked 
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longer distances
284
. A 6MWT distance of <300 metres also predicted an increase in 
severity of heart failure as well as a reduction in ability to perform daily activities
296
.  
 
The 6MWT has good correlation with other objective measures of aerobic exercise 
capacity such as oxygen uptake at peak exercise (V02) previously determined through 
treadmill of cycle ergometry tests. Compared to these established measures of aerobic 
exercise capacity the 6MWT was much easier to perform and more closely related to 
daily physical activities in older people
275;279
. Many old, frail and severely limited 
patients were physically unable to perform standard maximal cycle ergometry or 
treadmill exercise testing. Individuals with walking aids were simply unable to 
participate. Therefore, this excludes a large proportion of people with functional 
impairment. Consequently, the 6MWT is a more inclusive method of measuring aerobic 
exercise capacity for older people. Although the endurance shuttle walk test appears to 
be a promising measure of maximal aerobic exercise capacity in patients with chronic 
respiratory problems
297
, it lacks validity in older people.  
 
Hand grip strength has shown to be a direct measure of skeletal muscle and disability
298
. 
In the Cardiovascular Health Study cohort grip strength remained a strong independent 
predictor of the 6MWT distance in both older men and women. The study showed the 
mean grip strength for women was 23Kg and 40Kg for men in the 65-69 year age 
groups. A 10Kg increment in grip strength in both men and women equated to an 
increase of 14m in the distance walked in 6MWT
282
. This demonstrates the use of the 
6MWT as measure of muscle strength. 
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The repetition of a test within a short period of time can produce a learning effect.  
The 6MWT tends to increase with test repetition for example, a learning effect occurs 
due to test familiarisation. The magnitude of this learning effect appears to vary widely 
between studies from 4.5% to 33% of the initial distance walked
32
. Results vary 
between the first and second repeated walk test but appeared to plateau from the third 
repeat onwards, in the absence of any change in clinical state. In a study involving 50 
healthy, young volunteers the initial learning effect was maintained during a 2-month 
period and that only a modest learning effect occurred with repeated testing (practice 
walks) on follow-up visits
299
. It is not known if results taken from studies involving 
young healthy volunteers could be extrapolated for older people recruited to clinical 
trials. For the purposes of this thesis it was decided that the use of practice testing would 
be difficult to perform in older people with mobility problems and functional 
impairment.  
  
The 6MWT has been shown to be responsive and so is a good measure of change in 
functional status over time. It has also been used to measure the treatment effect for 
both pharmacological and non-pharmacological interventions. A randomized controlled 
trial which recruited older people in retirement villages, involved intervention of a 12-
month exercise program, combining strengthening and aerobic exercises. The 
intervention group maintained their level of physical function and showed a reduction in 
falls by 22%. However, the control group showed a mean reduction in the 6MWT 
distance of 15 metres
300
. In a 6 month single-blinded randomized controlled trial older 
people with self-reported functional impairment were assigned to a home based 
progressive strength, balance and general physical activity group with encouragement. 
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The intervention group showed an 18 metres improvement in 6MWT compared to the 
control group.
301
   
 
In a double-blind randomized controlled trial the 6MWT was used to assess the 
response to treatment with perindopril in older patients with left ventricular systolic 
dysfunction. The treatment group of the study showed a 37.1m significant improvement 
in 6MWT distance compared to placebo (-0.3m) (p<0.01) after a 10-week period
194
. A 
similar response to perindopril was also seen in a group of older functionally impaired 
non-heart failure patients. Results from the study showed a mean difference in 6MWT 
of 31.4m (95% CI 10.8m to 51.9m, p<0.003) between the treatment and placebo 
group
196
. For the purposes of this thesis a change in 6MWT distance of 30 metres was 
considered a clinically relevant change in an older population with functional 
impairment. 
 
The current literature supports the use of the 6MWT as a sub-maximal exercise test to 
measure physical performance in a variety of people including those who suffer with 
chronic heart failure, COPD and in older adults. The 6MWT may also be suitable in 
elderly patients who find it difficult to complete adequate treadmill exercise tests
279;286
. 
It is a simple, inexpensive performance based measure. It is particularly useful in 
assessing functional status in older people as it reflects the capacity to perform daily 
activities. More importantly, it is a reproducible test which is responsive to change and 
has been useful to assess response to intervention in an older population
302
. 
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Secondary outcomes  
The “Timed-Get-Up and Go” test (TGUG) 
The “Timed-Get-Up and Go” test (TGUG) is a useful tool for measuring clinically 
significant changes in the mobility of frail patients. It is a useful measure of explosive 
muscle power rather than endurance. The time taken to complete the task reflects the 
degree of functional impairment.  
 
The participant was instructed to sit with their back against the upright of a standard 
armchair (measuring 46 cms from the seat to the ground), with their arms rested on the 
arms of the chair. At the word ‘Go’ the participant got up from the chair, using their 
hands to push up from arms of the chair, walked a 3 metre distance at their normal pace, 
turned around and returned to their seated position. Participants were encouraged to use 
their own walking aids if required. The total time taken to perform the task was 
recorded in seconds.  
 
The original ‘Get-Up and Go’ test was developed by Mathias and colleagues in 1986 to 
measure balance. The performance was graded on a 5-point scale but was found to be 
too subjective. In order to overcome this subjectivity, the test was modified to include 
the time taken to perform the task (TGUG)
303
. It is a simple short test to assess basic 
mobility especially in patients with functional impairment
304
.  
 
The test incorporates everyday movements and is a useful method in assessing global 
functional status. Firstly, rising from a sitting to standing position requires both strength 
and technique. Secondly, walking a path of 3 metres requires both acceleration and 
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deceleration as a participant prepares to turn. Finally, turning around to sit requires 
balance and orientation while adapting body position to the chair.  
 
It also correlates with other established assessment tools for activities of daily living 
such as the Barthel Index (r=-0.78)
304
. In clinical practice, the TGUG test has been 
widely used in the functional assessment of older people and has shown to be a reliable 
method for predicting falls risk 
305;306
. It is currently recommended by both the 
American and British Geriatrics Societies as a screening tool for falls risk
307
. 
The TGUG test has shown to have good test-retest reliability in several specific 
populations including community dwelling older adults
304;306
, people with Parkinson 
disease
308
, older people with unilateral limb amputation
309
 and those with chronic stroke 
disease
310
. However the test has been reported to have poorer test-retest reliability in 
patients with cognitive impairment
311
. In a cohort of cognitively impaired (mean MMSE 
18.7+5.6) participants in a residential home, the addition of verbal cuing during TGUG 
performance, helped patients overcome any variability of the test
312
. This demonstrates 
the potential versatility of the test in older people with cognitive impairment.  
 
As well as being a useful tool for predicting risk of falls, balance problems and risk of 
future institutionalisation
313
. The TGUG test is a simple, inexpensive assessment tool 
for physical function
314
. The TGUG test has shown good validity when compared to 
other measures of functional status such as gait speed, Berg balance test and Barthel 
index
304
.  
 
The more time taken to perform the test indicates a greater degree of functional 
impairment
304
. A wide range of TGUG scores have been reported in studies involving 
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older people. In a study involving both community-dwelling and institutionalised older 
patients, individuals who performed the TGUG test >12 seconds were more likely to 
suffer from mobility impairment
315
. However, 9% of the institutionalised patients were 
unable to perform the test
306
. The TGUG is a sensitive and specific measure of 
predicting older adults who are at risk of falling. In one study 30 community dwelling 
frail elders who took >14 seconds to perform the TGUG were found to be at greater risk 
of falling but this result was not verified in other studies mainly due to the fact that 
individuals in the study did not have any underlying pathology
316
. In contrast, older 
adults with underlying neurological pathology required >30 seconds to complete the 
task. They were more dependent in activities of daily living and scored lower in the 
Berg Balance Scale
304
. In a large meta-analysis of 21 studies reporting TGUG scores in 
older healthy people, individuals who performed the task in <20 seconds were more 
likely to be independent in transfers and the time taken to perform the task increased 
with age
317
. 
 
The TGUG is a useful tool for assessing response to intervention such as response to 
change in rehabilitation programs in elderly orthopaedic patients
318
. It has also been 
used to assess changes in functional status in pharmacological interventions
196
. 
 
The TGUG test is a simple, inexpensive test which is a useful measure basic mobility in 
older people and can be easily used in a clinical setting. For the purposes of this thesis 
the TGUG test was used to assess changes in functional status with spironolactone 
intervention in older people. 
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The Incremental Shuttle walk test (ISWT) 
The ISWT is a set paced walking test which is a useful method to measure exercise 
capacity. The ISWT was carried out along a quiet corridor free from obstacles and 
distractions. Participants walked up and down a 10 metre course (1 shuttle). The course 
was identified by two cones inset 0.5 metre from either end of the 10 metre course 
(Figure 2.4). The speed at which the participant walked was dictated by a pre-recorded 
audio signal (bleep), played on a compact disc (CD) player. Standardised instructions 
for the test were pre-recorded on the CD and played to each participant prior to 
commencing the test. Participants were advised to stand at the first cone in preparation 
for the beginning of the test. 
The start of the test was indicated on the CD by a triple bleep. Thereafter the CD 
emitted a single bleep at regular intervals, at which point the participant should have 
turned around the cone in an attempt to walk back down the course. The speed of the 
walking increased in increments (0.17m/s) every minute. Participants were advised to 
continue to walk until they could not maintain the speed or until they became too tired, 
breathless or experienced any discomfort. The total number of completed shuttles and 
total time taken in seconds to complete the task were recorded.  
 
Field walking tests are often used as objective measures of disability. However, the 
majority are self-paced tests when patients may not reach their maximal aerobic 
exercise capacity, depending on how the test is conducted. Self-paced tests are also 
influenced by factors such as encouragement and are therefore more difficult to 
standardise
294
.  
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The ISWT was initially developed by Singh and colleagues in 1992 in order to 
overcome some of the shortfalls of self-paced walk tests. Singh demonstrated that as an 
externally paced field walk test, the ISWT incorporated an incremental and progressive 
structure, stressing patients to a symptom limited maximal performance
297
. An 
association was also noted in the ISWT between a graded increase in work rate and an 
increase in cardiovascular response as shown with an increase in heart rate, which was 
not observed in previous self-paced walk tests. Unlike treadmill or cycle ergometry, this 
test is based on walking, a familiar daily activity. As a standardised test the ISWT also 
allows valid comparisons both within and between participants. Participants who 
complete the same distance in the ISWT experience the same work rate compared to 
self-paced walk tests.  
 
Figure 2.4 – Diagram of the shuttle walk test (Singh et al)
297
 
 
  10 metres     
 
 
 
 
The original study by Singh and colleagues demonstrated a close association between 
distances covered in the ISWT and the distance covered in the 6MWT. They also noted 
that the ISWT was reproducible after only one practice 
297
. Compared to the 6MWT in 
patients with COPD, the shuttle walk test appears to be more responsive to change in 
clinical condition
319
. However, the main disadvantage of the ISWT is its lack of validity 
in older people.  
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Reproducibility of the ISWT has been demonstrated not only in patients with COPD but 
also in other patient populations. In 10 patients with dual chamber pacemakers the 
ISWT was repeated on three separate occasions. There was no significant difference in 
the duration of the tests or relative cardiac outputs generated during the three 
consecutive tests
320
. This suggests no learning effect and good reproducibility. The 
study also showed good responsiveness to change with exercise duration and peak 
relative cardiac output significantly different between patients with different dual 
chamber pace makers.  
 
Performance during the ISWT has shown to be predictive of maximum oxygen uptake 
(VO2) during laboratory treadmill testing in patients with ischaemic heart disease
321
, 
heart failure
322
 or chronic pulmonary disorders
323
.  
 
The ISWT is a useful measure of response to treatment in pulmonary rehabilitation 
programs in patients with COPD. Singh et al showed minimal clinically significant 
improvement for the ISWT in patients with COPD following pulmonary rehabilitation 
of 47.5 metres. Patients were also able to distinguish an additional benefit if the change 
in distance walked was greater than 78.7 metres
324
. This demonstrates the use of the 
ISWT as a measure of exercise capacity following intervention. However, it is 
worthwhile noting that the distance walked in older people is more likely to be limited 
by lower limb tiredness or weakness rather than breathlessness; therefore results may 
vary in an older population. 
  
The feasibility and reproducibility of the ISWT was analysed in a cohort of 82 non-
institutionalised older adults (>70 years), 50 of whom suffered from COPD. The study 
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showed that, although there was no association between the ISWT distance and age, the 
test was feasible and reproducible in an older population. 88% of subjects with COPD 
completed the test. A correlation was found between the ISWT distance walked and 
measures of activities of daily living (r=0.51)
325
. This could suggest a potential role of 
the ISWT as a marker for disability in this age group. However, results from this study 
should be treated with caution as most subjects were selected on the basis they were 
independent in self-care therefore, further research is required for its use in frail older 
people. More importantly the study showed that the ISWT was sensitive to change 
following the administration of bronchodilators. This demonstrates that the ISWT could 
be an appropriate measure of response to change in interventional studies in an older 
population.  
 
Peripheral muscle mass and strength has been shown to relate to both laboratory cycling 
and self-paced walk tests. More recently, a study involving 85 stable COPD patients 
(mean age= 67 years, SD= 9 years) showed that improvement in ISWT performance 
from strength training closely correlated with quadriceps muscle strength but not muscle 
mass
326
. This suggests that muscle strength is important for maximal exercise capacity 
as measured by the ISWT and that muscle quality, but not muscle quantity, has a greater 
influence on peak walking performance. It was also suggested that reductions in 
exercise capacity in COPD patients may have reciprocal effects on muscle strength 
because of muscle disease and de-conditioning. Therefore, a similar effect might also be 
expected in older sedentary adults. It also demonstrates the potential use of the ISWT in 
interventional studies as it measures not only functional but physiological changes in 
individuals.  
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The endurance shuttle walk test (ESWT) was later developed in order to measure a 
person’s ability to sustain sub-maximal exercise which is necessary to perform daily 
activities
327
. In a cohort of patients with COPD the ESWT showed good repeatability 
after one practice walk and was more sensitive to change following a 7 week pulmonary 
rehabilitation program that the ISWT. However, the test does require patients to do a 
warm-up practice test for approximately 100 seconds prior to the start of the test. This 
addition could potentially exclude very frail or disabled patients from being assessed
327
. 
Therefore, for the purposes of this study it was concluded that the ESWT would be an 
inappropriate test to perform as it would exclude very frail or functionally impaired 
older people whom we are seeking to assess.  
 
In this thesis the ISWT was used to measure change in maximal exercise capacity (peak 
VO2) with spironolactone in older people. It has good reproducibility and is responsive 
to change. It can also be carried out in a smaller space compared to 6MWT making it 
useful in a busy clinical setting.  
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EuroQol questionnaire (EQ–5D and Visual Analogue Scale) 
The aim of the EuroQol questionnaire is to assess overall wellbeing and health status in 
addition to functional status by using a single index score. It is divided into two sections 
the EuroQol EQ-5D utility section and the Visual Analogue Scale (EQ-VAS). The EQ-
5D is a brief questionnaire with a self-reported description section, consisting of five 
domains (mobility, self care, usual activities, pain and discomfort and anxiety and 
depression). Each of the domains has a three point categorical response scale associated 
with ‘health today’. Participants are asked to choose one of the three descriptive 
statements regarding their health from level 1 “no problem”, level 2 “some or moderate 
problems” or level 3 “extreme problems”.  All 5 responses are recorded as a 5-digit 
code giving a total of 243 possible EuroQuol health states. This was then converted to a 
single index quality of life score ranging from 0 to 1.  
 
The EQ-VAS incorporates a 20 cm vertical visual scale which represents overall health 
status. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable 
health state). Participants were asked to draw a line from the box marked ‘your own 
health state today’ to the appropriate point along the visual analogue scale to indicate 
where they thought their overall health state was on that day.  
 
The EQ-5D questionnaire was first developed in 1987 by the EuroQuol group as a 
standardised non-disease-specific instrument for assessing quality of life
328
. It was 
purposefully developed as a generic measure of quality of life that has been extensively 
validated as a reliable test in both the general population and in other patient groups
328-
330
.  The advantage of using this quality of life questionnaire is that as well as being 
simple to use, it can be used to compare measures of quality of life between people of 
  
 
129 
 
different age groups and between people with different co-morbidities. These 
comparators are particularly relevant to an older population. 
With only five domains to address it is considered to be simple to complete especially in 
an elderly population. The EQ-5D has been widely used as a measure of health status in 
older people and has been demonstrated to be both valid and reliable in measuring 
health status. In particular, it has been useful in assessing patients in which a substantial 
change in health status is expected, such as in patients following surgical repair of hip 
fracture. Consequently, it is a valuable tool when assessing response to intervention
331
.  
Other studies found that both EQ-5D and EQ-VAS are sensitive to self-reported 
changes in disease severity in chronic diseases, such as rheumatoid arthritis or multiple 
sclerosis
330;332
. There has been conflicting evidence for the use of the EQ-5D and EQ-
VAS in measuring health status. In patients with ankylosing spondolytis the EQ-VAS 
was found to be more responsive to change than the EQ-5D
333
. In a further study 
involving a cohort of patients with inflammatory bowel disease, the EQ-VAS was more 
responsive than EQ-5D in measuring deterioration in health. However, EQ-5D was 
more responsive to improvement in health state in patients with active disease
334
 while 
in patients with Parkinson’s disease the EQ-5D closely correlated with disease severity 
than the EQ-VAS
335
. There is now evidence to suggest that EQ-5D more closely 
correlates to functional impairment than EQ-VAS
330;336
. The EQ-5D also correlates well 
to people’s perception of their disabilities (Barthel Index, Health Assessment 
Questionnaires and Modified Rankin Scale). In this case EQ-5D appears to be a valid 
tool for assessing health related quality of life and in particular impairment in mobility, 
while EQ-VAS is therefore a useful in measuring overall health and wellbeing. This 
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makes the EuroQuol questionnaire a useful measure for both functional impairment and 
a measure of overall health status in our study involving older people.  
 
Functional Limitation Profile (FLP) 
The Functional Limitation Profile (FLP) is a useful tool in measuring health status by 
assessing the impact of illness on daily activities and behaviour. 
The FLP is a UK modified version of the Sickness Impact Profile (SIP) used to assess 
health status in individuals with both acute and chronic illnesses
337
. The FLP is regarded 
as a good measure of functional status when assessing functional impairment covering a 
minimum to maximum degree of functional impairment while being sensitive to small 
changes within the range of limitation
338
.  
 
The FLP covers 136 items grouped into 13 different categories. Each category relates to 
a different aspect of daily functioning: Physical (ambulation, mobility, body care, and 
movement) social (social interaction, communication, emotional behaviour, alertness 
and behaviour) and the remaining categories (eating, work, sleep, household 
management and recreation and pastimes). Each item is given a score which reflected 
the relative severity of limitation associated with the item. For the 13 different 
categories there is a list of 136 statements. The participants are instructed to listen to 
each of the descriptions as read by the supervisor. They are required to choose only one 
statement per category that best describes them emotionally, physically and socially on 
that day. Each description within the category is weighted on a scoring system going 
from severe impairment to less severe impairments physically, emotionally or socially. 
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If the participant is unable to choose a suitable description it was documented as no 
response. Once all 13 categories are completed scores are added and two sub-scores 
were given for physical domain (total score = 454) and psychosocial domain (total score 
= 567). All domains are then added together to give a grand total score (total score = 
1652). The higher the score, the more functionally impaired the individual. 
 
The aim of the FLP/SIP is to assess the impact of illness on behaviour
339
. The items in 
the profile cover three major aspects of health as recommended by the World Health 
Organization including physical, mental and social. Developers of the SIP / FLP 
conceptualized illness as “changes in behaviour associated with carrying out an 
individual’s activities of daily living”
337
. It is intended to provide a measure of health 
status in individuals and populations with chronic and acute illness and to measure 
illness-related functional limitation, while remaining sensitive to change. 
In the original study involving the development of the SIP, a weak correlation between 
category score indicated minimal overlap between categories so recognising each 
category as an important entity of the whole instrument. Bergner et al also reported 
consistently high test-retest reliabilities for the overall SIP score
340
. The SIP correlates 
closely with other generic measures of health status such as the Short Form 
Questionnaire (SF-36) in physical, emotional and overall functioning in elderly male 
veterans
341
. The Nottingham Health Profile (NHP) is another commonly used measure 
of health-related behaviour. Although the NHP has shown sensitivity to change between 
different types of patient groups and is responsive to major treatment effects such as 
heart transplant and coronary bypass surgery there is insufficient evidence for its 
responsiveness to less dramatic interventions. Unlike the NHP, the SIP is more 
responsive to treatment effects in interventional studies and is acceptable to complete, 
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with little evidence to suggest problems with compliance in an older population
342
.The 
main disadvantage of the questionnaire is primarily the length of time it takes to 
complete which, on averages takes between 20-40 minutes.  Some researchers have 
suggested that the SIP/FLP should be shortened by deleting items which are not 
considered relevant to their specific population. There is debate whether this will 
jeopardise the validity of the category as well as the overall score. Although abbreviated 
versions have been used in patients with rheumatoid arthritis and nursing home patients 
there is a lack of evidence to suggest their use in a wider older population
343
. 
 
The SIP has shown to be a useful measure of physical functioning and has been used in 
interventional studies to monitor change in functional state. In one study endurance 
exercise training improved exercise capacity as well as improving quality of life and 
functional state, in a cohort of older women with heart failure suggesting a correlation 
between exercise capacity and functional state as measured by in the physical category 
of SIP/FLP
344
. In a longitudinal study involving patients with rheumatoid arthritis, 
changes in the physical domain of the SIP corresponded more closely to changes in 
patients’ clinical findings than changes in the psycho-social domain of the profile
345
. 
 
Overall the SIP/FLP is a valid and reliable measure of general as well as functional 
status. It also demonstrated good correlation to other functional status measures and is 
acceptable to use in an older population
346
. This makes the FLP a useful measure of 
baseline health status. In this thesis we will also use the FLP to monitor functional state 
in response to intervention with spironolactone in an older population. 
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The Hospital Anxiety and Depression Scale (HADS) 
The HADS is a self report scaling system of fourteen items on a 4-point scale (range 0-
3). It is divided into an anxiety sub-scale (HADS-A) and a depression sub-scale 
(HADS-D). Each sub-scale incorporates seven of the total fourteen items intermingled 
in the questionnaire. Each of the 14 items related to symptoms of anxiety or depression. 
The participant is then instructed to choose only one of four answers rated on the 4-
point scale, in relation to their general mood over the preceding month. After all 14 
items are completed a total score for each sub-scale is calculated form the total of its 
respective 7 items (total of each sub-scale range 0-21). 
The HADS was initially developed as a screening tool for identifying and quantifying 
severity in patients with anxiety and depression. However, it was later felt that as a 
diagnostic tool it failed to incorporate some of the somatic symptoms of depression. The 
lack of measurement of somatic symptoms proves useful as a measure of psychological 
status as it excludes the influence of chronic disease on physical state.  
 
Epidemiological studies have shown that both anxiety and depression are prevalent in 
an elderly population with up to 12% of the community dwelling elderly population in 
Europe suffering from depression and up 27% in older institutionalised patients
347;348
. 
The prevalence of anxiety disorders in community dwelling older people has been 
estimated to be 15%
349
. Depression can also contribute to a decline in health state and is 
a poor prognostic indicator in many chronic diseases such as diabetes mellitus
350
, renal 
failure
351
, and heart failure
352
. 
 
Depression is a strong predictor of mortality as well as deterioration in functional state. 
Patients with depressive symptoms had an 82% higher risk of either functional decline 
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or death
353
. Older people with persistently elevated depressive symptoms experience a 
steep functional decline when compared to non-depressed or temporarily depressed 
older people
354
. Anxiety has also been associated with worse exercise performance in 
patients with emphysema
355
. When assessing changes in functional state it is therefore 
important to measure symptoms of anxiety and depression.  
 
The HADS provides a valid and reliable screening tool for depression and anxiety. It 
has been suggested that there are two cut-off sub-scale scores for detecting anxiety or 
depression 8 to 10 = borderline cases requiring follow up assessment while, valid cases 
requiring further management score >11
356
.   
 
The HADS questionnaire correlates well with other questionnaires for anxiety and 
depression such as the Beck Depression Inventory (BDI)
357
 and the State Trait anxiety 
score (STAI)
358
.  In a systematic review of 747 papers that used HADS scale, the 
sensitivity and specificity of HADS-A and HADS-D range from 0.7 to 0.9 with a 
threshold of each subscale >8.  
 
Most other rating scales for anxiety and depression were developed for use in 
psychiatric populations and invariably included somatic symptoms. The Hamilton 
Depression scale is one of the most popular scales for detecting depression. However, it 
contains a number of items which relate to somatic symptoms of depression. In older 
people there is often an overlap between the somatic symptoms of anxiety and 
depression and symptoms of chronic disease. It could therefore be speculated that 
depression could be overestimated in an older population using these scales. The 
Geriatric Depression Scale (GDS) has been developed for use in older adults and has the 
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advantage of avoiding the use of somatic symptoms. However, the validity of the GDS 
appears to be dependent on the degree of cognitive impairment, as subjects with 
cognitive impairment were more likely to be unable to complete the questionnaire
359
. In 
contrast, HADS has shown good validity to screen depressive symptoms in older people 
in comparison to GDS
359
. The lack of measurement of somatic symptoms in the 
questionnaire avoids an overlap between physical and psychological health. The simple 
structure of the HADS has also made it a useful screening tool for depression in patients 
with intellectual disabilities
360
.  
 
Anxiety and depression have been shown to have a negative effect on quality of life in 
older people
361
. With a growing number of clinical trials involving an older research 
population, the prevalence of anxiety and depression in this age group could impact on 
clinical outcomes of randomized controlled trials. As part of a study to determine the 
cost benefits of influenza vaccine in fit, healthy older people aged 65-74 years of age, 
the participant’s symptoms of anxiety and depression were monitored using HADS, 
quality of life measured by the EQ-5D and functional ability was measured by the 
Barthel Index. The study showed that although the prevalence of anxiety and depression 
was low for this age group, individuals with anxiety or depression (HADS>8) were 
more likely to suffer from perceived systemic side effects after influenza vaccination
361
. 
The EQ-5D quality of life score and the Barthel Index were also significantly reduced in 
patients with both anxiety and depression. Therefore, when measuring outcomes such as 
quality of life and functional ability in older people care must be taken to ensure that 
anxiety and depression does not affect results more than the intervention.  
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HADS is a useful tool for measuring psychological status in older people and has been 
widely used in clinical settings. For the purpose of this thesis the HADS questionnaire 
was chosen as a measure of psychological state in older people. 
 
Other Measures 
Urea and electrolytes including serum magnesium 
A 3mL sample of venous blood was taken from each participant in a gold vacutainer for 
analysis of renal function (serum sodium, potassium, urea and creatinine) and serum 
magnesium levels. Samples were delivered to the Biochemistry Department at 
Ninewells Hospital, Dundee. Samples were taken at weeks 0, 2,5,10 and 20 to monitor 
changes in renal function with spironolactone treatment. Results of urea and 
electrolytes, including serum magnesium, were checked by LB the following day and 
results were recorded. Serum magnesium was measured to monitor changes in the 
RAAS. As well as increasing sodium re-absorption from the distal and collecting 
tubules, aldosterone also promotes excretion of magnesium and potassium from the 
body. Magnesium is involved in muscle ATP production which facilitates muscle 
contractility and function. In this thesis, serum magnesium was measured to assess 
changes in the RAAS and to asses if there was a relationship between serum magnesium 
and functional state in older people without heart failure. 
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Plasma Aldosterone 
Venous blood samples for aldosterone were taken at baseline and 20 weeks to measure 
changes in the RAAS. A 5 ml sample of venous blood was taken in a green Lithium 
heparin vacutainer. The sample was kept on ice and then centrifuged as soon as possible 
for 10 minutes at 3000rpm at 4
0
C. Plasma was extracted from the centrifuged sample 
and placed in 1ml sample tube with a minimum requirement of 0.5 mls. The sample was 
then transferred to a -20
0
C freezer and stored until the last participant has completed 
their final visit, at which point the samples were assayed. At the end of the study, 
Aldosterone was measured using the ALDOCTK-2 kit (DiaSorin Inc, US). 
 
Aldosterone is a key regulatory hormone for electrolytes. It binds to mineralocorticoid 
receptors (MR) within the epithelial cells of the distal convoluted tubules of the kidney 
nephron, promoting sodium re-absorption and potassium excretion and binds to MRs in 
the non-epithelial cells (e.g. heart, blood vessels and brain). Spironolactone acts as a 
competitive antagonist, blocking the binding of aldosterone to the MR and interferes 
with sodium/potassium exchange, reducing urinary potassium excretion and increasing 
serum potassium levels. Spironolactone has shown to produce a sustained increase in 
plasma aldosterone, consistent with inhibition of the negative regulatory feedback of 
RAAS. However the increase in plasma aldosterone does not overcome the effects of 
spironolactone. 
 
In this thesis plasma aldosterone was chosen to monitor the inhibition of the RAAS with 
spironolactone and whether there was a relation between aldosterone blockade and 
physical function in older people without heart failure.  
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Plasma B-type Natriuretic peptide (BNP) 
A 7ml sample of venous blood was taken in a purple vacutainer containing potassium 
EDTA. The sample was kept on ice and then centrifuged as soon as possible for 10 
minutes at 3000rpm at 4
0
C. A 2ml aliquot of plasma was extracted and placed in a 5ml 
sample bottle. The sample was then transferred to a -70
0
C freezer and stored until the 
last participant has completed their final visit at which point the samples were assayed. 
At the end of the study the BNP was assayed with the Bachem radioimmune assay kit 
(Bachem, Peninsula Laboratories, Inc, US). 
 
Atrial natriuretic peptide (ANP) is synthesised in the atrium and is released in response 
to atrial stretch. This peptide plays an important part in sodium and water homeostasis.  
ANP is also involved in cardiovascular function where it is elevated in congestive 
cardiac failure
362
. In contrast, BNP is released from the cardiac ventricles. Levels are 
significantly elevated in overload states such as congestive cardiac failure. BNP 
correlates better than ANP to severity of congestive cardiac failure as well as mortality 
in patients with chronic congestive heart failure
363
. 
 
Natriuretic peptides have a range of physiological actions including induction of 
natriuesis and diuresis, vasodilatation, inhibition of cardiac remodelling, inhibition of 
sympathetic outflow and inhibition of RAAS
362
. 
 
More recently, elevated BNP levels have been associated with a wide range of other 
cardiovascular diseases including atrial fibrillation
364
, left ventricular hypertrophy
194
 
and coronary heart disease
365
.  
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Plasma BNP levels rise with age. In a cohort of subjects aged 55-64 years plasma BNP 
levels were 26+2 pg/ml. This level increased to 31+2 pg/ml and 64+6 pg/ml in subjects 
aged 65-74 years and >75 years respectively
366
. In a group of functionally impaired 
older people an elevated plasma BNP level was strongly associated with all-cause and 
cardiovascular mortality even without a prior cardiovascular event
367
. 
 
Studies have shown a correlation between BNP and functional capacity as measured by 
the New York Heart Association (NYHA) classification and exercise tolerance 
(measured by 6MWT). An increasing level of plasma BNP has been associated with a 
worse performance in the 6MWT
368
. Elevated BNP levels have been associated with 
impairment in maximum exercise performance (V02) and also differentiated between 
chronic heart failure patients with moderately and severely impaired exercise 
performance
369
. Individuals with a raised plasma BNP level are more likely to be 
limited in daily physical activities
370
. It is suggested that BNP should be used as a 
surrogate bio-marker to assess functional capacity in patients with heart failure. Patients 
with chronic COPD tend to have a rise in plasma BNP due to increased right-sided 
myocardial stress as a result of pulmonary hypertension. This rise in plasma BNP 
significantly correlated to a rise in one-year mortality in COPD patients with normal 
systolic function
371
. 
 
BNP may have a role in assessing efficacy in pharmacological interventions as well as 
associated changes in functional status in patients with heart failure, either through an 
improvement in exercise tolerance or functional status by improvement in NYHA 
class
372
. A correlation has been shown between improvement in exercise duration and a 
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fall in plasma BNP via ACE inhibition
373
. The correlation between BNP levels and 
exercise tolerance with ACE inhibition was shown to be dose related
374
. It could be 
suggested that similar effects may be seen with other heart failure therapies such as 
spironolactone and angiotensin II receptor blockers.  
 
In this thesis, BNP levels were measured to assess the relationship between BNP and 
physical function and whether the use of spironolactone would reduce BNP levels in 
older people without heart failure. 
 
Plasma cortisol 
A 5 ml sample of venous blood was taken in a green Lithium heparin vacutainer. The 
sample was kept on ice and then centrifuged as soon as possible for 10 minutes at 3000 
rpm at 4
0
C. Plasma was extracted from the centrifuged sample and placed in 1ml 
sample tube with a minimum plasma volume of 20 uL required for analysis . The 
sample was then transferred to a -20
0
C freezer and stored until the last participant has 
completed their final visit, at which point the samples were assayed. At the end of the 
study plasma cortisol levels were analysed measured using a radioimmunoassay 
(supplied by Diasorin, UK) and the inter-assay coefficients of variance were 8.6%.  
The actions of cortisol are mainly triggered through the glucocorticoid receptors in the 
tissues; however cortisol has a similar affinity for the MR as aldosterone. Levels of 
glucocorticoids are around 100 times higher than mineralocorticoids in the circulation. 
To allow the selective mineralocorticoid action the enzyme 11-! HSD exists in the 
mineralocorticoid target tissues and catalyses the deactivation of glucocorticoids.  
  
 
141 
 
Basal cortisol levels increase with age. Cortisol is known to cause inhibit the synthesis 
of muscle proteins
375
 and conditions of hypercortisolism are associated with muscle 
weakness and atrophy. More recently Peeters et al found a negative association between 
high cortisol levels and physical performance in older women
376
. Studies have shown 
that mineralocorticoid antagonism with spironolactone, can lead to a negative feedback 
on the hypothalamic-pituitary axis (HPA), resulting in a subsequent rise in ACTH and 
cortisol. In this thesis plasma cortisol levels were measured to evaluate the relationship 
between cortisol levels and physical function in older people and to assess the effects of 
spironolactone on the HPA axis.  
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2.7 Power and sample size calculation 
The minimum clinically important difference in distance walked in 6MWT is 30 
metres
286
. Based on results from a previous study in our department involving 
functionally impaired older people without heart failure, the anticipated mean 6MWT 
distance was 300 metres, with a standard deviation for change in 6MWT distance of 50 
metres
196
. 
 
A power calculation estimated that a sample size of 88 participants (44 participants per 
group) was predicted to have 80% power to detect a 30 metre difference in the distance 
walked in the 6MWT between groups at p=0.05 significance level, using a two-sided 
test.  
 
Trials involving older people will inevitably have people who drop out due to either 
illness or death. A previous study in this target population in our department showed a 
drop out rate of 27% at 20 weeks
196
. In anticipation of a drop out rate of 27% a 
projected sample size of 120 participants was required in order to yield 44 completing 
participants per group.  
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2.8 Data entry and management 
Data from study visits were recorded for each participant on a CRF by LB. Other data 
recorded included log sheets for concomitant medication, adverse events and serious 
adverse events.  
 
Data entry and management were performed independently by the Robertson Centre for 
Biostatistics (RCB) at the University of Glasgow. The centre is part of UK Clinical 
Research Network (UKCRN) registered Glasgow Clinical Trials Unit. All RCB studies 
are managed to the highest possible standards in accordance with the International 
Conference on Harmonisation good clinical practice guidelines. The RCB has extensive 
experience of managing data in the context of privacy and data protection legislation, 
including the Data Protection Act of 1998 and the European Union Data Protection 
Directive 95/46/EC. As a result, extensive data security systems and procedures are in 
place including firewall protected networking facilities and secure data transfer 
protocols. It is audited every six months by the British Standards in Industry and has 
also been subject to rigorous external audits from Medicine and Healthcare Products 
Regulatory Authorities (MHRA). 
 
For this study, RCB was involved in CRF design, data processing (data entry and 
verification) and data management (including data querying and validation). In addition, 
RCB provided a system for reporting serious adverse events to Pharmacovigilance and 
to other authorities such as MHRA when relevant.  
 
All completed CRF’s were checked by LB, and sent to RCB by courier. All entered data 
was then transferred back to LB on Microsoft Excel comma separated variable files. 
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Data was then transferred from Microsoft Excel database to Statistical Package for 
Social Sciences (SPSS) software version 18.0 for statistical sub-group analysis.  
 
2.9 Statistical Analysis 
Data were entered onto a database by RCB and analysed using SAS statistical package, 
(version 9.2). Analyses were performed only after all data were entered and the database 
had been locked. The allocation of treatment code was obtained (as group A or B) from 
Tayside Pharmaceuticals after the database had been locked. Analyses of the primary 
and secondary outcomes were performed prior to breaking the treatment codes. 
Subgroup analyses were performed by LB using SPSS statistical package (version 
18.0), after treatment codes were broken.  
 
Using intention-to-treat analysis, differences between treatment groups for outcome 
measures were assessed using Student’s t-test. Analyses of covariance (ANCOVA) 
models were used to compare the change in outcomes across the treatment groups at 10 
and 20 weeks. To compensate for effect of regression to the mean, the change in 
outcome measures from baseline were analysed using ANCOVA models, using baseline 
outcome measures and age as covariates. As a safeguard against any data missing at 
random, analysis of the primary outcome was performed using multiple imputation.  
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3. RESULTS 
3.1 Recruitment 
Participants were recruited from the Medicine for the Elderly services in NHS Tayside 
and from 6 GP practices within Primary care, using the East of Scotland node of the 
Scottish Primary Care Research Network (SPCRN). Recruitment took place over an 18 
month period from December 2008 and June 2010.  
 
A total of 3398 potential participants (2626 from Primary Care and 772 from Medicine 
for the Elderly) had a preliminary screening assessment of eligibility. Initial screening 
was carried out by checking the hospital medical case notes of those attending the 
Medicine for the Elderly services or by checking the electronic patient database of those 
from Primary Care. Of these 571/3398 (17%) from Medicine for the Elderly were found 
to be ineligible. The remaining 2827 were contacted by letter, of these 2626 letters were 
sent to older people in Primary Care and 201 letters were sent to older people attending 
the Medicine for the Elderly services. From the total number of people who were 
contacted by letter 87% (2460/2827) failed to reply. A higher proportion of older people 
attending the Medicine for the Elderly service failed to reply (185/201) compared to 
those in Primary Care (2275/2626). 
 
All 367 potential participants (351 from Primary Care and 16 from Medicine for the 
Elderly service) who replied were contacted by telephone and screened further to assess 
eligibility. Of these, 130 participants were invited to attend a detailed screening visit at 
either the Royal Victoria Hospital in Dundee or Perth Royal Infirmary from which 120 
participants were recruited to the study. Figure 3.1 shows the flow of participants 
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through the study and the reasons for failing the hospital screening visit. The majority of 
participants recruited were from Primary Care (106/120) and only 12% (14/120) were 
recruited from the Medicine for the Elderly services.  
 
Despite using the GP practice electronic patient database to exclude potential 
participants already taking medications that would affect the renin-angiotensin-
aldosterone system, 7% (26/351) of those from Primary Care were found to be already 
taking either an ACE inhibitor or Angiotensin receptor antagonist. A further 1% (4/351) 
was already taking spironolactone. Those who were found to be already taking either an 
ACE inhibitor of Angiotensin receptor antagonist, came from the same GP practice, 
where the Practice Manager carried out the database search instead of the SPCRN 
research co-coordinator. Of the 4 individuals who were prescribed spironolactone, 3/4 
had recently started on the tablet by their GP for newly diagnosed heart failure and 1/4 
was prescribed the drug at a hospital outpatient clinic but the GP had not been made 
aware of the change in medication.   
 
Almost half (180/351) of the people who replied from Primary Care did not meet 
inclusion criteria on telephone screening as they reported no problems with activities of 
daily living. As the electronic patient databases used in Primary Care do not hold 
information regarding patients’ functional state, letters were sent to people in Primary 
Care with a wide range of physical abilities. Their baseline functional state was 
established only after telephone screening. In contrast, patients who attended the 
Medicine for the Elderly services usually had a full functional assessment carried out 
which was documented in their hospital case notes.  Table 3.1 summarises the reasons 
for people not meeting the inclusion criteria.  
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Assessed for eligibility (n= 3398) 
Primary Care (n=2626) 
Medicine for Elderly (n=772) 
Figure 3.1. CONSORT Diagram 
 
Invited to screening 
visit  
(n=130) 
Letters sent 
(n=2827) 
Excluded (n=571) 
Inclusion criteria 
not met 
Withdrawal (n=1) 
Adverse event, skin rash  
Telephone screening  
(n=367) 
Randomised 
(n=120) 
Allocated to placebo  
(n=60) 
Allocated to spironolactone 
(n=60) 
Completed 10 weeks 
(n=57) 
 
Completed 20 weeks 
(n=57) 
Completed 10 weeks 
(n=56) 
Completed 20 weeks 
(n=55) 
Failed screening (n=10) 
 eGFR <30ml/min (n=2) 
 SBP <100mmHg (n=1) 
 No ADL problems (n=3) 
 On ACE inhibitor (n=2) 
 Refused to participate 
 (n=2) 
 
No reply (n=2460) 
 
Excluded (n=237) 
Inclusion criteria 
not met 
Withdrawals (n=3) 
Declined to continue (n=2) 
Adverse event, 
hyponatraemia (n=1) 
Withdrawals (n=4) 
Declined to continue (n=3) 
Adverse event,  
septic arthritis (n=1) 
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Table 3.1 Reasons for participants not meeting study inclusion criteria  
Reasons for non-
eligibility 
Medicine for the 
Elderly Services 
(n=571) 
Primary Care 
 
(n=237) 
Overall number 
 
(n=808) 
On ACE inhibitor or 
ARB 
 
158 (27.8%) 26 (10.9%) 184 (22.7%) 
On spironolactone 
 
32    (5.6%) 4    (1.7%) 36   (4.5%) 
MMSE < 15 
 
57   (10.0%) 0 57   (7.1%) 
eGFR < 30ml/min 
 
42   (5.2%) 6    (2.5%) 48   (5.9%) 
Presence of  LV 
systolic dysfunction 
 
85   (11.9%) 4    (1.7%) 89 (11.0%) 
Previous history of 
orthostatic hypotension 
 
46   (8.1%) 5     (2.1%) 51   (6.3%) 
Nursing Home resident 
 
37   (6.4%) 0 37   (4.6%) 
Wheelchair bound 
 
28   (4.9%) 2     (0.8%) 30   (3.7%) 
In another trial 
 
4     (0.7%) 0 4      (0.5%) 
No problems with 
activities of daily living 
 
72   (12.6%) 180 (75.9%) 252 (31.2%) 
Intolerance to 
spironolactone 
 
5     (0.9%) 0 5    (0.6%) 
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3.2 Baseline characteristics  
Of the 120 patients randomised 54% (65/120) were male. Participants had a mean (SD) 
age of 75 years (6) with 27% aged 80 years or over. Sixty five percent (90/120) were 
prescribed >4 medications with 13% (16/120) prescribed >10 medications. Although 
19% (23/120) of participants were diagnosed with COPD only 35% (8/23) were 
prescribed regular inhaled steroids. This may suggest that participants with COPD were 
either well controlled or were diagnosed with COPD but were not symptomatic. Table 
3.2 shows baseline characteristics of the participants.  
 
Participants were generally well matched between treatment groups. Of the participants 
in the spironolactone group 37% (22/60) required a walking aid compared to 23% 
(14/60) in the placebo group. A significant proportion of participants in the 
spironolactone group were found to have Parkinson’s disease (6/60) compared to the 
placebo group (1/60) (p=0.05). For all other co-morbidities the participants within each 
of the two treatment groups were well matched.  
 
The mean baseline systolic blood pressure was 149mmHg (SD 20) and 65% (79/120) of 
participants had a baseline systolic blood pressure of >140mmHg of which only 9% 
(7/79) were already prescribed antihypertensive therapy. Participants in the 
spironolactone group were found to have a slightly higher systolic and diastolic blood 
pressure at baseline, with a between group mean difference of 4 (95% CI -3 to 12) 
mmHg and 3 (95% CI -1 to 7) mmHg respectively. However, this was not statistically 
significant. 
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Overall, the baseline renal function was particularly good for this cohort of patients with 
a mean eGFR of 88 ml/min (SD 17). Participants in the spironolactone and placebo 
groups were well matched for baseline renal function and serum magnesium. Baseline 
data for aldosterone and B-type natriuretic peptide hormone level (BNP) were skewed 
and between group differences were analysed using Mann Whitney tests.  
 
Aldosterone levels were 25% higher in the placebo group compared to the 
spironolactone group at baseline (p=0.04). In the placebo group 48% (29/60) had 
baseline aldosterone levels of >100 pg/ml compared to 37% (22/60) in the 
spironolactone group (p=0.18). Of the participants in the placebo group with a baseline 
aldosterone >100 pg/ml, 34% (10/29) were known to have hypertension compared to 
9% (2/22) of participants in the spironolactone group (p=0.03). Two of the participants 
in the placebo group with aldosterone levels >100 pg/ml (328.9 pg/mL, 251.6 pg/mL) 
were taking 2 or more antihypertensive medications for resistant hypertension which 
could account for the significant difference in aldosterone between groups at baseline. 
When these individuals were excluded from analysis the difference between the groups 
in baseline aldosterone levels was not significant (p=0.13).  
 
The overall median BNP was 24.6 (IQR 27.9) pg/ml. Patients over 80 years had a 
median BNP of 31.9 (IQR 44.9) pg/ml. The median baseline BNP value was similar to 
values found in other studies involving older people without heart failure
377
. The 
median BNP in males was slightly higher than in females (26.1 pg/ml vs. 22.2 pg/ml) 
although not statistically significant (p=0.50).  
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Table 3.2 Baseline characteristics of participants randomised to spironolactone or 
placebo. 
 Spironolactone 
(n=60) 
Placebo 
(n=60) 
P 
Mean age (yrs) (SD) 75.1 (5.6) 74.2 (6.5) 0.43 
Male sex 31 (52.5%) 34 (56.7%) 0.65 
Weight (Kg) 78.2 (14.0) 77.0 (18.7) 0.69 
Height (cms) 168 (7) 165 (10) 0.15 
MMSE† 29 (2) 29 (2) 0.67 
Walking aid 
None 
1 stick 
2 sticks 
Zimmer frame 
Triwheel walker 
 
37 (62.7%) 
17 (28.8%) 
2 (3.4%) 
2 (3.4%) 
1 (1.7%) 
 
46 (76.7%) 
11 (18.3%) 
1 (1.7%) 
0 
2 (3.3%) 
 
0.10 
0.18 
0.18 
0.15 
0.57 
Past Medical History 
Hypertension 
Ischaemic Heart Disease 
Peripheral Vascular Disease 
Myocardial Infarction 
Diabetes Mellitus 
COPD 
Stroke / TIA 
Parkinson’s Disease 
Osteoarthritis 
 
19 (32.2%) 
8 (13.6%) 
3 (5.1%) 
2 (3.4%) 
5 (8.5%) 
10 (16.9%) 
5 (8.5%) 
6 (10.2%) 
24 (40.7%) 
 
16 (26.7%) 
7 (11.6%) 
2 (3.3%) 
1 (1.7%) 
7 (11.7%) 
13 (21.7%) 
4 (6.7%) 
1 (1.7%) 
30 (50.0%) 
 
0.50 
0.76 
0.63 
0.55 
0.56 
0.52 
0.71 
0.05 
0.31 
SIMD decile  
1-3 
4-6 
7-10 
SIMD (Median, IQR) 
 
20 (33.9%) 
19 (32.2%) 
20 (33.9%) 
5 (4) 
 
22 (36.7%) 
14 (23.3%) 
24 (40.0%) 
6 (5) 
 
0.86 
0.31 
0.42 
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Drug History 
Loop diuretics 
Thiazide diuretics 
Aspirin 
Statins 
Calcium channel blockers 
Beta blockers 
Bronchodilators 
Inhaled steroids 
Total no. of medications (median, 
IQR) 
 
3 (5%) 
8 (13.3%) 
17 (28.3%) 
15 (25.0%) 
10 (16.7%) 
3 (5.0%) 
3 (5.0%) 
4 (2.7%) 
5 (3) 
 
3 (5%) 
11 (18.3%) 
18 (30.0%) 
9 (15.0%) 
6 (10.0%) 
5 (8.3%) 
5 (8.3%) 
4 (2.7%) 
5 (3) 
 
1.00 
0.43 
0.71 
0.17 
0.30 
0.53 
0.53 
1.00 
0.97 
Systolic BP (mmHg)  
Diastolic BP (mmHg) 
152 (22) 
83 (9) 
147 (18) 
80 (10) 
0.27 
0.06 
Blood results 
Potassium (mmol/L) 
Sodium (mmol/L) 
Urea (mmol/L) 
Creatinine (umol/L) 
eGFR (ml/min) [MDRD formula] 
Magnesium (mmol/L) 
BNP (pg/ml)† 
Aldosterone (pg/ml)† 
 
4.3 (0.4) 
140.1 (2.9) 
5.9 (1.5) 
73.0 (15.2) 
88.4 (17.5) 
0.88 (0.1) 
24.8 (26.8) 
84 (67) 
 
4.4 (0.4) 
140.1 (3.0) 
6.2 (1.7) 
72.7 (13.9) 
87.2 (15.8) 
0.87 (0.1) 
24.5 (26.7) 
105 (94) 
 
0.27 
0.97 
0.07 
0.82 
0.72 
0.93 
0.30 
0.04 
 
(Table 3.2 Continued) 
 
Except where mentioned, values are mean (SD).  
†Data displayed as median (interquartile range). 
Student’s t-test for continuous variables and Pearson’s chi squared for discrete 
variables. Data analysed using Mann-Whitney tests for non-parametric variables. 
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The majority of participants were recruited from Primary Care compared to the 
Medicine for the Elderly services (88% vs. 12% respectively). Table 3.3 shows the 
baseline characteristics in each group. Participants were well matched for age, sex, 
weight, co-morbidities and blood tests at baseline. However, 71% (10/14) of 
participants recruited from the Medicine for the Elderly department required a walking 
aid, compared to 25% (26/106) of those recruited from Primary Care (p<0.01). 
Participants from the Medicine for the Elderly department had a greater total number of 
medications and a lower mean systolic and diastolic blood pressure at baseline 
compared to those from Primary Care. Although there was a significant difference in 
cognitive function between groups this may not be of clinical relevance. The groups 
were well matched for baseline renal function. 
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Table 3.3 – Baseline characteristics of participants recruited from the Medicine for 
the Elderly services and participants recruited from Primary Care. 
 Participants 
recruited 
from 
Medicine for 
the Elderly 
(n=14) 
Participants 
recruited from 
Primary Care   
 
(n=106) 
P value 
Age  
 
77.2 (5.6) 74.3 (6.0) 0.12 
Male (%) 
 
9/14 (64) 56/106 (77) 0.14 
Weight (Kg) 
 
73.2 (10.9) 78.1 (16.9) 0.33 
Walking aids (%) 
 
10/14 (71) 26/106 (25) <0.01 
Past Medical History (%) 
 
Hypertension 
Ischaemic Heart Disease 
Peripheral vascular disease 
 
 
Diabetes Mellitus 
 
Parkinson’s Disease 
 
Osteoarthritis 
 
 
4/14 (29) 
 
2/14 (14) 
 
0/14 (0) 
 
2/14 (14) 
 
5/14 (36) 
 
2/14 (14) 
 
 
32/106 (30) 
 
13/106 (13) 
 
5/106 (5) 
 
10/106 (9) 
 
2/106 (2) 
 
37/106 (35) 
 
 
 
0.79 
 
0.65 
 
0.45 
 
0.42 
 
0.45 
 
0.32 
Total number of medications 7 (3) 5 (3) 0.03 
MMSE† 
 
 
27 (5) 
 
29 (2) 
 
0.01 
Baseline blood pressure 
 
- Systolic BP (mmHg) 
- Diastolic BP(mmHg) 
 
 
137.9 (23.2) 
 
75.8 (8.3) 
 
 
 
150.9 (19.1) 
 
82.4 (9.8) 
 
 
0.03 
 
0.03 
 
Blood Results 
 
- Sodium (mmol/L) 
- Potassium (mmol/L) 
- Urea (mmol/L) 
 
 
 
139.7 (3.3) 
 
4.38 (0.37) 
 
5.8 (1.5) 
 
 
 
 
140.1 (2.9) 
 
4.37 (0.37) 
 
6.1 (1.6) 
 
 
 
 
0.61 
 
0.92 
 
0.61 
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- Creatinine (umol/L) 
- Magnesium(mmol/L)  
- Aldosterone (pg/ml)† 
- BNP (pg/ml)† 
-  
68.5 (16.1) 
 
0.86 (0.1) 
 
74.7 (50.2) 
 
28 (64) 
73.5 (14.3) 
 
0.89 (0.1) 
 
101.1 (83.6) 
 
24 (24) 
0.86 
 
0.87 
 
0.02 
 
0.22 
 
Except where mentioned, values are mean (SD).  
†Data displayed as median (interquartile range). 
Student’s t-test for continuous variables and Pearson’s chi squared for discrete 
variables. Data analysed using Mann-Whitney tests for non-parametric variables. 
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3.3 Outcome measures 
Differences between the two groups for both the primary and secondary outcomes were 
analysed using Student t-test. Repeated measure regression models were used to 
compare the two groups after 10 weeks and 20 weeks for both the primary and 
secondary outcomes. Although most of the main outcome measures were well matched 
at baseline, several of the secondary outcomes including the EuroQol (EQ-5D) and the 
Hospital Anxiety and Depression Scale, HADS-D score showed differences between the 
spironolactone and placebo group. As a result analyses were also carried out adjusting 
for baseline measures and age to try to reduce the effect of regression to the mean.  
 
Baseline outcome measures 
The groups were well matched for baseline 6MWT distance, TGUG and distance 
walked in ISWT as shown in Table 3.4. The spironolactone group had a marginally 
higher HADS-D score with a mean between group difference of 1.0 (95% CI 0.05 to 
2.0) compared to the placebo group. The EuroQol EQ-5D utility score at baseline was 
0.08 (95% CI 0.01 to 0.15) lower in the spironolactone group relative to the placebo 
group but this was not significant (p=0.07).  
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Table 3.4 – Mean baseline outcome measures of participants in the spironolactone 
and placebo groups. 
 Spironolactone 
 
Mean (SD) 
Placebo 
 
Mean (SD) 
P value 
 
Baseline 6MWT distance 
(metres) 
 
336 (120) 
 
345 (102) 
 
0.74 
Baseline ISWT distance 
(metres) 
 
220 (131) 241 (139) 0.99 
Baseline Timed-Get-Up and 
Go (seconds) 
 
13.1 (6.2) 13.5 (5.1) 0.69 
Baseline Hospital Anxiety and 
Depressions Scale 
questionnaire 
HADS-A score 
 
4.2 (3.4) 4.7 (3.4) 0.87 
Baseline Hospital Anxiety and 
Depression Scale 
questionnaire 
HADS-D score 
 
4.8 (3) 3.8 (2.5) 0.06 
Baseline EuroQol EQ-5D 
utility 
 
0.59 (0.2) 0.67 (0.2) 0.07 
Baseline EuroQol EQ-VAS 
(%) 
 
72.7 (16.7) 72.4 (15.3) 0.91 
Baseline Functional limitation 
Profile (FLP) total score 
 
807 (198) 773 (180) 0.34 
 
Data presented as mean (SD) unless stated otherwise. 
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Table 3.5 shows a comparison of the baseline outcome measures in those recruited from 
Primary Care compared to those recruited from Medicine for the Elderly department. 
Results show that participants recruited from the Medicine for the Elderly department 
were more functionally impaired at baseline compared to those recruited from Primary 
Care as shown by a higher FLP score. Participants recruited from Medicine for the 
Elderly walked a shorter 6MWT distance than those from Primary Care at baseline, with 
a between group difference of -137 (95% CI -210 to -65) metres which was significant 
(p<0.001). Medicine for the Elderly participants took 9.3 seconds longer to perform the 
TGUG and walked a shorter ISWT distance, with a between group difference of -134 
(95% CI -233 to -35), (p<0.001) metres compared to the Primary Care participants. 
They also had a higher baseline HADS-D score than Primary Care participants 
indicating the presence of depressive symptoms.  
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Table 3.5 – A comparison of the baseline outcome measures of those recruited 
from Medicine for the Elderly compared to those recruited from Primary Care. 
 
 Medicine for the 
Elderly 
(n=14) 
Mean (SD) 
Primary Care 
 
(n=106) 
Mean (SD) 
P value 
 
Baseline 6MWT distance 
(metres) 
 
218 (112) 
 
356 (103) 
 
<0.01 
Baseline ISWT distance 
(metres) 
 
 
110 (131) 
 
244 (129) 
 
<0.01 
Baseline Timed-Get-Up and 
Go (seconds) 
 
 
21.7 (10) 
 
12.4 (4.1) 
 
<0.01 
Baseline Hospital Anxiety and 
Depressions Scale 
questionnaire 
HADS-A score 
 
4.8 (4) 
 
4.4 (3) 
 
0.69 
Baseline Hospital Anxiety and 
Depression Scale 
questionnaire 
HADS-D score 
 
5.9 (2.2) 
 
4.1 (2.8) 
 
0.03 
Baseline EuroQol EQ-5D 
utility 
 
 
0.55 (0.22) 
 
0.64 (0.19) 
 
0.14 
Baseline EuroQol EQ-VAS 
(%) 
 
 
69.6 (15.3) 
 
72.7 (16) 
 
0.53 
Baseline Functional limitation 
Profile (FLP) total score 
 
 
933 (191) 
 
775 (184) 
 
<0.01 
 
Data presented as mean (SD) unless stated otherwise. 
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Primary outcome – Change in six minute walk distance 
The mean change in the 6MWT distance in the spironolactone group increased by 9.1% 
(30.5 metres) compared to 9.8% (33.7metres) in the placebo group at 20 weeks 
(p=0.71). However, the observed difference in 6MWT distance was -3.2 metres (95% 
CI -28.9 to 22.5) in the spironolactone compared to placebo group at 20 weeks which 
was not significant (p=0.81) (see Figure 3.2). Nor was there a significant difference 
between groups in distance walked at 10 weeks (Table 3.6). 
 
Of those in the placebo group 73% (40/55) walked further compared to 65% (38/58) in 
the spironolactone group at 20 weeks. Fifty five percent (15/27) of participants aged 
>80 walked further after 20 weeks. The changes in 6MWT distance at 10 weeks and 20 
weeks were analysed by using different models for adjustment, as shown in Table 3.7. 
Data were analysed adjusting for baseline 6MWT distance and age as covariates in 
order to reduce any effect of regression to the mean. After adjusting for these covariates 
the change in 6MWT distance in the spironolactone group was 3.7 metres (95% CI -
28.6 to 21.2) lower compared to placebo at 20 weeks but this was non-significant.  
 
In order to preserve valid statistical inference any missing values which were missing at 
random were also analysed as a complete data set using multiple imputation. Despite 
analysing the data set for missing values using the multiple imputation method, there 
was no significant change in the 6MWT distance between groups at 10 weeks and 20 
weeks. 
 
Baseline 6MWT distance has a wide standard deviation this was due to the wide 
variation in baseline physical function in the study cohort. The 6MWT distance at 
  
 
161 
 
baseline correlated to functional state at baseline, measured by the Functional 
Limitation Profile (FLP) questionnaire. A lower 6MWT distance correlated to an 
increase in FLP total score (Pearson’s r=-0.46, p<0.01). However there was no 
correlation between the change in 6MWT distance and change in FLP at 20 weeks 
(Pearson’s r= -0.13, p=0.17).  
 
In order to assess whether the variation in participants’ baseline physical function  
influenced the primary outcome analyses were also performed by dividing participants 
into two groups; those who walked a distance greater than the median 6MWT distance 
(367 metres) and those who walked less than the median 6MWT distance at baseline 
(Figure 3.3). In those with a baseline distance greater than the median value the mean 
change in distance in the spironolactone group at 20 weeks was 44.3 metres (95%CI 
11.6 to 76.9) compared to a change of 35.2 metres (95% CI 3.7 to 66.7), (p=0.68) in the 
placebo group. In those with a baseline distance less than the median value the mean 
change in distance from baseline in the spironolactone group at 20 weeks was 18.1 
metres (95% CI 0.8 to 35.4) compared to 32.1 metres (95% CI 13.5 to 50.6) in the 
placebo group (p=0.28).  This shows that irrespective of baseline 6MWT distance there 
was no significant change in walking distance with spironolactone. 
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Table 3.6 – Mean change in 6MWT distance from baseline at 10 weeks and 20 
weeks, unadjusted measures. 
 
Outcome 
measure 
Time Spironolactone 
 
 
 
(95% CI) 
Placebo 
 
 
 
(95%CI) 
Difference between 
groups 
[Spironolactone -
Placebo] 
(95% CI) 
P 
value 
 
 
 
10 
weeks 
 
 
27.4 
(11.4 to 43.5) 
 
 
27.5 
(11.3 to 43.8) 
 
-0.1  
(-22.9 to 22.7) 
 
0.99 
 
Change in 
6MWT 
distance 
(m) 
 
 
 
20 
weeks 
 
 
30.5 
(12.5 to 48.5) 
 
 
33.7 
(15.4 to 52.0) 
 
-3.2  
(-28.9 to 22.5) 
 
0.81 
 
 
 
Table 3.7 – Mean change in 6MWT distance from baseline using models for 
adjustment. 
 
Outcome measure Time Difference between groups 
[Spironolactone -Placebo] 
(95% CI) 
P  
value 
 
 
 
10 weeks 
 
 
-1.6 (-23.5 to 20.3) 
 
0.89 
Change in 6MWT 
distance (m) 
 
Adjusted for 
baseline distance and 
age 
 
20 weeks 
 
 
-3.7 (-28.6 to 21.2) 
 
0.77 
 
10 weeks 
 
 
-1.8 (-25.2 to 21.6) 
 
0.88 
Change in 6MWT 
distance (m) 
 
Multiple imputation 
and adjusted for 
baseline distance and 
age 
 
20 weeks 
 
-6.1 (-29.7 to 17.6) 
 
 
0.62 
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Figure 3.2 Mean change in 6MWT distance at 10 and 20 weeks. Vertical lines 
represent standard deviation. 
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Figure 3.3 - Mean 6MWT distance at baseline, 10 weeks and 20 weeks in 
individuals who walked above and below the median  
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The incremental shuttle walk 
The mean distance walked in the incremental shuttle walk test (ISWT) at baseline in the 
spironolactone group was 220 metres (SD131) and 241 metres (SD139) in the placebo 
group, with no significant difference found between the groups. There were no 
significant differences between groups as measured by the change in ISWT from 
baseline at either 10 weeks or 20 weeks. Nor was there any significant change in ISWT 
between groups after adjusting for baseline ISWT distance and age as covariates, as 
shown in Table 3.8. 
 
Two participants in the spironolactone group were unable to perform the shuttle walk 
test at baseline, (n=1) due to joint pain and (n=1) fatigue. This was mainly due to the 
fact that the incremental shuttle walk test was performed after the 6MWT with a 30 
minute rest interval between the tests. 
 
Males walked 59 metres significantly further than females at baseline (p=0.02). Taking 
this into consideration, we adjusted the change in ISWT distance from baseline, using 
gender as a covariate. This showed a mean change in the distance walked of 33 metres 
(95% CI 13.7 to 52.8) in the spironolactone group and 19 metres (95% CI -0.8 to 38.6) 
in the placebo group at 20 weeks. However, there was no significant change between 
groups at 20 weeks (p=0.31).  
 
Participants with walking aids had a mean baseline ISWT distance of 122 metres (SD 
102) compared to 274 metres (SD 121) in those without walking aids ( p<0.01 ). Those 
with walking aids appeared to find it more difficult to turn around the cones at either 
ends of the 10-metre course. Adjusting analyses to exclude participants with walking 
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aids showed a between group change of 7.3 metres (95% CI -24.9 to 39.5) in the 
spironolactone group at 20 weeks compared to the placebo group but this was not 
significant (p=0.65).  
 
Table 3.8 Mean change in ISWT distance from baseline, unadjusted and adjusted 
measures. 
 
 
Outcome 
measure 
Time Spironolactone 
 
 
 
(95% CI) 
Placebo 
 
 
 
(95%CI) 
Difference 
between groups 
[Spironolactone -
Placebo] 
(95% CI) 
P 
value 
 
 
 
10 
weeks 
 
 
13.9 
(-0.42 to 28.3) 
 
17.6 
(3.2 to 31.9) 
 
-3.7  
(-24.0 to 16.3) 
 
0.72 
 
Change in 
ISWT 
distance (m) 
 
Unadjusted 
 
20 
weeks 
 
 
25.4 
(8.4 to 42.4) 
 
22.4 
(4.9 to 39.9) 
 
3.1  
(-21.4 to 27.5) 
 
0.81 
 
10 
weeks 
 
 
13.3 
(-1.0 to 27.6) 
 
18.2 
(3.9 to 32.5) 
 
-4.9  
(-25.2 to 15.4) 
 
0.63 
Change in 
ISWT 
distance (m) 
 
 
Adjusted* 
 
 
20 
weeks 
 
 
24.6 
(7.6 to 41.6) 
 
23.3 
(5.8 to 40.7) 
 
1.4  
(-23.0 to 25.8) 
 
0.91 
 
 
*Adjusted model using baseline ISWT distance and age as covariates 
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The Timed-Get-Up and Go (TGUG) 
The mean time taken to do the Timed-Get-Up and Go (TGUG) in the study population 
was 13.3 seconds (SD 5.7). This value was similar to previous studies in older people 
with mobility problems
315
. The mean time taken to perform the TGUG was 14.4 
seconds (SD 4.6) in patients with a falls history. The time taken to do the TGUG was 
0.2 seconds less in the spironolactone group compared to placebo group at 10 weeks 
(p=0.72) with an insignificant change of 0.04 seconds at 20 weeks (p=0.95). At baseline 
the placebo group took 0.4 seconds longer to perform the TGUG test (p=0.69). After 
adjusting for baseline TGUG and age as covariates there were still no significant 
changes in the time taken to perform the test at both 10 weeks (p=0.8) and 20 weeks 
(p=0.87) as shown in Table 3.9. 
Table 3.9 – Mean change in the Timed-Get-Up and Go test. 
Outcome 
measure 
Time Spironolactone 
 
 
 
(95% CI) 
Placebo 
 
 
 
(95%CI) 
Difference 
between groups 
[Spironolactone -
Placebo] 
(95% CI) 
P 
value 
 
 
 
10 
weeks 
 
 
-1.4 
(-2.2 to -0.6) 
 
-1.2 
(-2.0 to -0.4) 
 
-0.2  
(-1.3 to 0.9) 
 
0.72 
 
Change in 
TGUG 
(s) 
 
Unadjusted 
 
20 
weeks 
 
 
-1.3 
(-2.2 to -0.3) 
 
-1.3 
(-2.3 to -0.4) 
 
0.04  
(-1.3 to 1.3) 
 
0.95 
 
10 
weeks 
 
 
-1.4 
(-2.1 to -0.7) 
 
-1.3 
(-1.9 to -0.6) 
 
-0.1  
(-1.1 to0.8) 
 
0.80 
 
Change in 
TGUG 
(s) 
 
Adjusted*  
 
20 
weeks 
 
 
-1.3 
(-1.9 to -0.6) 
 
-1.4 
(-2.2 to -0.5 
 
0.1  
(-1.1 to 1.3) 
 
0.87 
 
* Adjusted model using baseline TGUG and age as covariates 
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Health Related Quality of Life and psychological state 
Table 3.10 shows the change in EuroQol EQ-5D and EQ-VAS from baseline. A rise in 
EQ-5D score or EQ-VAS indicates an improvement in quality of life. There was a 
highly significant difference in the EQ-5D utility score of 0.1 (95% CI 0.03 to 0.18) in 
the spironolactone compared to the placebo group at 20 weeks (p=0.006). Although not 
statistically significant, the baseline EQ-5D utility score was 0.08 lower in the 
spironolactone group compared to the placebo group.  Despite adjusting for baseline 
EQ-5D and age as covariates there was still a significant difference between the groups, 
with a mean change of 0.07 (95% CI 0.01 to 0.13) in the spironolactone group 
compared to the placebo group at 20 weeks (p=0.04). Within the EuroQol EQ-5D 
subgroups the most significant change was found within the pain/discomfort domain 
(p<0.01), with joint pain due to osteoarthritis as the main cause of pain. Change in the 
EQ-5D in the spironolactone group did not correlate to a change in 6MWT distance at 
20 weeks (Pearson’s r=0.16, p=0.09).  
 
Although there was a slight improvement in the spironolactone group at 10 weeks, in 
the EQ-VAS questionnaire this change was not significant. There was no significant 
difference in the change of EQ-VAS between the two groups at 10 weeks or 20 weeks. 
 
The Hospital Anxiety and Depression Score (HADS) is a useful measure of 
psychological status in patients. According to Zigmond et al the cut-off scores for 
detecting anxiety and depression a HADS score of 8-10 suggest borderline cases and 
scores >11 suggest a valid diagnosis of anxiety or depression
356
. In this study 6% 
(7/120) of participants reached the threshold for a diagnosis of anxiety but only 2% 
(2/120) reached the threshold for a diagnosis of depression with 12% of participants 
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having borderline depression. Table 3.11 shows the change in HADS score from 
baseline. There was a significant fall in the HADS-D score of 0.84 in the spironolactone 
group compared to placebo group at 10 weeks (p=0.03) i.e. an improvement in mood. 
However, no significant between group difference was found in HADS-D score at 10 
weeks after performing analysis adjusting for baseline score and age as covariates 
(p=0.11). There was no significant difference between groups in HADS-D score at 20 
weeks. No significant between group difference was seen in HADS-A score at 10 weeks 
or 20 weeks.  
 
In the Functional Limitation Profile (FLP) questionnaire the mean baseline FLP score 
was high in both groups, with a total FLP score of 807 (SD 198) in the spironolactone 
group compared to 773 (SD 180) in the placebo group. A rise in FLP score indicates 
increased functional impairment.  There were no significant differences in the change in 
total FLP scores between groups at either 10 weeks and 20 weeks (Table 3.12). There 
were also no significant differences found between groups in the physical and 
psychosocial domains of the questionnaire during the study. After adjusting for baseline 
total FLP score and age as covariates, the change in total FLP score between groups was 
13 (95%CI -40 to 66) at 20 weeks in the spironolactone compared to placebo, but this 
was not statistically significant (p=0.62). 
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Table 3.10 – Mean change in the EQ-5D and EQ-VAS from baseline, unadjusted 
and adjusted measures. 
Outcome 
measure 
Time Spironolactone 
 
 
 
(95% CI) 
Placebo 
 
 
 
(95%CI) 
Difference 
between groups 
[Spironolactone -
Placebo] 
(95% CI) 
P 
value 
 
 
 
10 
weeks 
0.05 
(0.04 to 0.10) 
0.01 
(-0.04 to 0.06) 
0.04 
(0.03 to 0.11) 
 
0.22 Change in 
EQ-5D 
 
 
Unadjusted 
 
20 
weeks 
 
0.11 
(0.06 to 0.16) 
0.01 
(-0.05 to 0.06) 
0.10 
(0.03 to 0.18) 
 
0.006 
 
10 
weeks 
 
0.04 
(-0.01 to 0.08) 
0.03 
(-0.02 to 0.07) 
 
0.01 
(-0.06 to 0.07) 
0.81 Change in 
EQ-5D 
 
 
Adjusted*  
20 
weeks 
0.09 
(0.05 to 0.14) 
 
0.02 
(-0.02 to 0.07) 
0.07 
(0.01 to 0.13) 
0.04 
 
10 
weeks 
 
4.2 
(0.2 to 8.3) 
2.8 
(-1.3 to  6.8) 
1.5 
(-4.3 to 7.2) 
0.62  
Change in 
EQ-VAS 
 
 
Unadjusted 
 
20 
weeks 
 
-0.3 
(-4.8 to 4.2) 
1.6 
(-3.0 to 6.2) 
-1.9 
(-8.3 to 4.5) 
0.55 
 
10 
weeks 
 
4.3 
(0.6 to 7.9) 
2.7 
(-0.9 to 6.4) 
1.6 
(-3.6 to 6.7) 
0.61 Change in 
EQ-VAS 
 
 
Adjusted †  
20 
weeks 
-0.4 
(-4.4 to 3.7) 
1.6 
(-2.5 to 5.7) 
-2.0 
(-7.8 to 3.8) 
 
0.57 
 
A rise in EQ-5D or EQ-VAS score indicates improvement in quality of life. 
 
*Adjusted model using baseline EQ-5D and age as covariates 
† Adjusted model using baseline EQ-VAS and age as covariates 
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Table 3.11 – Mean change in HADS-A and HADS-D score from baseline, 
unadjusted and adjusted measures. 
Outcome 
measure 
Time Spironolactone 
 
 
 
(95% CI) 
Placebo 
 
 
 
(95%CI) 
Difference 
between groups 
[Spironolactone -
Placebo] 
(95% CI) 
P 
value 
 
 
 
10 
weeks 
 
 
-0.11 
(-0.79 to 0.57) 
 
-0.23 
(-0.91 to 0.45) 
 
0.12  
(-0.83 to 1.09) 
 
0.80 
 
Change in  
HADS-A 
score 
 
Unadjusted 
 
20 
weeks 
 
 
0.33 
(-0.35 to 0.96) 
 
-0.45 
(-1.12 to 0.21) 
 
0.78  
(-0.17 to 1.69) 
 
0.11 
 
 
10 
weeks 
 
 
-0.14 
(-0.80 to 0.53) 
 
-0.20 
(-0.87 to 0.46) 
 
0.07  
(-0.87 to 1.01) 
 
0.89 
 
Change in  
HADS-A 
score 
 
 
Adjusted*  
 
20 
weeks 
 
 
0.28 
(-0.35 to 0.90) 
 
-0.43 
(-1.06 to 0.21) 
 
0.70  
(-0.19 to 1.60) 
 
0.12 
 
 
10 
weeks 
 
 
-1.11 
(-1.61 to -0.56) 
 
-0.25 
(-0.77 to 0.28) 
 
-0.84 
(-1.58 to -0.09) 
 
0.03 
 
Change in  
HADS-D 
score 
 
Unadjusted 
 
20 
weeks 
 
 
-0.23 
(-0.78 to 0.31) 
 
-0.04 
(-0.59 to  0.51) 
 
-0.20 
(-0.97 to 0.58) 
0.62 
 
10 
weeks 
 
 
-0.96 
(-1.44 to -0.47) 
 
-0.38 
(-0.87 to 0.11) 
 
-0.57 
(-1.27 to 0.12) 
 
0.12 
 
Change in 
HADS-D 
score 
 
 
Adjusted*  
 
20 
weeks 
 
 
-0.14 
(-0.68 to 0.39) 
 
-0.13 
(-0.66 to 0.41) 
 
-0.02 
(-0.78 to 0.74) 
 
 
0.95 
 
A rise in HADS-A and HAD-D indicates worsening symptoms of anxiety or depression. 
* Adjusted model using baseline measures and age as covariates. 
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Table 3.12– Mean change in Functional Limitation Profile (FLP) domains from 
baseline, unadjusted measures. 
 
 Time Spironolactone 
 
 
 
(95% CI) 
Placebo 
 
 
 
(95%CI) 
Difference 
between groups 
[Spironolactone -
Placebo] 
(95% CI) 
P 
value 
 
 
 
10 
weeks 
 
 
-16 
(-49 to 17) 
 
-17 
(-52 to 14) 
 
1 (-45 to 47) 
 
0.97 
 
Change in  
FLP 
Total Score 
 
20 
weeks 
 
 
-14 
(-54 to 25) 
 
-22 
(-52 to 14) 
 
8 (-49 to 64) 
 
0.78 
 
10 
weeks 
 
 
-10 
(-24 to 4) 
 
-8 
(-22 to 5) 
 
-2 (-21 to 18) 
 
0.86 
 
Change in 
FLP 
Physical 
domain  
20 
weeks 
 
 
-1 
(-16 to 13) 
 
-5 
(-20 to 9) 
 
4 (-17 to 25) 
 
0.71 
 
10 
weeks 
 
-15 
(-34 to 5) 
 
-6 
(-26 to 13) 
 
-8 (-36 to 20) 
 
0.56 
 
 
 
Change in  
FLP 
Psychosocial 
Domain  
20 
weeks 
 
-1 
(-23 to 21) 
 
-9 
(-32 to 13) 
 
-8 (-23 to 40) 
 
0.58 
 
 
An increased FLP score indicates increased severity of functional impairment. 
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3.4 Changes in Blood Pressure  
There was a significant fall in systolic and diastolic blood pressure with spironolactone 
at 10 weeks, as shown in Table 3.13. The systolic blood pressure in the spironolactone 
group fell by 7.3 (95% CI 1.3 to 13.4) mmHg relative to the placebo group at 10 weeks 
(p=0.02). Despite adjusting for baseline systolic blood pressure as a covariate, systolic 
blood pressure was still lower in the spironolactone compared to placebo group at 10 
weeks (p=0.03). There was a significant fall in diastolic blood pressure in the 
spironolactone group at 10 weeks, with a mean difference of -5.3 (95% CI -9 to -1.5) 
mmHg in the spironolactone group compared to placebo group. However, there was no 
significant difference between groups after adjusting for baseline diastolic blood 
pressure (p=0.053).  Non-significant falls were seen in both systolic and diastolic blood 
pressure in the spironolactone group at 20 weeks (Figures 3.4 and 3.5). 
 
There was no significant fall in postural blood pressure with spironolactone compared to 
placebo at 20. The mean postural fall in systolic blood was 5 mmHg (SD 15) in the 
spironolactone group compared to 2 mmHg (SD 16) in the placebo group at 20 weeks 
(p=0.36).  The mean postural fall in diastolic blood pressure in the spironolactone and 
placebo group was minimal at 20 weeks (-0.8mmHg vs. 0.8mmHg respectively) 
(p=0.26). Systolic blood pressure fell by >20 mmHg on standing in 7 participants in the 
spironolactone group and 2 participants in the placebo group (p=0.59). Diastolic blood 
pressure fell by >10 mmHg on standing in 7 patients in the spironolactone group and 6 
patients in the placebo group (p=0.96).  
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Table 3.13–  Mean change in systolic and diastolic blood pressure from baseline, 
both adjusted and unadjusted for baseline measures. 
 
Outcome 
measure 
 
Time 
 
Spironolactone 
 
(95% CI) 
 
Placebo 
 
(95% CI) 
 
Difference 
between groups 
[Spironolactone -
Placebo] 
(95% CI) 
 
P 
value 
 
10 
weeks 
 
-7.7 
(-11.9 to -3.5) 
 
-0.32 
(-4.6 to 4.0) 
 
 
-7.3 
(-13.4 to -1.3) 
 
0.02 
Change in 
Systolic 
Blood 
pressure 
(mmHg) 
 
Unadjusted 
 
 
20 
weeks 
 
-9.3 
(-14.0 to -4.5) 
 
 
-2.6 
(-7.4 to 2.2) 
 
-6.6 
(-13.4 to 0.1) 
 
0.055 
 
10 
weeks 
 
 
-7.1 
(-10.9 to -3.1) 
 
-0.9 
(-4.9 to 3.0) 
 
-6.1 
(-11.6 to -0.6) 
 
0.03 
Change in 
Systolic 
blood 
pressure 
(mmHg) 
 
Adjusted 
for 
baseline* 
 
20 
weeks 
 
 
-8.5 
(-12.7 to 4.3) 
 
-3.4 
(-7.6 to 0.9) 
 
 
-5.1 
(-11.1 to 0.8) 
 
 
0.09 
 
10 
weeks 
 
 
-4.6 
(-7.2 to -2.0) 
 
0.7 
(-2.0 to 3.4) 
 
-5.3 
(-9.0 to -1.5) 
 
<0.01 
Change in 
Diastolic 
blood 
pressure 
(mmHg) 
 
Unadjusted 
 
20 
weeks 
 
-4.8 
(-7.5 to -2.2) 
 
-1.7 
(-4.4 to 1.0) 
 
 
-3.1 
(-6.9 to -0.6) 
 
 
0.10 
 
10 
weeks 
 
-3.5 
(-5.7 to -1.3) 
 
-0.4 
(-2.6 to 1.8) 
 
-3.1 
(-6.3 to 0.1) 
 
0.053 
Change in 
Diastolic 
blood 
pressure 
(mmHg) 
 
 
Adjusted 
for 
baseline† 
 
 
20 
weeks 
 
-3.8 
(-6.0 to -1.6) 
 
-2.8 
(-5.0 to -0.5) 
 
-1.1 
(-4.2 to 2.1) 
 
0.50 
 
*Analysis performed using baseline systolic blood pressure as a covariate 
†Analysis performed using baseline diastolic blood pressure as a covariate 
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Figure 3.4 – Mean change in systolic blood pressure at 10 and 20 weeks in 
spironolactone and placebo groups. Vertical lines show 95% CI.  
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Figure 3.5 – Mean change in diastolic blood pressure at 10 and 20 weeks in 
spironolactone and placebo groups. Vertical lines show 95% CI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
177 
 
3.5 Changes in renal function and serum magnesium 
Table 3.14 summarises the changes in blood tests from the baseline in the 
spironolactone and placebo groups. Spironolactone was associated with a significant 
rise in serum potassium with a between group difference of 0.2 (95% CI 0.1 to 0.3) 
mmol/L compared to placebo group at 20 weeks (p<0.01). Figure 3.6 shows the mean 
serum potassium in both groups over the 20 weeks.  
 
Spironolactone was also associated with a small but significant increase in serum 
creatinine at both 10 weeks and at 20 weeks. Analysis showed a 9% increase in mean 
serum creatinine from baseline in the spironolactone group compared to a 3% increase 
in the placebo group at 20 weeks (p=0.03). Mean baseline serum creatinine was higher 
in those aged >80 years compared to those <80 years old (80 mmol/L vs. 74 mmol/L), 
(p=0.30). Despite adjusting analyses using age and sex as covariates, there was still a 
significant increase in serum creatinine in with spironolactone with a between group 
difference of 4.2 (95% CI 0.4 to 7.9) mmol/L in the spironolactone group compared to 
placebo group at 20 weeks (p=0.03). There was no significant difference found in serum 
urea between the two groups at both 10 weeks and 20 weeks. 
 
Although there was an initial fall in serum sodium at 10 weeks with the mean difference 
in the spironolactone group of -1.3 mmol/L (95% CI -2.3 to -0.3) relative to the placebo 
group (p=0.02), this was not sustained by 20 weeks. There was no significant change in 
serum magnesium between groups at both 10 weeks and 20 weeks. 
 
The changes in serum sodium, potassium and creatinine are similar to changes found in 
participants taking spironolactone in the RALES study
262
. However, unlike the RALES 
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study, none of the participants on spironolactone in this study had medication 
discontinued due to serious hyperkalaemia (K
+
 >5.5mmol/L). This was probably due to 
the fact that participants in the RALES study were already taking an ACE inhibitor and 
had heart failure. Spironolactone was well tolerated in this study involving older people.  
 
Table 3.14. The changes in renal function and serum magnesium from baseline. 
Assay Time Spironolactone 
(95%CI) 
Placebo 
(95%CI) 
P value 
 
Change at 10 
weeks 
0.2 
(0.1 to 0.3) 
 
0.0 
(-0.1 to 0.0) 
 
<0.01 
Serum 
potassium 
 
(mmol/L) Change at 20 
weeks 
0.2 
(0.1 to 0.3) 
0.0 
(-0.1 to 0.1) 
 
<0.01 
Change at 10 
weeks 
-1.4 
(-2.2 to -0.7) 
-0.2 
(-0.9 to 0.5) 
 
0.02 
 
Serum 
Sodium 
 
(mmol/L) 
Change at 20 
weeks 
-0.9 
(-1.6 to -0.3) 
 
-0.6 
(-1.2 to 0.1) 
 
0.43 
Change at 10 
weeks 
 
6.3 
(4.1 to 8.6) 
1.0 
(-1.2 to 3.2) 
 
<0.01 
Serum 
Creatinine 
 
(umol/L) Change at 20 
weeks 
6.7 
(6.1 to 9.4) 
2.5 
(-0.2 to 5.2) 
 
0.03 
Change at 10 
weeks 
0.5 
(0.1 to 0.8) 
0.2 
(-0.2 to 0.5) 
 
0.18 
 
Serum 
urea 
 
(mmol/L) Change at 20 
weeks 
0.5 
(0.2 to 0.9) 
0.4 
(0.0 to 0.7) 
 
0.67 
Change at 10 
weeks 
-0.02 
(-0.03 to 0.00) 
-0.02 
(-0.03 to 0.00) 
 
0.57 
Serum 
Magnesium 
 
(mmol/L) 
 
Change at 20 
weeks 
-0.02 
(-0.04 to -0.01) 
-0.03 
(-0.05 to -0.01) 
 
0.55 
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Figure 3.6 – Mean serum potassium in the spironolactone and placebo groups. 
Vertical lines represent SDs. 
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3.6 Changes in B-type Natriuretric Peptide and Aldosterone  
Data at baseline and 20 weeks for both BNP and aldosterone were not normally 
distributed and the between groups comparisons were performed using Mann Whitney 
tests. As data for change in BNP and aldosterone at 20 weeks were normally distributed, 
analyses for changes between groups were performed using Student’s t-tests.  
 
Spironolactone was associated with a significant rise in aldosterone, with an increase of 
116.8 pg/ml (95%CI 166.1 to 167.6) compared to placebo at 20 weeks (p<0.01). 
Despite adjusting for baseline aldosterone as a covariate, spironolactone was associated 
with a 60% increase in serum aldosterone from baseline, with a between group 
difference of 112.0 pg/ml (95%CI 60.0 to 164.0) compared to placebo group at 20 
weeks (p<0.01). The rise in plasma aldosterone with spironolactone correlated with the 
rise in serum potassium (Pearson’s r=0.30, p=0.002), in keeping with aldosterone 
blockade. No correlation was found between changes in aldosterone levels and change 
in 6MWT distance (r=0.11, p=0.25) at 20 weeks. Figure 3.7 shows the median 
aldosterone levels at baseline and 20 weeks in both groups. 
 
Although BNP levels did fall by 3.0 pg/ml (95% CI -7.5 to 13.6) in the spironolactone 
group compared to placebo at 20 weeks, this was not significant. Baseline BNP did not 
correlate with any other outcome or baseline characteristic.  
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Table 3.15– Changes in plasma BNP and aldosterone levels at 20 weeks 
 
 
Assay 
 
Time 
 
Spironolactone 
(95% CI) 
n=57 
 
Placebo 
(95% CI) 
n=55 
 
Difference 
between groups 
[Spironolactone 
-Placebo] 
(95% CI) 
 
P 
value 
 
BNP 
 
(pg/ml) 
 
 
Change 
at 20 
wks 
 
-4.2 
(-11.6 to 3.3) 
 
-1.2 
(-8.6 to 6.4) 
 
3.0 
(-7.5 to 13.6) 
 
0.57 
 
 
Aldosterone 
 
(pg/ml) 
 
Change 
at 20 
wks 
 
 
136.9 
(101.3 to 172.7) 
 
20.1 
(-15.9 to  56.2) 
 
116.8 
(66.1 to 167.6) 
 
 
0.001 
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Figure 3.7 – Plasma aldosterone levels in spironolactone and placebo groups at 
baseline and 20 weeks. Boxes are represent median and IQRs. Vertical lines 
represent range of results.  
 
 
Outliers are denoted by • 
 
 
 
Baseline 
20 weeks 
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3.7 Changes in plasma cortisol levels  
Plasma cortisol levels were measured at baseline and 20 weeks to investigate the effects 
of mineralocorticoid receptor blockade on glucocorticoid levels. Cortisol levels are 
known to fluctuate throughout the day, with peak levels early morning around 8am and 
trough levels around midnight. Due to the diurnal variation of plasma cortisol levels, the 
statistical analysis of cortisol was stratified according to the time of day the blood 
samples were taken at baseline and 20 weeks in each individual. Blood samples were 
taken at two different times of day; mid-morning (around 11am) or mid-afternoon 
(around 3pm). Of the 112 participants who completed the study, 17 participant samples 
were excluded from the analysis. Reasons for exclusion were as follows: blood samples 
were taken at a different time of day at baseline and 20 weeks (n=15) and volume of 
sample insufficient to perform the analysis (n=2). Thus, cortisol levels were analysed at 
baseline and 20 weeks in the remaining 95 participants.  Although the mean plasma 
cortisol levels were higher in the spironolactone group compared placebo at baseline, 
the difference in plasma cortisol levels between groups at baseline was not statistically 
significant (p=0.32). Thirty-five participants had their cortisol levels checked mid-
morning at baseline and 20 weeks, with a between group difference higher in the 
placebo group compared to the spironolactone group. Due to the small rise in cortisol 
levels in the spironolactone group mid-morning there was no significant between group 
change in cortisol levels at 20 weeks (p=0.26) (Table 3.16).  
 
In contrast, to the mid-morning samples, spironolactone caused a significant rise in 
plasma cortisol mid-afternoon, with a between group difference of 78.4 nmol/L (95% CI 
22.8 to 133.9) (p=0.007). Despite adjusting analysis for baseline, cortisol levels there 
was still a significant rise in plasma cortisol of 77.2 nmol/L (95% CI 24.0 to 130.5) in 
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the spironolactone group compared to the placebo group (p=0.005). The rise in plasma 
cortisol was similar to the rise in cortisol seen in hypertensive diabetic patients after 4 
weeks of spironolactone
250
. No significant correlation was shown between change in 
mid-afternoon cortisol levels and change in 6MWT distance (Pearson’s r= -0.11, 
p=0.37). 
 
Table 3.16 – Change in plasma cortisol between groups at 20 weeks 
 
 
 
 
 
 
 
 
 
Assay 
 
Time 
 
Spironolactone 
 
(95% CI) 
 
Placebo 
 
(95% CI) 
 
Difference 
between groups 
[Spironolactone 
– Placebo] 
at 20 weeks 
 
(95% CI) 
 
P 
value 
Baseline 
 
 
285.0 
(238.6 to 333.8) 
250.0 
(203.4 to 304.2) 
Cortisol 
(nmol/L) 
 
11 am 
 
(n=35) 
Change at 
20 weeks 
19.1 
(-48.1 to 86.3) 
 
70.3  
(8.6 to 131.2) 
 
 
 
-51.3 
(-142.4 to 39.9) 
 
 
 
0.26 
Baseline 266.2 
(226.9 to 295.1) 
269.5 
(232.8 to 304.8) 
Cortisol 
(nmol/L) 
 
3pm  
 
(n=60) 
Change at 
20 weeks 
66.1 
(27.1 to105.1) 
-12.3 
(-51.9 to 27.3) 
 
 
78.4 
(22.8 to133.9) 
 
 
 
0.007 
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3.8 Adverse events 
A total of 16 adverse events occurred to 8 in the placebo group and 8 in the 
spironolactone group. Table 3.17 summarises the reasons for participants developing 
adverse events during the study. Of the participants who completed the trial 95% 
(106/112) remained on medication at 20 weeks. 
 
Six participants had their study medication discontinued due to adverse events. 
Medication was discontinued in 4 participants in the spironolactone group: serum 
sodium <130mmol/L (n=2), fall in systolic blood pressure <100mmHg (n=1) and skin 
rash (n=1). Medication was discontinued in 2 participants in the placebo group: 
persistent dizziness (n=1), skin rash (n=1). Two thirds of the participants whose 
medication was discontinued remained in the study and completed the outcomes at 20 
weeks in order to preserve intention to treat analysis.  
 
Five participants (2 in the spironolactone group and 3 in the placebo group) were unable 
to tolerate up-titration of dose at 2 weeks due to a rise in serum potassium (>5.0 mmol/L 
but <5.5 mmol/L). All 5 participants remained on the lower medication dose (12.5mg 
spironolactone/placebo) for the duration of the study. No individual experienced serious 
hyperkaelaemia (potassium >5.5 mmol/L).   
 
Two participants in the placebo group experienced serious adverse events during the 
study. One was hospitalised for septic arthritis prior to starting the study medication and 
the second was admitted to hospital for an elective hip replacement for severe 
osteoarthritis and did not wish to continue the medication after the operation.  
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Table 3.17 Reasons for adverse events 
Adverse event Spironolactone 
(n=8) 
Placebo 
(n=8) 
Serious adverse events 
- Hospitalisation 
 
0 
 
2 
Hip Arthroplasty (1) 
Septic Arthritis (1) 
Adverse  events 
Rash 
 
1 
 
 
1 
Abdominal discomfort  
1 
0 
Hyponatraemia 2 
 
0 
Dizziness 0 
 
1 
Fall 0 
 
1 
Hypotension 1 
 
0 
Gynaecomastia 1 
 
0 
Rise in potassium 
>5.0mmol/L but <5.5mmol/L 
 2* 
 
3* 
Serious hyperkalaemia 
Potassium >5.5mmol/L 
0 
 
0 
 
* Patients remained in the study on a lower dose of spironolactone/placebo.  
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3.9 Adherence to study medication 
Adherence to study medication was assessed by tablet counting with “Good adherence” 
>85% of the expected value. The median adherence was 99% in both groups with 89% 
of the spironolactone group and 94% of the placebo group achieving >85% adherence to 
medication, as shown in Table 3.18. Participants with a tablet count lower than expected 
were assumed to have taken extra tablets in error. Thirty percent of participants in the 
spironolactone group took extra tablets with no apparent serious adverse effects.  
 
 
Table 3.18 – Adherence to medication in both groups at 20 weeks.  
 
 Spironolactone 
(n= 54) 
Placebo 
(n= 53) 
Median Adherence %  
(Range) 
99 (44-121) 99 (51-110) 
No. of participants with 
>85% adherence of 
expected (%) 
 
48 (89) 
 
50 (94) 
No of participants who 
missed > 25% of tablets (%) 
 
3 (6) 
 
2 (4) 
No. of patients taking extra 
tablets (%) 
 
16 (30) 
 
9 (17) 
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3.10 Subgroup Analysis  
Primary Outcome 
Initial analyses of the primary outcome showed there was no significant difference in 
change in 6MWT distance with spironolactone compared to placebo. However, it is 
possible that any potential effect of spironolactone on change in 6MWT distance could 
have been masked by factors such as variation of age or sex within the study population. 
Several other factors may have also blunted the effects of spironolactone. Firstly, the 
use of other medications which alter potassium balance such as loop and thiazide 
diuretics may affect muscle contractility. Secondly, as spironolactone is widely used in 
patients with heart failure and hypertension, the effects within these participants may 
differ from those without hypertension. Thirdly, the effects of spironolactone at 
lowering blood pressure may have been potentiated when used in combination with 
other antihypertensive medications or when given to participants with disease processes 
affecting the autonomic nervous system (e.g. Parkinson’s disease). Fourthly, the effects 
of spironolactone may have been offset by the use of synthetic steroids.   
 
There was also a small but non-significant difference between the two groups at 
baseline in severity of mobility problems as measured by the number of people who 
used walking aids. Fewer participants in the placebo group used a walking aid which 
may have been a factor in the slight improvement in 6MWT distance in the placebo 
group at 20 weeks. The subgroups were analysed using fixed effect ANCOVA test to 
evaluate if there was any factor which contributed to the lack of effect of spironolactone 
on change in walking distance. Table 3.19 shows the subgroup analyses. As numbers in 
the subgroup analyses were small it is difficult to achieve statistical significance. From 
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the fixed effect comparison between groups there was a deterioration in the change in 
walking distance in spironolactone group relative to the placebo group, depending on 
whether participants had a systolic blood pressure <140 mmHg at baseline or if they had 
no previous history of hypertension. However, these differences were not statistically 
significant. There was also an indication that participants in the spironolactone group 
showed a decline in change of walking distance relative to the placebo group if 
participants were taking oral diuretics or corticosteroids. However, due to the small 
numbers within the subgroups neither these results were not statistically significant.  In 
order to test these subgroup hypotheses further a much larger study population would be 
required. 
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Table 3.19 – Subgroup analysis of factors that could affect the change in baseline 
6MWT distance (between group difference between spironolactone and placebo)  
Subgroup 
 
No. of 
subjects 
 
(n=) 
Mean 
difference 
in 6MWT 
distance 
between 
groups 
95% CI P 
value 
Comparison 
between 
subgroups 
 
P value 
All patients 
 
112 -3.2 (-38.9 to 22.5) 0.81  
Male 
 
61 -11.3 (-42.3 to 19.7) 0.47 
Female 
 
51 5.7 (-38.1 to 49.5) 0.79 
 
0.44 
Walking aids 
 
35 -15.2 (-43.6 to 73.9) 0.60 
No walking aids used  
 
77 -11.2 (-39.1 to 16.7) 0.43 
 
0.89 
Age <80 years  
 
Age >80 years 
84 
 
28 
-1.1 
 
-4.2 
(-45.1 to 43.0) 
 
(-35.8 to 27.4) 
0.96 
 
0.79 
 
0.83 
Oral diuretics 
      Loop diuretics 
      Thiazide diuretics 
24 
6 
18 
 
-16.6 
-30.3 
2.3 
(-55.5 to22.3) 
(-138.8 to77.5) 
(-55.1 to 59.6) 
0.38 
0.48 
0.93 
Not on diuretics 
 
88 2.9 (-27.0 to32.8) 0.85 
 
 
0.23 
Taking 
antihypertensive 
medication  
(including diuretics) 
33 0.3 (-39.3to39.9) 0.98 
Not taking 
antihypertensive 
medication  
(including diuretics) 
79 -13.0 (-40.4to39.9) 0.34 
 
0.73 
On B-blockers 
 
7 -13.3 (-120.9 to44.3) 0.75 
Not on B-blockers 
 
105 -2.2 (-28.8 to 24.3) 0.87 
 
0.85 
On Ca
2+
 channel 
blockers 
 
15 0.79 (-56.1 to 57.7) 0.47 
Not on Ca
2+
 channel 
blockers 
97 -11.1 (-35.5 to13.3) 0.37 
 
0.74 
On alpha blockers 
 
8 -0.4 (-114.2 to13.4) 0.99 
Not on alpha blockers 104 -3.9 (-30.2 to 23.1) 0.78 
0.96 
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SBP >140 mmHg 
 
73 -6.1 (-29.3 to 17.1) 0.60 
SBP <140mmHg 
 
37 -33.9 (-77.1 to 9.3) 0.12 
 
0.43 
History of 
hypertension 
 
32 20.0 (-40.2 to 80.3) 0.5 
No history of 
hypertension 
80 -13.3 (-41.0 to14.4) 0.34 
 
0.49 
 
 
History of 
osteoarthritis 
 
38 -28.1 (-64.1 to7.8) 0.12 
No previous history 
of osteoarthritis 
74 7.1 (-20.9 to 35.3) 0.61 
 
0.35 
No history of 
Parkinson’s Disease 
105 11.7 (-124.6 to 
147.9) 
0.84 
History of 
Parkinson’s Disease 
7 -3.6 (-30.7 to 23.5) 0.79 
 
0.87 
Rise in serum K
+
 
during the study 
62 -6.1 (-37.1 to14.5) 0.39 
No rise in serum K
+
 
during the study 
50 -5.3 (-51.2 to40.4) 0.81 
 
0.43 
Rise is plasma 
aldosterone during the 
study 
81 -14.7 (-49.6 to20.3) 0.40 
No rise in plasma 
aldosterone during the 
study 
31 10.4 (-36.5 to57.3) 0.65 
 
0.51 
A fall in BNP during 
the study 
 
59 -9.0 (-34.9 to 16.8) 0.65 
A rise in BNP during 
the study 
 
53 -1.2 (-54.0 to 51.5) 0.96 
 
 
0.75 
Baseline creatinine 
clearance <60ml/min 
28 -12.5 (-37.9 to 12.9) 0.33 
Baseline creatinine 
clearance>60ml/min 
84 -1.6 (-50.0 to 46.7) 0.93 
 
0.58 
Not taking 
corticosteroids 
104 
 
-4.9 (-27.5 to17.7) 0.67 
Taking corticosteroids 
 
8 -41.3 (-128.9 to 
46.3) 
0.1 
 
0.35 
Participants recruited 
from MFE services 
14 19.9 (-44.2 to 83.9) 0.51 
Participants recruited 
from Primary Care 
106 -5.4 (-33.5 to 22.6) 0.7 
 
0.55 
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EuroQol (EQ-5D) 
Initial analysis showed there was a significant improvement in quality of life as 
measured by improvement in EQ-5D utility scores in the spironolactone group 
compared to placebo group at twenty weeks, after adjusting for baseline EQ-5D scores 
and age as covariates (p=0.04). 
 
The EQ-5D utility score comprises of 5 domains including mobility, self-care, usual 
activities, pain / discomfort and anxiety / depression. The most significant change 
within the domains of the EQ-5D was found in pain / discomfort, with 35% (20/57) of 
participants in the spironolactone group showing improvement in pain compared to 5% 
(3/55) of those in the placebo group at 20 weeks (p<0.01) (Table 3.20) 
 
Subgroup analyses were done to examine which particular subgroup improved quality 
of life (EQ-5D) relative to placebo (Table 3.21). It is possible that the beneficial effects 
of spironolactone in improving quality of life could have been age or gender dependent. 
Secondly, as one of the most important factors in the improvement of EQ-5D was due 
to improvement in pain perception, it is possible that spironolactone may have a 
beneficial role in inflammatory diseases such as osteoarthritis and rheumatoid arthritis. 
Thirdly, as quality of life includes not only physical but psychological health status, it is 
possible that participants with established mood disorders may show variations in 
quality of life scores in contrast to those without mood disorders.  
 
A comparison of various subgroups was done using fixed effect ANCOVA to evaluate 
if any hypothesis for the improvement in EQ-5D utility score in the spironolactone 
group could be generated.  
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From the fixed effect comparison between subgroups suggests that spironolactone 
might possibly be more effective at improving quality of life in participants aged <80 
years old who require a walking aid. There was also a statistically significant 
improvement in quality of life in participants with osteoarthritis in the spironolactone 
group compared to placebo group (p=0.02). However, the fixed effect comparison was 
not significant when comparing this to participants without osteoarthritis, possibly due 
to small subgroup numbers. Those in the spironolactone group were also found to have 
improved quality of life if they were already taking analgesia and, in particular, if they 
were taking opioid analgesia (p=0.03). This may also support the hypothesis of the 
potential anti inflammatory effects of spironolactone. However, as this study was not 
powered to detect this effect, no firm conclusions can be made. Finally, in contrast to 
our initial hypothesis spironolactone did not improve quality of life in participants 
taking antidepressant medication. This may be due to the relatively small numbers of 
participants with a diagnosis of depression in this study. In conclusion, a larger study 
would be required to test this hypothesis further. 
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Table 3.20 – Change in EQ-5D domain scores at 20 weeks between groups.  
 
EQ-5D domains Spironolactone 
No. of participants with 
improved EQ-5D 
subgroup scores at 20 
weeks (%) 
(n=57) 
Placebo  
No. of participants with 
improved EQ-5D 
subgroup scores at 20 
weeks (%) 
(n=55) 
P 
value 
Mobility domain 
 
19/57 (33) 12/55 (22) 0.15 
Self-care domain 
 
10/57 (18) 7/55 (13) 0.47 
Usual activities 
domain 
 
14/57 (25) 17/55 (31) 0.77 
Pain/Discomfort 
domain 
20/57 (35) 3/55 (5) <0.01 
Anxiety/Depression 
domain 
5/57 (8) 6/55 (10) 0.61 
 
Changes in EQ-5D subgroups were discrete values therefore between group significance 
was analysed by Pearsons Chi squared test.  
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Table 3.21 – Subgroup analysis for factors that could affect change in EQ-5D  
Subgroup 
 
No. of 
subjects 
 
(n=) 
Mean 
difference in 
EQ-5D  
(Spironolactone-
Placebo) 
95% CI P 
value 
Comparison 
between 
subgroups 
 
P value 
Male 
 
61 0.10 (0.01 to 0.2) 0.06 
Female 
 
51 0.11 (0.01 to 0.2) 0.06 
0.96 
Walking aids 35 0.22 (0.05 to 0.40) 0.01 
No walking aids 77 0.07 (0.1 to 0.14) 0.08 
0.05 
Age <80 years  84 0.10 (0.01 to 0.19) 0.03 
Age >80 years 28 -0.10 (-0.21 to 0.03) 0.06 
0.94 
Taking 
antidepressants 
9 -0.10 (-0.47 to 0.27) 0.54 
Not taking 
antidepressants 
103 0.12 (0.05 to 0.20) 0.01 
 
0.09 
History of 
hypertension 
33 0.13 (-0.03 to 0.29) 0.11 
No history of 
hypertension 
79 0.09 (0.01 to 0.17) 0.04 
 
0.59 
History of IHD 32 0.17 (-0.13 to 0.47) 0.25 
No history of IHD 80 0.09 (0.02 to 0.17) 0.02 
 
0.49 
History of PD 7 0.09 (-0.65 to 0.83) 0.77 
No history of PD 105 0.11 (0.03 to 0.18) 0.01 
 
0.94 
History of 
osteoarthritis 
38 0.16 (0.03 to 0.30) 
 
0.02 
No history of 
arthritis 
74 0.08 (-0.01 to 0.18) 0.08 
 
0.33 
Taking analgesia at 
baseline 
- Paracetamol 
- NSAIDs 
- Opioids 
43 
 
8 
8 
27 
0.18 
 
0.04 
0.13 
0.30 
(0.02 to 0.35) 
 
(-0.34 to 0.41) 
(-0.29 to 0.54) 
(0.11 to 0.48) 
0.03 
 
0.82 
0.49 
0.003 
Not taking 
analgesia at 
baseline 
62 0.06 (-0.01 to 0.14) 0.09 
 
0.12 
Rise in plasma 
aldosterone levels 
during the study 
81 0.12 (0.02 to 0.22) 0.02 
No rise in plasma 
aldosterone levels 
during the study 
31 -0.01 (-0.1 to 0.08) 0.80 
0.25 
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4. DISCUSSION 
 
 
This study found that spironolactone did not improve physical function compared to 
placebo, as measured by the change in 6MWT distance at 20 weeks. The observed 
difference was 3.2 metres less in the spironolactone group compared to the placebo 
group at 20 weeks. This was much lower than the 30 metre distance required to produce 
a clinically significant effect. As shown by the 95% confidence intervals, which do not 
include a 30 metre improvement, it is highly unlikely that a clinically significant 
improvement in the 6MWT distance was missed. Recent evidence suggests that the 
minimum important clinical difference in the 6MWT distance in older people may be as 
low as 20 metres
378
. Even this more conservative value falls outside the 95% confidence 
intervals derived from the imputed data set. The lack of change in other measures of 
physical function including the TGUG, ISWT and FLP (a self-reported measure of 
physical function) with spironolactone reinforces our finding with the primary outcome. 
 
4.1 Primary outcome  
 
Several factors which may have contributed to the lack of effect of spironolactone on 
physical function: 
 
Baseline six minute walk distance of study population 
The mean baseline 6MWT distance was 340 metres, which was higher than previous 
studies involving frail older people
194;196
. This suggests that the study cohort was less 
impaired than those in previous studies. This may have been due to the fact that the 
majority of participants recruited were recruited from Primary Care, who were younger, 
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took less medication and required fewer walking aids than those who were recruited 
from Medicine for the Elderly services.  A clinically significant improvement in 
exercise capacity may have been more difficult to detect in participants with a higher 
6MWT distance. Pepin et al showed that COPD patients with a high mean baseline 
6MWT distance were less responsive to change in exercise capacity following 
bronchodilator therapy compared to the endurance shuttle walk test
379
. It was suggested 
that the lack of responsiveness observed was related to a ceiling effect. However no 
ceiling effect was shown in this study.  
 
Dosage of spironolactone 
During the first 2 weeks, participants received 12.5 mg of spironolactone/ placebo and 
were then up-titrated to 25 mg for the remaining 18 weeks.  The RALES study showed 
that 25 mg of spironolactone was pharmacologically effective at blocking 
mineralocorticoid receptors and 25 mg and was clinically effective at reducing 
morbidity and mortality in CHF patients
262
.  Serious hyperkalaemia occurred most 
frequently at daily doses of 50 mg of spironolactone. However serious hyperkalaemia 
was only reported in 2% of patients in the RALES study in which the mean+SD age 
was 66+12 years compared to another study of spironolactone which showed that the 
hyperkaelamia and renal impairment occurred in up to 30% of patients aged over 75 
years
380
.  
 
Spironolactone increases the risk of hyperkalaemia and renal impairment in older 
people
381
. The risk of having serious hyperkalaemia is much higher in older people 
receiving 50 mg of spironolactone or more
382
 
383
. To maintain participant safety in this 
study it was decided that a dose of 25 mg of spironolactone should not be exceeded. 
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Although it could be argued that the dose of spironolactone may have been insufficient 
to produce optimal pharmacological effects, this is probably not true for several reasons. 
Firstly, in contrast to previous studies, which reported higher rates of hyperkalaemia, 
participants in this study were excluded if they were already taking an ACE inhibitor 
and therefore their risks of hyperkalaemia were low to start with. Secondly, aldosterone 
levels were 60% higher with spironolactone indicating sufficient aldosterone blockade. 
Finally spironolactone increased both serum creatinine and potassium and reduced 
blood pressure at a similar rate to the RALES study where the dose of spironolactone 
was found to be pharmacologically effective
262
. This shows that the dose of 
spironolactone in this study was sufficient to provide pharmacological effects and that 
higher doses of spironolactone may have led to higher rates of hyperkalaemia without 
any further pharmacological benefit. 
 
Adherence to study medication 
Non-adherence to medication is often a major problem, with up to 59% of older people 
not taking their medication as prescribed
384
. Common reasons for non-adherence in 
older people include sensory deficits, cognitive problems, confusion over medication 
instructions or the belief that medication is not needed
385
.  
 
Adherence to medication was calculated by tablet-counting at each study visit. The 
median adherence in both the spironolactone and placebo group was 99%, higher than a 
randomised trial of multivitamins in community dwelling older people (91%)
386
. Many 
clinical trials classify good adherence between 80-90%, therefore this study achieved 
very good adherence in both groups
387
. However a higher proportion of participants in 
the spironolactone group (30%) took extra tablets during the study and one individual 
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had 120% adherence rate. Despite a higher proportion of participants in the 
spironolactone group taking extra tablets, this was not associated with an increase in 
adverse effects.  
 
Measuring adherence through tablet-counting, makes the assumption that every tablet 
missing from the medication bottle is taken by the participant. Ideally adherence to 
medication should be measured by the ‘gold standard’ method of urine or serum 
analysis of the drug or a measurable metabolite related to the drug
388
. A significant rise 
in plasma aldosterone occurred with spironolactone, which supports a level of 
adherence to medication in the spironolactone group.  
 
Power of the study 
A final sample size of 120 participants provided a 80% power to detect a 30 metre 
change in distance walked in 6MWT, assuming a standard deviation of 50 metres at the 
0.05 significance level, allowing for a 30% drop out rate. In reality 120 participants 
were recruited with only a 7% drop out rate, leaving 112 completers at 20 weeks. 
Despite spironolactone increasing the 6MWT distance by 31 metres (SD 79) the change 
in distance walked was 3 metres less than the placebo group at 20 weeks, which was not 
statistically significant. In this study the number of participants recruited was sufficient 
to detect a clinical effect in the primary outcome. 
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Other pharmacological effects of spironolactone 
i) A rise in Angiotensin II (Ang II) 
Spironolactone significantly increased aldosterone levels at 20 weeks (p<0.01). 
Although Ang II levels were not measured in this study, previous studies have shown 
that spironolactone is associated with a rise in both aldosterone and Ang II. The rise in 
aldosterone levels associated with spironolactone in our study was consistent with 
Rousseau et al who investigated neurohormonal levels in a subgroup of the RALES 
study
389
. Rousseau showed that spironolactone contributed to a significant increase in 
both aldosterone and Ang II levels after six months. It has been suggested that 
aldosterone blockade may cause a rise in aldosterone and Ang II through a positive 
feedback mechanism on the RAAS.  Van de Wal et al showed that the use of 
spironolactone in CHF patients was an independent predictor of higher Ang II levels 
despite ACE inhibition
390
. In addition these patients also had higher plasma renin and 
Ang I levels with MR antagonism. It is possible that this rise in renin and Ang I 
associated with spironolactone may have induced a positive feedback on the RAAS thus 
forming more Ang II and aldosterone. Another suggestion is that the rise in Ang II with 
aldosterone blockade may also occur due to non-ACE conversion of Ang I to Ang II 
which has been shown in myocardial tissue, although the mechanism is unclear
391
.  This 
could also explain why Ang II increases despite ACE inhibition in other studies. 
 
High levels of Ang II are associated with negative cardiovascular effects and endothelial 
dysfunction
220
. Spironolactone has been shown to be associated with a rise in Ang II 
and poor endothelial function in type II diabetics without heart failure
250
. High levels of 
Ang II in animal models have been shown to induce muscle wasting and increase 
muscle protein degradation, which can ultimately lead to reduced muscle mass and 
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strength
229
.  Therefore it could be speculated that a potential rise in Ang II with 
spironolactone, may have counteracted any potential benefit of aldosterone blockade on 
vascular endothelial function or skeletal muscle function.  
 
ii) A reduction in androgen levels 
Spironolactone has anti-androgen effects by binding to the androgen receptor and 
blocking the activation of dihydrotestosterone. The anti-androgenic effects of 
spironolactone are used as a treatment for hyperandrogenic disorders such as hirsuitism 
and acne vulgaris.  
 
However these anti-androgenic effects may be associated with a detrimental effect on 
muscle function. Studies have shown that androgen replacement in hypogonadal men 
increases both muscle mass and strength
112
. One possible mechanism for sarcopenia in 
older people is low androgen levels which are commonly seen in older men. It could be 
speculated that the anti-androgen effects of spironolactone may have counteracted any 
potential benefits in terms of muscle mass and strength. As androgen levels were not 
measured in this study further research would be required to test this hypothesis.  
 
iii) An increase in plasma cortisol  
Spironolactone increases plasma cortisol levels
392
. Conditions of hypercortisolism, 
including Cushing’s syndrome and medical treatments with glucocorticoid therapies are 
associated with muscle weakness and atrophy
393
. Cortisol causes a decline in muscle 
strength and causes muscle atrophy by inhibiting muscle protein synthesis
394
. The 
Longitudinal Ageing Study in Amsterdam showed an association between high salivary 
cortisol levels and a reduction in hand grip strength in older people
395
. More 
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importantly, high cortisol levels have been associated with poor physical function in old 
age.  
 
Studies have shown that spironolactone increases plasma cortisol levels. When 
spironolactone binds to the mineralocorticoid receptor the clearance route for both 
mineralocorticoids and glucocorticoids is lost and hence the rise in available 
mineralocorticoid stimulates the glucocorticoid receptor. In addition, positive feedback 
may occur resulting in an increased production of ACTH and a rise in plasma cortisol 
secretion
396
. It could be suggested that the lack of effect of spironolactone on physical 
function may have been due to a rise in plasma cortisol, thus neutralising any beneficial 
effect of aldosterone blockade on skeletal muscle function.  
 
In our study random plasma cortisol levels were measured at baseline and 20 weeks. A 
significant rise in plasma cortisol levels were seen in the spironolactone group in 
comparison to the placebo group in blood samples taken mid-afternoon. No significant 
correlation was found in our study between 6MWT distance and plasma cortisol levels 
at baseline. It could be speculated that the higher cortisol levels found within the 
spironolactone group may have contributed to deleterious effects on muscle function 
and offset any beneficial effect that may have occurred with aldosterone blockade. 
However the results from this study cannot confirm this hypothesis. As plasma cortisol 
levels fluctuate throughout the day with peak levels early morning (around 10am) and 
trough levels at night (around midnight), random cortisol results may not always be 
reliable. Our study was not designed to monitor changes in cortisol levels and further 
research would be required to assess this hypothesis.    
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Spironolactone is not effective at improving exercise capacity 
in the absence of heart failure 
Spironolactone did not improve exercise capacity in our study. Whilst studies have 
shown an improvement in exercise capacity with spironolactone, the evidence exists in 
patients with heart failure
258
. As there was no improvement in exercise capacity in our 
study cohort of older people without heart failure, it could be assumed that the 
beneficial effects on exercise capacity with spironolactone are due to an improvement in 
cardiac function.  
 
4.2 Secondary outcomes 
There was no significant change between groups in the ISWT at 20 weeks. The mean 
ISWT distance at baseline was 228 metres which is in keeping with previous studies 
involving older patients
297;322
. 
 
In contrast to the 6MWT, not everyone was able to perform the ISWT at baseline. The 
ISWT was performed on the same day as the 6MWT therefore it is possible that 
participants were still recovering from the effects of the six-minute walk test. Dyer et al 
also showed in older (> 70 years) patients with COPD only 88% of participants were 
able to complete the ISWT at baseline mainly due to fatigue
325
.  
 
In our study, participants with walking aids found it particularly difficult to turn at 
either end of the course and subsequently led to them walking a shorter distance 
compared to those without walking aids. Previous studies have not highlighted this issue 
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as the participants selected to perform the ISWT were usually younger and fitter or had 
COPD who were limited by symptoms of dyspnoea and not immobility. 
 
Singh et al showed the minimal clinically important difference in exercise capacity with 
the ISWT in COPD patients, was 47.5 metres
324
. In contrast, the change in ISWT 
distance between the spironolactone and the placebo group at 20 weeks was just 3.1 
metres. The 95% confidence intervals do not include a change of 47.5 metres in the 
ISWT, therefore it is unlikely that a clinical effect was missed. However it must be 
remembered that this study was not powered to detect a change in ISWT distance.  
There was no significant change between groups in the time taken to perform TGUG. 
Unlike other field walking tests which measure endurance, the TGUG test is a useful 
measure of explosive muscle power required to get up out of the chair and walk at a 
quick pace. The mean TGUG of 13.3 seconds was similar to that reported in older 
people with established mobility problems, with 55% of participants taking >12 seconds 
to perform the test
315
. However, this result was lower than previous studies involving 
older patients at risk of falls (TGUG > 15 seconds)
315
. This shows that although 
participants had a moderate degree of physical impairment no significant change in 
muscle power was seen. 
 
Spironolactone improved health related quality of life measured by EQ-5D.  After 
adjusting for baseline EQ-5D score and age, spironolactone still improved EQ-5D by a 
clinically important difference
397
.  Improvements in EQ-5D in older people have been 
associated with an improvement in 5-year survival
398
. 
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The EQ-5D incorporates 5 domains in measuring quality of life including: mobility, 
usual activities, self-care, pain or discomfort and anxiety with depression. Subgroup 
analysis showed that of the 5 domains, there was a significant between group 
differences at 20 weeks within the pain domain, with 35% of participants in the 
spironolactone group reporting an improvement in pain score, with joint pain from 
osteoarthritis reported as the commonest cause of pain.  
 
Spironolactone has been shown to have anti-inflammatory effects through suppression 
of pro-inflammatory cytokines. Previous animal studies have shown that aldosterone 
blockade reduces pro-inflammatory cytokine production and subsequent myocardial and 
vascular damage
220
.  Spironolactone inhibits the production of key pro-inflammatory 
cytokines including TNF-" in studies of human blood leucocytes of patients with 
rheumatoid arthritis
254
. Aldosterone induces the activation of NADPH oxidase which is 
a major source of reactive oxygen species (ROS) and oxidative stress. This in turn also 
leads to an increase in pro-inflammatory cytokines such as TNF-"
254
.  TNF-" also 
induces the production of other cytokines including IL-1", IL-1! and IL-6 which are 
involved in numerous pathological inflammatory processes including arthritis. 
Therefore, it could be speculated that the improvement seen in quality of life with 
spironolactone may have been related to its potential anti-inflammatory effects. Further 
research is needed to test this hypothesis.  
 
Unlike the EQ-5D there was no significant difference between treatment groups in 
change in the EQ-VAS score in this study at 20 weeks. There is conflicting evidence for 
the use of EQ-5D utility and EQ-VAS in measuring health state. EQ-5D is more useful 
at measuring change in health state in specific diseases such as Parkinson’s disease and 
  
 
206 
 
rheumatoid arthritis which commonly lead to deteriorations in physical function
330;335
. 
The EQ-VAS has shown to be a better measure of overall health state and general well 
being. As the participants in this study were selected to have mobility problems this 
may explain the change in response in the EQ-5D utility and not EQ-VAS. This finding 
is in keeping with studies carried out involving a similar population with mobility 
problems
196
.  
 
The Functional limitation Profile (FLP) is a self-reported measure of the impact of 
illness on daily activity. There was no significant difference in FLP scores between the 
groups at 20 weeks. The lack of change in self-reported function supports the lack of 
change in physical function shown in our primary outcome.  
 
Spironolactone was not associated with a significant change in psychological state as 
measured by the Hospital Anxiety and Depression Scale (HADS) questionnaire at either 
10 or 20 weeks. In contrast, previous studies have suggested that high plasma 
aldosterone levels are associated with clinical depression
399
 and spironolactone 
improved mood in women with premenstrual syndrome
400
. However, as the majority of 
participants in our study were euthymic any change in mood would be difficult to 
detect. 
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4.3 Changes in renal function and RAAS 
measurements 
Participants had a mean baseline creatinine clearance of 88 ml/min which indicates mild 
renal impairment
401
. The baseline renal function in this study was better than the other 
longitudinal studies involving older people with multiple co-morbidities
402
. 
Spironolactone was associated with small but significant increases in serum potassium 
and creatinine with only a minor fall in sodium by 10 weeks. The changes in serum 
sodium, potassium and creatinine were similar to the changes found in the RALES 
study
262
. However, unlike the RALES study none of the participants had study 
medication discontinued due to serious hyperkalaemia (potassium >5.5 mmol/L). This 
was probably because participants in the RALES study were already taking an ACE 
inhibitor and had heart failure so therefore were at greater risk of serious hyperkalaemia. 
As expected, spironolactone was associated with a significant rise in plasma 
aldosterone, suggesting aldosterone blockade. 
 
There was no significant change in serum magnesium between the two groups. This 
contradicts previous studies where spironolactone promoted magnesium retention by 
preventing magnesium excretion
230
. However this may be because the majority of 
studies involving spironolactone were conducted in patients with CHF, taking long-term 
magnesium losing diuretics and who had lower baseline magnesium levels.  
 
BNP levels did not significantly change in either the spironolactone or placebo group at 
20 weeks. There was also no correlation between change in 6MWT distance and change 
in BNP levels during the study in either group. Previous studies have suggested a 
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correlation between BNP levels and physical activities therefore the lack of change in 
BNP may reflect the lack of change in exercise capacity during the study
370
. 
 
4.4 Changes in Blood Pressure 
Spironolactone was associated with a significant fall in both systolic and diastolic blood 
pressure at 10 weeks but did not cause postural hypotension and was well tolerated in a 
cohort of older people.  
 
This was a smaller reduction in blood pressure compared to the Anglo-Scandinavian 
Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) study, where 
spironolactone was given to patients with resistant hypertension. The study showed a 21 
mmHg reduction in systolic blood pressure and a 9 mmHg reduction in diastolic blood 
pressure with spironolactone. However it is difficult to extrapolate the results from the 
ASCOT-BPLA study, as these patients had resistant hypertension and without routine 
screening of secondary causes it is possible that some participants with 
hyperaldosteronism may have been recruited
403
.  
It has been suggested that the magnitude of blood pressure reduction is more important 
than the type of antihypertensive agent
404
.  The reduction in diastolic blood pressure in 
this study was similar to results shown in the PROGRESS trial where a reduction in 
diastolic blood pressure of between 5 to 6 mmHg was associated with a 28% reduction 
in risk of stroke
405
. In a large meta-analysis involving 62,605 hypertensive patients a 
reduction in diastolic blood pressure of 5-6 mmHg was also associated with a 16% 
reduction in myocardial infarction
406
.  
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Current British Hypertension Society guidelines recommend spironolactone as a fourth 
line therapy in patients with resistant hypertension
263
. This study indirectly boosts the 
case for using spironolactone as an antihypertensive in older people since it was well 
tolerated with associated reductions in blood pressure.  
 
4.5 Recruitment 
The recruitment of frailer older people to a clinical trial is difficult. Our study 
population represented only 3.5% of the total population screened; however this was in 
keeping with previous randomised controlled trials in frailer older people
407
. A total of 
87% of potential participants contacted by letter failed to reply, with a greater 
proportion of non-responders coming from those attending the Medicine for the Elderly 
services. This may be because patients were attending the Day Hospital or clinics in 
Medicine for the Elderly department for an ongoing medical problem and therefore may 
be unwell or reluctant to take additional medication. Also the letters sent to those in 
Primary Care were signed by their own GP’s which may have encouraged more people 
to reply, if their GP was happy for them to participate. 
Twenty three percent of potential participants did not meet inclusion criteria. The main 
reason for individuals from the community not meeting inclusion criteria was if they 
had no problems with activities of daily living. Individuals who volunteer for research 
may be healthier which may only represent one end of the spectrum of the general older 
population.  
 
Through review of participant demographics we believe our study cohort is 
representative of a frail older population. Comorbid disease is prevalent in older people. 
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Participants in the study had a range of comorbid diseases including hypertension 
(29%), COPD (19%) and Parkinson’s disease (5%). Given that participant selection 
focused on participants with mobility impairment it was not surprising that 45% of 
participants had osteoarthritis. Rates of ischaemic heart disease and diabetes mellitus 
were lower than community dwelling older people recruited to the Cardiovascular 
Health Study
282
.  This is probably because ACE inhibitors and angiotensin receptor 
blockers are commonly prescribed in these patients. However in this study participants 
were excluded if they were taking these medications.  
 
The majority of patients within our study cohort, were recruited from a Primary Care 
setting. Although mean 6MWT distance in our study cohort was similar to other studies 
involving community dwelling older people
300
, and older people with mobility 
limitations
408
 it was higher than previous studies assessing exercise capacity from our 
department
194;196
. The mean TGUG was 13.3 seconds which is in keeping with results 
from other studies which include older people with mobility problems but it is was 
lower than frail older residential people with a high falls risk
316
. Participants in this 
study walked 70 metres further at baseline in the ISWT compared to previous studies 
involving older patients
325
. However the majority of studies using the ISWT involve 
patients with COPD, who are mainly limited by breathlessness when performing the test 
rather than mobility problems. 
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4.6 Strengths and limitations 
As a parallel group randomised controlled trial, participants and investigator were blind 
to treatment. All data were entered and the analysis of the primary outcome performed 
prior to breaking the treatment code. All outcomes were measured by a single 
investigator. Outcomes were measured using Standard Operating Procedures without 
reference to results from previous visits, thus eliminating both investigator and 
participant bias.  
 
Data entry and analysis was performed independently by the Robertson Centre for 
Biostatistics, Glasgow. Data were entered by the data manager and the database was 
audited on several occasions in order to prevent data entry errors. Data were analysed 
using intention-to-treat analysis in order to minimise any deviation from randomised 
allocation or missing responses, which may have occurred due to participants not 
completing the study. 
 
This study had several limitations. Firstly, the use of self-reported problems in activities 
of daily living, by using the Barthel Index, as a means of assessing functional status. 
Traditionally self-reports or proxy-reports have proved useful in assessing functional 
ability of older people as they are easy to administer and inexpensive, however self-
reports measure perceived function and may have introduced subject bias. The Barthel 
Index is also limited by ceiling and floor effects which may limit its responsiveness to 
change
409
. Sinoff et al showed that the self-reported Barthel ADL Index was found to 
have limitations in the very old (>85 years old) and in patients with cognitive 
impairment
410
. Measuring physical performance by direct observation may have 
provided a more objective way to measure the participants functional state
411
. Physical 
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performance tests such as the ‘sit-to-stand tests’ have been shown to be useful 
predictors of disability
412
. Giampolini et al showed that hand grip strength is a good 
predictor of disablity; with a reduction in grip strength associated with increased 
disability at 4 years after adjusting for cofounders including osteoarthritis
413!" 
"
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Thirdly an apparent ‘learning effect’ was seen in the 6MWT in both groups at 20 weeks. 
No practice tests were performed prior to measuring the 6MWT distance at each visit. 
Studies have shown that the 6MWT distance tends to increase after repeated test 
administration, therefore producing a learning effect because of test familiarisation
414
. 
The learning effect seen in previous studies varies in magnitude from 4.5-33% of the 
initial distance, however the distance plateaus after the third repeat
299
. The study 
showed a learning effect in both groups at 20 weeks, with each group showing a 9% 
increase in distance walked from baseline. Although studies in COPD and CHF patients 
have suggested good reproducibility of the 6MWT after only one test, relatively few 
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studies have performed reliability studies of the test in older people. Kervio examined 
the reliability of the 6MWT in healthy older people and found that similarly at least two 
familiarisation tests were required to eliminate a learning effect
415
. Therefore, it is 
possible that the learning effect may have been mitigated if participants had performed 
at least 2 practice walks. However as this study included a frail older population with 
established mobility problems practice tests in the 6MWT may have been difficult to 
accomplish.  
 
Although results of the RAAS measures were only available at the end of the study, the 
investigator monitored blood results for participants’ renal function and magnesium 
levels at each study visit. Knowledge of the participants’ potassium or creatinine levels 
may have led to unblinding of the investigator resulting in investigator bias. However it 
is important to note that meticulous monitoring of blood results was essential to ensure 
patient safety. This ensured that in the event of a participant developing serious 
hyperkalaemia immediate action would be taken by the investigator. In an ideal 
situation this would have been avoided by employing an additional staff member to 
monitor participants’ renal function independently from the research team. 
 
Randomisation 
Randomisation was carried out by Tayside Pharmaceuticals, using a computer generated 
random numbers table. As randomisation was performed independently from the study 
team, treatment allocation was concealed. Treatment codes were placed in a sealed 
envelope and were held by Tayside Pharmaceuticals. After the study was completed and 
all data were entered, allocation to treatment group ‘A’ or ‘B’ was performed by a 
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person independent of the research team. Treatment codes were only broken after 
analysis of the primary outcome was performed.   
Blinding  
The following strategies were implemented in order to preserve blinding within the 
study: Participants were randomised and the treatment allocation was concealed from 
both the participant and investigator throughout the study which prevented the 
introduction of bias to the study. Results of BNP and aldosterone were only available at 
the end of the study. Analyses of these measures were performed at the end of the study 
to prevent investigator unblinding.Data were entered onto the computer database by an 
independent organisation and the database was ‘locked’ prior to the treatment codes 
being broken. Data analysis of the primary outcome was performed blind.  
 
4.7 Adverse events 
There were no serious adverse events in our study associated with spironolactone. Two 
participants were hospitalised prior to commencing their study medication due to 
unrelated medical problems. Only 7% of participants withdrew from the study. This was 
much lower compared to the RALES study where 25% of participants were withdrawn 
and Witham et al showed that up to 42% of older patients with heart failure were 
withdrawn from taking spironolactone due to adverse effects
416
. There were no episodes 
of serious hyperkalaemia in our study cohort. 
 
The majority of participants tolerated the up-titration of spironolactone to 25 mgs after 2 
weeks. Only 3% of individuals in the spironolactone group were down-titrated to 12.5 
mg spironolactone due to a rise in potassium, which was much lower than participants 
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in Cicoira’s study, where 8% of participants in older people with heart failure were 
down titrated to 12.5 mg of spironolactone due to adverse effects
258
. 
4.8 Conclusion 
This study showed that spironolactone did not improve exercise capacity in older people 
without heart failure. Previous studies suggested that spironolactone may improve 
physical function by preventing skeletal myocyte loss
225
, improve vascular endothelial 
function
248
 by improving skeletal muscle blood flow
249
 and improve muscle 
contractility by increasing muscle magnesium and potassium
231
. However the majority 
of these studies were performed in animals or in patients with CHF, where 
improvements in physical function were more likely due to improvements in cardiac 
function. The fact that ACE inhibitors did improve exercise capacity in functionally 
impaired older people without heart failure supports the role of other inhibitors of the 
RAAS in preventing sarcopenia. However the lack of effect with spironolactone shows 
that blocking aldosterone alone does not prevent decline in physical function with age.  
 
Spironolactone was associated with improvement in health related quality of life, 
despite having no effect on exercise capacity. Previous studies with spironolactone have 
shown improvements in quality of life in association with improvements in exercise 
capacity or cardiac symptoms in patients with CHF
258;262
. To the best of our knowledge 
this was the first study to show an improvement in quality of life in older people 
without heart failure in the absence of any improvement in physical function. The most 
significant improvement in quality of life was in the pain domain of the EuroQol EQ-
5D, with joint pain from osteoarthritis as the commonest cause of pain. It is possible 
that improvement in quality of life may have occurred due to other pharmacological 
effects of spironolactone including an anti-inflammatory effect. Previous studies have 
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shown spironolactone to have anti-inflammatory potential as it can reduce pro-
inflammatory cytokines, which are stimulated in a range of inflammatory disorders 
including arthritis. This observation suggests possible wider pharmacological effects of 
spironolactone in older people.  
 
Current British Hypertension Society guidelines recommend spironolactone as a fourth 
line therapy for resistant hypertension
263
. Our findings support findings by Wei et al
266
 
that spironolactone is a safe drug to use if closely monitored
266
. It also provides 
reassurance that spironolactone was generally well tolerated with relatively few adverse 
effects and no postural hypotension in a frail older population. 
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5. FUTURE RESEARCH 
ACE inhibitors and spironolactone on exercise capacity 
The ACE inhibitor perindopril improved exercise capacity in functionally impaired 
older people without heart failure at 20 weeks
196
, however there is a lack of evidence to 
suggest whether this improvement in physical function can be sustained with long term 
ACE inhibition. High levels of angiotensin II and aldosterone have a negative impact on 
muscle function. Levels of angiotensin II and aldosterone fall within the first 10 months 
of taking an ACE inhibitor. However observational studies have shown that aldosterone 
levels eventually return to baseline with the long term use of ACE inhibitors due to 
‘aldosterone escape’
257
. The subsequent rise in aldosterone may counteract the initial 
benefits of ACE inhibitors on exercise capacity. The initial improvement in exercise 
capacity may be sustained long term with the addition of aldosterone receptor blocker, 
spironolactone.  
 
Spironolactone and health related quality of life 
Spironolactone improved quality of life in functionally impaired older people without 
heart failure. Further randomised placebo controlled trials involving spironolactone 
would be useful to investigate whether an improvement in quality of life could be 
generalised in a wider older population.  
 
In this study spironolactone was associated with improved pain score in the EuroQol 
EQ-5D, especially in participants with osteoarthritis. Osteoarthritis is one of the 
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commonest causes of disability in older people, mainly affecting the weight-bearing 
joints. Older people with symptomatic osteoarthritis are more likely to have problems 
with activities of daily living, poorer quality of life and increased risk of falls.  
 
Although the EuroQol EQ-5D questionnaire is a valid measure of change in general 
health state in chronic conditions including arthritis it is less responsive to moderate 
changes in pain score, which makes it more difficult to relate these findings to the 
general population. Randomised placebo-controlled trials are now required to 
investigate whether spironolactone improves pain as measured by validated 
measurement tools which have been used to assess pain in older osteoarthritis patients 
i.e. the pain Visual Analogue Scale (VAS)
417
. 
 
Spironolactone and inflammation 
One theory for the improvement in quality of life, in particular the improvements seen 
in the pain domain of quality of life, could be due to the potential anti-inflammatory 
properties of spironolactone. Studies have shown that spironolactone inhibits 
inflammatory cytokine production in patients with arthritis and reduces vascular 
inflammation
254
. In older people chronic inflammation is a strong predictor of physical 
disability and mortality
16
. Further studies are needed to investigate the anti-
inflammatory potential of spironolactone and the possible long-term benefits on 
morbidity and mortality in older people. 
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8. APPENDICES 
 
Appendix A - Participant screening proforma 
 
Patient no……………… 
Exclusion Criteria 
On spironolactone ! Age <65 years ! Uncontrolled hypertension ! 
Heart Failure ! Creatinine >200mmol/L/ eGFR <30ml ! Addisons disease ! 
Serum Na <130mmol/L ! Potassium >5.0mmol !MMSE <15/30 ! wheelchair 
bound !systolic blood pressure <100mmHg ! On ACE inhibitor ! 
On Angiotensin Receptor Blocker ! In another trial / within 3 months of completing 
another trial ! symptomatic postural hypotension ! living in nursing home ! 
 
Inclusion Criteria 
Age > 65 years ! 
Functional disability:  Walking aids    ! 
   Help with ADL ! 
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Functional State Self reported / discharge from Medicine for the Elderly Services 
a) Mobility:      no aids   !     one aid    !     two aids   !   frame  !   rollator ! 
 
b) Manages stairs: yes  !      with help  !     no  ! 
 
c) Toileting : independent  !  needs help ! 
 
d) Dressing:    independent !    minimal help  !     needs help   ! 
 
e) Grooming (hair/teeth/shave):    independent  !    needs help   ! 
 
f) Bathing:      independent   !     needs help ! 
 
g) Kitchen:    capable    !     snack only   !      incapable   !     not applicable ! 
 
h) Feeding:        independent !    needs help    ! 
 
i) Bowels:         continent     !   occasional accident  !   incontinent  ! 
 
j) Bladder:    continent  !  catheter  ! urodomes ! occ.accident  !   
 
incontinent ! 
 
 
 
 
Eligible to take part in study:                                 YES !       NO ! 
 
Study Information given:               YES !       NO ! 
 
 
Date…………………………………        Signature……………………………….. 
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Appendix B – Letter of invitation 
 
Ageing and Health 
Division of Medical Sciences 
University of Dundee 
DD1 9SY 
Tel: 01382 632436 
Date:  /  /   
 
 
Dear Mr/Mrs, 
 
Research Project: Effect of Spironolactone On Exercise Capacity In Older People 
Without Heart Failure:  
A Double Blind Placebo Controlled Trial 
 
We are delighted to invite you to take part in our research project. We are interested in 
seeing whether a medicine called spironolactone, commonly used in patients with heart 
failure could help to improve your muscles.  Improving muscles can help to reduce the 
risk of disability. 
 
We are approaching you about this research because you have recently attended the 
Medicine for the Elderly services at Perth Royal Infirmary and do not have heart failure.  
 
Full details of what the study is about and what would be involved are enclosed in the 
Patient Information Leaflet. If you are interested, we would be delighted to hear from 
you and can arrange to meet you to answer any questions you may have. Please kindly 
fill in the attached reply slip if you are interested in hearing more about the research and 
send it back to us in the enclosed stamped addressed envelope.  
 
In the meantime, please feel free to contact us by telephone on Dundee 632436 during 
office hours if you have any queries. 
 
Yours sincerely 
 
 
Dr Louise Burton     Professor Marion E T McMurdo 
Clinical Research Fellow                 Head of Section of Ageing and Health 
University of Dundee                University of Dundee  
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Appendix B – letter of invitation 
 
Reply slip: Effect of spironolactone on exercise capacity in older people  
 
 
Only complete if you wish to learn more about the study 
 
Name……………………………………………………………..………. 
 
Address……………………………………....…………………...……... 
 
……………………………………………………………………………. 
 
………….………………………...………..… Postcode ………........... 
 
Telephone number……………....……… 
 
 
Best time to contact………..…………… 
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Appendix C – Participant Information Leaflet 
 
 
PATIENT INFORMATION SHEET 
 
Effect Of Spironolactone On Exercise Capacity In Older People Without Heart 
Failure: A Double Blind Placebo Controlled Trial 
 
 
We invite you to participate in a research project.  We believe it to be of 
potential importance.  However, before you decide whether or not to participate, 
we need to be sure that you understand firstly why we are doing the study, and 
secondly what it would involve if you agreed to take part.  We are therefore 
providing you with the following information. Please take time to read it carefully 
and be sure to ask any questions you have, and, if you want, discuss it with 
others.  We will do our best to explain and provide any further information you 
may ask for now or later.  You do not have to make an immediate decision. 
 
Why are we doing this study? 
Recent evidence suggests that a medicine called spironolactone that is 
commonly used in patients with heart failure could have a beneficial effect on 
muscle function.  This improvement in muscle function can lead to decreased 
effort in performing day to day activities and increase exercise capacity even in 
people without heart failure. 
 
We are doing this study to find out if spironolactone will improve improve 
muscle function in older people without heart failure.  
 
Why have I been chosen? 
You have been chosen for this research because you are over 65 years old. 
 
Do I have to take part? 
Participation in this study is entirely voluntary and you are free to refuse to take 
part or to withdraw from the study at any time without having to give a reason 
and without this affecting your future medical care or your relationship with 
medical or nursing staff looking after you. 
 
What will happen to me if I take part? 
The study will last for 5 months and you will be given either the spironolactone 
or placebo (dummy) capsules. You have a 50/50 chance of receiving either 
treatment. 
 
You will be requested to come to the Royal Victoria Hospital in Dundee or Perth 
Royal Infirmary, three times over these 5 months. We will arrange a free taxi to 
bring you to the Hospital and take you back home each time. Each visit will last 
between one and two hours.  
 
You will be asked to perform some walking tests and asked to answer a few 
questionnaires.  
 
  
 
259 
 
We will take down details of what medicines you are taking.  
 
We will measure your blood pressure and take some blood samples (no more 
than a few teaspoonfuls).  
 
We will do an echocardiography scan of your heart. This is a scan similar to that 
done on pregnant women to look at their babies. 
 
What do I have to do? 
 You are required to take the medication (1 capsule per day) every day for 5 
months. 
 
We will ask you to do the following at each visit: 
 
- Walk up and down a corridor for six minutes. You may rest on the way as 
many times as you need to. 
- Walk around a short course in time to a beeping sound for as long as you can. 
- Get out of a chair and walk a few paces. We will time you. 
- Answer three questionnaires about how much you are able to do and how you 
feel.  
 
What is being tested? 
We want to test whether those who receive the spironolactone during the study 
improve in their walking and other tests compared to those who received the 
placebo. This would give us an idea whether the medicine has effects on 
physical function in older people.  
 
Will taking part in the study affect your usual care? 
We will not alter any of your medication or interfere with your treatment in any 
way. 
 
What are the possible discomforts, risks and side effects? 
Spironolactone is a diuretic therefore you may experience an increase in urine 
output, an upset stomach, dizziness or kidney problems with increases in blood 
levels of potassium. Therefore your potassium levels will be monitored 
throughout the study. Men may experience possible breast enlargement.The 
blood test may cause some minor discomfort. 
 
Taking part in this study could lead to mild tiredness. 
 
What are the possible benefits of taking part? 
Those of you who receive the spironolactone may improve your muscle function 
and exercise capacity. This may potentially reduce disability and dependence. 
 
What happens if something goes wrong? 
This is very unlikely, but if something does go wrong then the University of 
Dundee has a scheme which could provide compensation, if appropriate. 
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Will my GP know about this research project? 
If you agree to take part, we will inform your GP. 
 
Will my taking part in this study be kept confidential? 
All the information collected will be kept strictly confidential.  All information will 
be kept in a locked room and held on a secure computer.  During the study all 
identifying information will be kept separately, and at the end of the study your 
name and address will be deleted.  Only the researchers involved in the study 
will have access to the information.  We will keep the information for 15 years.  
  
What will happen to the results? 
The results will be examined by the researchers and a report produced.  You 
will not be identified in this report.  The results will be shared with the funder for 
the study (Scottish Chief Scientist Office), and be added to the growing 
evidence on the effects of these medicines. We will write to let you know the 
results at the end of the study. 
 
Will I continue to receive the medicine used in this study after it finishes?  
 You will not continue to receive the medicine after the study finishes.   
 
Who is organizing and funding this research? 
The study has been organized by Prof Marion McMurdo, Dr Deepa Sumukadas, 
Dr Miles Witham and Prof Allan Struthers. The study is funded by the Scottish 
Chief Scientist Office 
 
Who has reviewed the study? 
The Tayside Committee on Medical Research Ethics, which has responsibility 
for scrutinising all proposals for medical research on humans in Tayside, has 
examined the proposal and has raised no objections from the point of view of 
medical ethics.  It is a requirement that your records in this research, together 
with any relevant medical records, be made available for scrutiny by monitors 
from NHS Tayside and the Regulatory Authorities. 
 
Thank you for reading this Information Sheet and considering taking part in this 
study. 
 
 
For further information contact: 
 
Dr Louise Burton, Research fellow, on telephone Dundee 632436. 
 
Dr D Sumukadas on telephone Dundee 632436 
 
Professor M E T McMurdo on telephone Dundee 632436 
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Appendix D – Consent form 
 
Study Number: 08/S1402/34 
Patient Identification Number for this trial:  
 
CONSENT FORM v1.3 Dated 16/11/09 
 
Title of Project: The effect of spironolactone on exercise capacity in functionally 
impaired older people without heart failure: a double blind placebo controlled 
trial 
 
Name of Researcher: Professor Marion E T McMurdo 
Please initial or tick box 
1.  I confirm that I have read and understood the information sheet dated 
21/10/2009 (version 1.3) for the above study.  I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
 
2.  I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without any medical 
care or legal rights being affected 
 
 
 
3.  I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by regulatory authorities or 
from the NHS Trust, where it is relevant to my taking part in this 
research.  I give permission for these individuals to have access to my 
records. 
 
 
4.  I agree to my GP being informed of my participation in the study. 
 
 
5.  I agree to the storage of my leftover blood samples for use in future 
research. 
 
 
6.  I agree to take part in the above study.  
 
 
______________________  ______________       ________________ 
Name of participant   Date    Signature 
 
 
______________________  ______________  _________________ 
Name of person taking consent Date    Signature 
 
 
When complete, 1 for participant; 1 for researcher site file; 1 (original) to be kept in 
medical notes 
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Appendix E- Letter to GP 
 
Ageing and Health 
Division of Medical Sciences 
University of Dundee 
DD1 9SY 
Ph: 01382 632436 
Fax: 01382 660675 
Date: --/--/-- 
 
Dr XYZ 
GP Surgery 
 
 
Dear Dr, 
 
Re: Mr/Mrs ABC, address 
 
Effect Of Spironolactone On Exercise Capacity In Older People Without Heart Failure: A 
Double Blind Placebo Controlled Trial 
 
Mr/Mrs ABC has very kindly agreed to take part in the above trial. Recent research suggests 
that modifying the renin-angiotensin system may have a role in improving exercise capacity in 
older people.   
 
We are running this trial to assess whether spironolactone can improve exercise capacity in 
older people without heart failure. Patients will be randomised to spironolactone or placebo for 
a 20 week period.  We will provide all of the trial medication. Both the patients and the 
assessors will be blinded to the nature of the therapy. All other medications can continue as 
usual. We will assess walking distance, ability to get out of a chair, quality of life and exercise 
capacity at the beginning, halfway through, and at the end of the study. We will also check 
blood pressure, serum sodium, potassium, urea, creatinine and magnesium at 0, 2, 5, 10 and 20 
weeks. Portable echocardiography will be done at the beginning and the end of the study. 
   
The project is funded by the Scottish Chief Scientists Office. The study has been approved by 
the Tayside Committee on Medical Ethics. If you have any questions about the study, or if there 
is any aspect of your patient’s healthcare that we can assist you with, please do not hesitate to 
call us on the numbers below.  
 
 
Yours sincerely, 
 
 
 
 
Dr Louise Burton     Professor Marion ET McMurdo 
Clinical Research Fellow   Head of Ageing and Health 
Ageing and Health    University of Dundee 
University of Dundee       
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Appendix F – Mini mental state questionnaire 
 
Mini Mental State Exam (MMSE) 
 
Date:  ………………  Study Number:  …………  
 
 
 
ORIENTATION      
 Year  Month Day Date Time 
 
____ / 5 
 Country Town District Road Number 
 
____ / 5 
REGISTRATION      
 Examiner names 3 objects (e.g. apple, table, penny) 
Patient asked to repeat (1 point for each correct) 
Patient to learn the 3 names repeating until correct 
 
 
 
____ / 3 
ATTENTION AND CALCULATION     
 Subtract 7 from 100, then repeat from result 
Continue 5 times: 100  93  86  79  65 
Or 
Spell W O R L D backwards – dlrow 
 
 
 
 
____ / 5 
RECALL       
 Ask for names of 3 objects learned earlier 
 
____ / 3 
LANGUAGE      
 Name a pencil and a watch 
 
____ / 2 
 Repeat “No ifs, ands or buts” 
 
____ / 1 
 Give a 3 stage command. Score 1 point for each stage 
Take this piece of paper, fold it in half, drop it on the floor 
 
 
____ / 3 
 Ask patient to read and obey a written command on a piece of 
paper stating “Close your eyes” 
 
 
____ / 1 
 Ask patient to write a sentence. Score if it is sensible and has a 
subject and a verb 
 
 
____ / 1 
COPYING       
 Ask patient to copy a pair of intersecting pentagons 
 
____ / 1 
 
 
    TOTAL ____ / 30 
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Close your eyes 
 
 
 
…………………………………………………………………………………………….. 
 
 
 
 
Write a Sentence: _________________________________________________ 
 
 
 
 
…………………………………………………………………………………………… 
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Appendix G – EuroQol (EQ-5D Utility section) questionnaire 
 
Date: …………… Study Number:   ……………  Visit Number:………. 
By Placing a tick in one box in each group, please indicate which statements best 
describe your own health state today. 
 
Mobility 
 
 
I have no problems in walking about 
 
 
I have some problems in walking about 
 
 
I am confined to bed 
 
 
 
Self-care 
 
 
I have no problems with self-care 
 
 
I have some problems washing or dressing myself 
 
 
I am unable to wash or dress myself 
 
 
 
Usual activities (e.g. work, study, housework, family or leisure activities) 
 
 
I have no problems performing my usual activities 
 
 
I have some problems with performing my usual activities 
 
 
I am unable to perform my usual activities 
 
 
 
Pain / Discomfort 
 
 
I have no pain or discomfort 
 
 
I have moderate pain or discomfort 
 
 
I have extreme pain or discomfort 
 
 
 
Anxiety / Depression 
 
 
I am not anxious or depressed 
 
 
I am moderately anxious or depressed 
 
 
I am extremely anxious or depressed 
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Appendix H– EuroQol (EQ-VAS section) 
 
Date:   ……………  
   
 
Study Number:    …………… 
 
 
Visit Number:     ………….. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      100   
 
 
 
 
 
      9•0 
 
 
 
 
      8•0 
 
 
 
 
                       
      7•0 
 
 
 
 
      6•0 
 
 
 
 
      5•0 
 
 
 
 
      4•0 
 
 
 
 
      3•0 
 
 
 
 
      2•0 
 
 
 
 
      1•0 
 
 
 
 
         
           0 
Your own 
health state today 
To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 
and the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good 
or bad your own health is today, in your opinion. 
Please do this by drawing a line from the box below to 
whichever point on the scale indicates how good or 
bad your health state is today. 
 
Best imaginable 
health state 
Worst imaginable 
health state 
  
 
267 
 
Appendix  I – HADS questionnaire 
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Appendix J – Functional Limitation Profile 
 
FUNCTIONAL LIMITATIONS PROFILE 
 
 
Ambulation items 
 
The following statements describe walking and use of stairs. Remember, 
think of yourself today. 
 
1 I do not walk at all  126 
2 I get about in a wheelchair  121 
3 I do not use stairs at all  106 
4 I only walk with help from someone else  98 
5 I get about only by using a walking frame, crutches, 
stick, walls or hold onto furniture 
 96 
6 I only go up and down stairs with assistance from 
someone else 
 87 
7 I only use stairs with a physical aid; for example a 
handrail, stick or crutches 
 82 
8 I walk by myself but with some difficulty; for 
example, I limp, wobble or stumble, or I have a stiff 
leg 
 71 
9 I do not walk up or down hills  64 
10 I go up and down stairs more slowly; for example 
one step at a time, or I often have to stop 
 62 
11 I walk shorter distances or I often stop for a rest  54 
12 I walk more slowly  39 
    
 SCORE           /126  
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Body care and movement items 
 
The following statements describe how you move about, bath, go to the 
toilet, dress yourself today. 
 
13 I am in a restricted position all the time  124 
14 I do not have control of my bowels  124 
15 I do not have control of my bladder  122 
16 I stay lying down most of the time  120 
17 I use a bedpan with help  107 
18 I do not bathe myself at all; but am bathed by 
someone else 
 100 
19 I do not get in and out of bed or chairs without the 
help of a person or mechanical aid 
 100 
20 I do not keep my balance  93 
21 I only stand up with someone’s help  93 
22 I do not bathe myself completely; for example, I 
need help with bathing 
 85 
23 I make difficult movements with help; for example 
getting in or out of the bath or car 
 82 
24 I hold onto something to move myself around in bed  82 
25 I only get dressed with someone’s help  82 
26 I get in and out of bed or chairs by grasping 
something for support or by using a stick or walking 
frame  
 79 
27 I spend most of the time partly dressed or in 
pyjamas 
 75 
28 I do not fasten my clothing; for example I require 
assistance with buttons, zips or shoelaces 
 68 
29 I only stand for short periods of time  67 
30 I move my hands or fingers with some difficulty or 
limitation 
 66 
31 I kneel, stoop or bend down only by holding onto 
something 
 61 
32 I have trouble putting on my shoes, socks or 
stockings 
 54 
33 I change position frequently  53 
34 I am very clumsy  47 
35 I dress myself, but do so very slowly  43 
    
 SCORE            /124  
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Mobility Items 
 
These next statements describe how you get about the house and outside 
 
36 I stay in bed most of the time  114 
37 I stay in one room  101 
38 I stay in bed more  91 
39 I stay at home most of the time  79 
40 I only get about in one building  76 
41 I only go out if there is a lavatory nearby  64 
42 I do not get about in the dark or in places that are 
not lit unless I have someone to help 
 57 
43 I do not use public transport now  52 
44 I do not go into town  47 
45 I only stay away from home for short periods  46 
    
 SCORE           / 114  
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Household management items 
 
The following statements describe your daily work around the home. 
When you answer, think of yourself today. 
 
46 I do not do any of the daily household chores that I 
would usually do 
 90 
47 I do not do any of the shopping that I would usually 
do 
 84 
48 I do not do any of the cleaning that I would usually 
do 
 78 
49 I have difficulty using my hands; for example turning 
taps, using kitchen gadgets, sewing or doing repairs 
 78 
50 I do not do any of the maintenance or repair work 
that I would usually do in my home or garden 
 75 
51 I do not do any of the clothes washing that I would 
usually do 
 75 
52 I have given up taking care of personal or 
household business affairs; for example paying 
bills, banking or doing household accounts 
 69 
53 I do not do heavy work around the house  59 
54 I only do housework or work around the house for 
short periods of time and I rest often 
 50 
55 I do less of the daily household chores than I would 
usually do 
 37 
    
 SCORE           / 90  
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Recreation and Pastime items 
 
The following statements describe the activities you usually do in your 
spare time, for relaxation, entertainment, or just to pass the time. Again, 
think of yourself today. 
 
56 I am not doing any of my usual inactive pastimes; 
for example. I do not watch TV, play cards, or read 
 91 
57 I am not doing any of my usual physical recreation 
or more active pastimes 
 81 
58 I am cutting down on some of my usual inactive 
pastimes; for example I watch TV less, play cards 
less or read less 
 50 
59 I am doing more inactive pastimes instead of my 
other usual activities 
 43 
60 I am cutting down on some of my usual physical 
recreation or more active pastimes 
 34 
61 I spend shorter periods of time on my hobbies and 
recreation 
 32 
62 I go out less often to enjoy myself  27 
63 I take part in fewer community activities  25 
    
 SCORE          / 91  
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Social Interaction items 
 
These statements describe your contact with family and friends today. 
 
64 I refuse contact with my family; for example I turn 
away from them 
 109 
65 I frequently get angry with my family; for example I 
hit them, scream or throw things at them 
 103 
66 I isolate myself as much as I can from the rest of my 
family 
 100 
67 I do not go out at all to visit people  91 
68 I stay alone much of the time  91 
69 I am disagreeable with my family; for example I act 
spitefully or stubbornly 
 86 
70 I make many demands on other people; for 
example I insist that they do things for me or tell 
them how to do things 
 76 
71 I avoid having visitors  73 
72 I do not look after my children or family as well as I 
usually do 
 66 
73 I am often irritable with those around me; for 
example I snap at people or criticise easily 
 64 
74 My sexual activity is decreased  64 
75 I pay less attention to the children  59 
76 I show less interest in other people’s problems; for 
example, I don’t listen when they tell me about their 
problems; I don’t offer to help 
 50 
77 I show less affection  44 
78 I often express concern over what might be 
happening to my health 
 44 
79 I talk less with other people  44 
80 I do not joke with members of my family as much as 
I usually do 
 38 
81 I go out less often to visit people  31 
82 I am cutting down the length of visits with friends  31 
83 I take part in fewer social activities than I used to; 
for example I go to fewer parties or social events 
 25 
    
 SCORE           / 109  
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Emotion Items 
 
The next statements describe your feelings and behaviour. Again, think of 
yourself today 
 
84 I have attempted suicide  141 
85 I talk hopelessly about the future  96 
86 I say how bad or useless I am; for example that I 
am a burden on others 
 89 
87 I am irritable and impatient with myself; for example, 
I run myself down, I swear at myself, I blame myself 
for things that happen 
 79 
88 I often moan and groan because of pain or 
discomfort 
 67 
89 I keep rubbing or holding areas of my body that hurt 
or are uncomfortable 
 59 
90 I laugh or cry suddenly  58 
91 I get sudden frights  56 
92 I behave nervously or restlessly  48 
    
 SCORE           / 141  
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Alertness items 
 
93 I sometimes get confused; for example I do not 
know where I am, who is around, or what day it is 
 115 
94 I have more minor accidents; for example I drop 
things, I trip and fall, or I bump into things 
 90 
95 I forget a lot; for example things that have 
happened recently, where I put things, or to keep 
appointments 
 85 
96 I have difficulty reasoning and solving problems; for 
example making plans, making decisions, or 
learning new things 
 78 
97 I am confused and start to do more than one thing 
at a time 
 74 
98 I have difficulty doing things which involve thought 
and concentration 
 71 
99 I do not keep my attention on any activity for long  52 
100 I react slowly to things that are said or done  52 
101 I make more mistakes than usual  49 
102 I do not finish things I start  45 
    
 SCORE           / 115  
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Sleep and Rest items 
 
These statements describe your sleep and rest activities today 
 
103 I sleep or doze most of the time, day and night  111 
104 I spend much of the day lying down to rest  96 
105 I sleep less at night; for example I wake up easily, I 
don’t fall asleep for a long time, or I keep waking up 
 86 
106 I sit around half asleep  84 
107 I sleep or doze more during the day  80 
108 I lie down to rest more often during the day  72 
109 I sit for much of the day  62 
    
 SCORE          / 111  
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Eating items 
 
The following statements describe your eating and drinking habits 
 
110 I eat no food at all except by tubes or intravenous 
infusion 
 143 
111 I do not feed myself at all but have to be fed  121 
112 I eat no food at all, but I take liquids  113 
113 I feed myself with help from someone else  95 
114 I feed myself but only with specially prepared food 
or special utensils 
 76 
115 I eat special or different food; for example I follow a 
soft food, bland, low fat, low salt or low sugar diet 
 52 
116 I just pick or nibble at my food  39 
117 I eat much less than usual  34 
118 I drink less fluids  33 
    
 SCORE          / 143  
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Communication items 
 
I am going to read out some statements about how much you talk to other 
people and write. Please think about yourself today 
 
119 I communicate mostly by nodding my head, pointing 
or using sign language or other gestures 
 127 
120 My speech is understood only by a few people who 
know me well 
 94 
121 I am understood with difficulty  89 
122 I don’t write except to sign my name  84 
123 I speak with difficulty; for example, I get stuck for 
words, I stutter, I stammer, I slur my words 
 76 
124 I often lost control of my voice when I talk; for 
example my voice gets louder or softer or changes 
unexpectedly 
 59 
125 I carry on a conversation only when very close to 
other people or looking directly at them 
 59 
126 I have trouble writing or typing  50 
127 I do not speak clearly when I am under stress  47 
    
 SCORE           / 127  
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Work items 
 
I am going to read out some statements about work. As I read them out, 
think of yourself today. If today is not a working day for you, think about 
your last working day 
 
128 I do not work at all  361 
129 I only work for short periods of time or often stop to 
rest 
 65 
130 I only do light work  56 
131 I work shorter hours  52 
132 I do not do my job as carefully and accurately as 
usual 
 50 
133 I often get irritable with my workmates; for example 
I snap at them or criticise them easily 
 42 
134 I am not getting as much work done as usual  41 
135 I do part of my job at home  40 
136 I work at my usual job but with some changes; for 
example I use different tools or special aids or I 
swap jobs with someone else 
 36 
    
 SCORE          /361  
 
 
TOTALS: 
 
Ambulation  /126   Recreation  / 91 
 
Body care  /124   Social   / 109 
 
Mobility  /114   Emotion  / 141 
 
Household  / 90   Alertness  / 115 
 
   Sleep / rest  / 111 
 
Physical domain total: / 454  Psychosocial 
      domain total:  / 567 
 
Eating    / 143 
 
Communication  / 127 
 
Work    / 361  GRAND TOTAL:  / 1652  
 
 
 
 
